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Abstract
Focal adhesion kinase (FAK) is a non-receptor tyosime kinase present in cell-ECM 
focal adhesions. As a part of the integrin signalling; complex, FAK is implicated to 
play a role in the mediation of integrin induced celll growth, motility and survival- 
processes that are also required for tumour development and progression. A role for 
FAK has thus been proposed in the process of tumoriigenesis. In support of this, FAK 
is found to be upregulated in various different tumours and tumour cell lines. 
However, the mechanisms that lead to the upregulat:iom of FAK in cancer cells have 
not been investigated thus far. The first part of thiis study focused on establishing 
some of the genetic alterations adopted by cancer ctellls to elevate the level of FAK 
protein. We used fluorescent in situ hybridisation ((FISH) to first confirm that fak 
localised to human chromosome 8 q in normal cells. Elevated FAK protein levels in 
cell lines derived from invasive squamous cell carcimoimas of the head and neck were 
accompanied by gain in fak gene copy number in alll (the cases examined. Moreover, 
increased fak gene dosage, including genetic alterations like amplification and 
isochromosome formation, were observed in cell limes derived from human tumours 
of lung, breast and colon. In addition, conversion froim adenoma to carcinoma, in an 
in vitro model for human colon cancer progression, w as accompanied by an elevation 
in FAK protein level and gain in fak gene copy number. Although, other genes like c- 
myc, lying near the fak locus, were also found to be co-amplified or increased in copy 
number, given the biological functions FAK is pmposed to play a role, it may 
contribute in exerting the selective pressure for the retention of the whole region in 
increased number of copies.
In order to further investigate the role of FAK in tumour development, we studied its 
importance in cell survival. For this we used an in viitrv model of apoptosis, wherein, 
apoptosis was induced in v-Src transformed Rat-1 cells after serum-deprivation and 
inhibition of v-Src activity. In particular, we examined the importance of FAK 
proteolysis in the induction of apoptosis. We found that although induction of 
apoptosis was accompanied by FAK cleavage, inhibition of FAK proteolysis was 
unable to promote cell survival.
The in vitro model of apoptosis using v-Src transformed Rat-1 cells was also 
characterised further in this thesis. Like FAK, the v-Src oncoprotein also resides in 
the focal adhesions where its constitutive kinase activity induces disruption of focal 
adhesions and cell transformation. Unlike other oncoproteins like c-Myc, and v-Jun, 
v-Src does not induce cell death under low serum conditions. However, the data 
described in this thesis suggested that v-Src primes the cells to undergo apoptosis, 
partly through disruption of integrin signalling, while providing them with a survival 
signal at the same time. Removal of this survival signal, thus, induced the cells to 
undergo apoptosis. Further investigations indicated that the surrogate integrin 
survival signal provided by v-Src required the activation of the PI 3-kinase/Akt 
pathway, while the MAP kinase pathway did not play any role in the mediation of the 
survival signalling.
In addition, the apoptotic response induced in v-Src transformed Rat-1 cells was 
shown to be accompanied by activation of caspases, and stress-activated kinase, p38. 
Cell death was inhibited by overexpression of the anti-apoptotic protein Bcl-2 or by 
the inhibtion of caspase and p38 activity simultaneously.
Acknowledgements
I would like to thank my supervisor, Dr. Margaret Frame, for her support and help 
during the entire course of my PhD, specially for teaching me the importance of 
doing nothing less than my best, and the Cancer Research Campaign for providing 
me with a studentship. A very special thanks to Val Fincham for teaching me all that 
I know about lab work and to Anne Wyke for proof-reading my thesis at such a short 
notice. I am very grateful to Ian Morgan, my advisor for his valuable suggestions and 
great support through some stressful times.
Thanks also to all the members of R1 and R ll ,  specially Dr. Debbie Riley for her 
helpful suggestions and co-operation. Thanks to all the PhD students, past and 
present, specially Mary, Rob, Paul and for making my three years at the Beatson 
really enjoyable and to Andy for helping me cope with ‘writing-up stress’ and also 
for helping me out in printing this thesis.
I am also grateful to all the staff members at the Beatson, specially, Iain White, Peter 
McHardy, and Tom McGuire for their technical help.
Finally, a very special thanks to my parents and my brother for their continuous help 
and support, without which, this thesis would not have become a reality.
Table of Contents
Section Page
Declaration i
Dedication ii
Abstract iii
Acknowledgements V
Table of Contents vi
List of Figures xiii
List of Tables xvi
Abbreviations xvii
Aim XX
Chapter 1: Introduction 1
1.1 Signalling at the focal adhesions: A role for integrins
1.1.1 Integrins
1 .1 . 2 Signal transduction through ECM-integrin interaction
1.1.3 Evidence for role of ECM-integrin signalling in cell growth
1.1.4 Mechanism of integrin-mediated activation of MAP
kinase pathway
1.1.5 Role of integrins in cell migration
1 .1 . 6 Mechanisms of integrin-mediated cell migration
1.1.7 Role of integrins in cell survival
1.2 Src
1 .2 . 1 Structure of Src
1 .2 . 2 Regulation of c-Src activity
1.2.3 From c-Src to v-Src
1.2.4 Ts LA29: A v-Src mutant
8 
10 
11 
12 
14 
14 
18 
19 
22
1.2.5 Role of c-Src in growth factor signalling 23
1.2.6 Signal-transduction pathways downstream of Src in
mediation of growth factor signalling 24
1.2.7 Role of c-Src in integrin-mediated signalling 25
1.2.8 Role of c-Src in integrin-mediated cell migration 25
1.2.9 Role of Src in integrin-mediated cell survival 26
1.3 Focal adhesion Kinase 27
1.3.1 Structure of FAK 27
1.3.2 FRNK: An alternatively spliced form of FAK 29
1.3.3 Phosphorylation sites in FAK and their importance in
substrate binding 30
1.3.4 Regulation of FAK phosphorylation and activation 31
1.3.5 Potential substrates of FAK 33
1.3.6 Functions of FAK 35
1.3.7 Role of FAK in cell motility 35
1.3.8 Role of FAK in cell proliferation 37
1.3.9 Role of FAK in cell survival 37
1.3.10 PYK2: A FAK homologue 39
2 Chapter 2: Materials and Methods 41
2.1 Materials 42
2.1.1 General Chemicals and Reagents 42
2.1.2 List of antibodies 45
2.1.3 Solutions 46
2.1.3.1 General solutions 46
2.1.3.2 Tissue culture solutions and medium 54
2.2 Methods 57
2.2.1 Isolation of fak  PAC clone 57
2.2.1.1 Random primed labelling of fak cDNA 57
2.2.1.2 Probing a library 57
2.2.1.3 Confirmation of the fak PAC clone 58
2.2.1.4 Isolation of DNA from PAC clones 60
2.2.2 Fluorescent in situ hybridisation (FISH) 60
2.2.2.1 Preparation of chromosomes from lymphocytes 60
22.2.2 Preparation of chromosomes from the BICR
vii
cell lines and HEK cells 61
2.2.2.3 Preparation of chromosomes from other cell
lines 62
2.2.2.4 Fixing chromosomes on slides 62
2.2.2.5 Biotin labelling for fak probe 62
2.2.2.6 Chromosome denaturation 63
2.22.1 Probe denaturation 63
2.2.2.8 Hybridisation of slides 63
2.2.2.9 Probe detection 64
2.2.2.10 Cutting and storage of frozen sections 65
2.2.2.11 Preparation of frozen sections 65
2.2.2.12 Probe detection for frozen sections 65
2.2.3 Protein analysis 65
2.2.3.1 Cell lysis 65
2.2.3.2 Protein assay 6 6
2.2.3.3 Immunoprecipitation 6 6
2.2.3.4 Calpain and ICE cleavage assays 67
2.2.3.5 SDS polyacrylamide gel electrophoresis 67
2.2.3.6 Western blotting analysis 67
2.2.4 DNA analysis 68
2.2.4.1 Bacterial transformations 6 8
2.2.4.2 Extraction of plasmid DNA 6 8
2.2.4.3 Calculation of DNA concentration 6 8
2.2.4.4 DNA agarose gel electrophoresis and isolation
of DNA fragments from agarose gel 69
2.2.4.5 DNA extraction from cells for DNA laddering 
analysis 69
2.2.4.6 Sub-cloning the constitutively active form
of p i 10 70
2.2.5 TUNEL assay 70
2.2.5.1 Fixing the cells 70
2.2.5.2 Staining the cells 71
2.2.5.3 Flow cytometric analysis 71
2.2.6 Caspase assay 72
2.2.6.1 Cell preparation 72
2.2.6.2 Caspase assay 72
2.2.7 Tissue culture 72
2.2.7.1 Recovering frozen cells 72
22.1.2 Preparing CEF from chick embryos 72
2.2.13 Cell culture 73
2.2.7.4 Trypsinisation 73
2.2.1.5 Freezing the cells 74
2.2.1.6 Irradiating feeder cells 74
2.2.1.1 Counting cells 74
2.2.7. 8  Cell transfection 74
3 Chapter 3: Results 1
Increased dosage and amplification of FAK in human cancer cells 76
3.1 Introduction 77
3.1.1 Importance of overexpression of proteins in tumours 77
3.1.2 Mechanisms of protein upregulation 78
3.1.3 How amplicons arise 79
3.1.4 Mechanism of formation of isochromosomes 80
3.1.5 Mechanism for gain of chromosomal copies 80
3.2 Isolation of fak  genetic probe 83
3.3 Localisation of the fak  probe to the human chromosome 8q24 8 6
3 A fak  gene copy number gain in the cell lines from a variety of
human epithelial tumour types 8 6
3.5 Increase in gene dosage of fak  is accompanied by an increase in 
protein level in >70% of the squamous cell carcinoma (SCC)
cell lines 92
3.6 Evidence for increase in fak gene dosage also in primary
tumour sections 96
3.7 Increase in fak  gene dosage accompanies the adenoma to carcinoma 
progression in an in vitro model of colon tumour development 96
3.8 Increase in fak  gene copy number is accompanied by an increase in
gain of c-myc gene copy number 98
3.9 Increase in c-myc copy number is not always associated with an 
increase in c-Myc protein level 100
3.10 Discussion 103
4 Chapter 4: Results 2
Role of focal adhesion kinase in cell survival 108
4.1 Introduction 109
4.2 FAK undergoes proteolysis in c-Myc induced apoptosis in CEF 109
4.3 Both calpain and caspases can cleave FAK in vitro 111
4.4 Caspases, not calpain are most likely responsible for FAK
proteolysis during apoptosis 113
4.5 Inhibition of FAK cleavage does not prevent apoptosis in 
transformed Rat-1 fibroblasts 118
4.6 Discussion 118
5 Chapter 5: Introduction 2 122
5.1 Apoptosis: Programmed cell death 123
5.1.1 Apoptosis vs Necrosis: mprphological distinction 123
5.1.2 Diverse stimuli can activate apoptosis 124
5.1.3 Interaction between different stimuli in the regulation
of an apoptotic response 125
5.2 Caspases 126
5.2.1 Function of caspases during apoptosis 128
5.3 Role of Bcl-2 family in cell survival 130
5.4 Role of mitochondrial dysfunction and cytochrome C in
apoptosis 131
5.5 Initiation and execution of apoptosis: caspases vs
cytochrome C release 133
5.6 Pro-apoptotic signal transduction pathways 134
5.7 Anti-apoptotic signal transduction pathways 138
5.7.1 Role of PI 3-kinase/Akt in survival signalling 138
5.7.2 Regulation of PI 3-kinase by PTEN 139
5.7.3 Downstream effectors of Akt that direct cell survival
and apoptosis 140
5.7.4 Other possible survival pathways 141
6 Chapter 6: Results 3
Characterisation of mediators of apoptosis after removal of
v-Src induced survival signal: the role of ZVAD.fmk-sensitive
caspases and p38 144
6.1 Introduction 145
6.2 Characterisation of cell death in v-Src transformed Rat-1 cells 145
6.3 Biochemical changes associated with apoptosis induced by 
inactivating v-Src in serum-deprived cells 146
6.4 Effects of interfering with caspase activity 148
6.5 Effects of blocking p38 activity 154
6 . 6  Inhibiting p38 and caspase activity simultaneously, reduced the 
percentage of cells undergoing apoptosis 157
6.7 Bcl-2 overexpression prevented induction of apoptosis 159
6 . 8  Discussion 161
7 Chapter 7: Results 4
Characterisation of survival signalling induced by v-Src in 
serum-deprived transformed Rat-1 cells: a possible role for 
PI 3-kinase/Akt pathway 166
7.1 Introduction 167
7.2 Role of PI 3-kinase downstream of v-Src 167
7.3 Effect of LY294002, is specific to v-Src transformed Rat-1 cells 172
7.4 Decreased Akt phosphorylation in cells treated with SB203580
and ZVAD.fmk and those overexpressing Bcl-2 175
7.5 Decreased MAP kinase activity in cells undergoing apoptosis 177
7.6 ERK does not play a role in the mediation of survival signal
xi
downstream of v-Src 179
7.7 Inhibiting PI 3-kinase and ERK activity simultaneously does not 
increase the effect of blocking PI 3-kinase alone 182
7.8 Discussion 182
8 Chapter 8: Final discussion, Summary and Future perspectives 188
8.1 FAK upregulation and oncogenesis 189
8.2 FAK proteolysis is not critical for apoptosis 191
8.3 Switching off v-Src in seum-deprived transformed Rat-1 cells
induces apoptosis 191
8.4 v-Src mediates survival via PI 3-kinase 193
9 References 197
10 Appendix
Agochiya, M., Brunton, V.G., Owens, D.W., Parkinson, E.K., Paraskeva, C., Keith, W.N. 
and Frame, M.C. (1999) Increased dosage and amplification of the focal adhesion kinase
gene in human cancer cells. Oncogene, 18, 5646-53.
Johnson, D., Agochiya, M., Samejima, K., Earnshaw, W., Frame, M. and Wyke, J. 
(manuscript accepted for publication) Regulation of apoptosis and survival by v-Src.
List of Figures
Figure 1 Signalling at the Integrins 4
Figure 2 Structures of c-Src and v-Src 16
Figure 3 Regulation of c-Src activity 20
Figure 4 Structure of FAK 28
Figure 5 Mechanism for regional duplication 81
Figure 6 From duplication to amplification 82
Figure 7 Isolation of fak  PAC clone 85
Figure 8 Localisation of fak to chromosome 8 q 87
Figure 9 No gain in fak copy number in a lung cancer cell line 90
Figure 10 Gain in fak gene copy number through amplification in some human
Cancer cell lines 91
Figure 11 Increase in fak gene dosage in head and neck carcinoma cell lines 94
Figure 12 Variation in expression of FAK in BICR cell lines 95
Figure 13 Elevated fak copy number in squamous cell carcinoma sections 97
Figure 14 A copy number gain of fak gene accompanies increased FAK protein
Expression during colonic adenoma to carcinoma conversion in vitro 99
Figure 15 Gain in fak  gene copy number in cancer cell lines is accompanied by
gain in c-myc copy number 101
Figure 16 Variation in c-Myc protein levels in BICR cell lines 102
Figure 17 c-Myc induced apoptosis is accompanied by FAK cleavage 110
Figure 18 FAK is cleaved in vitro by both calpain I and caspases 112
Figure 19 In vitro cleavage of FAK generates similar sized fragments as those
Detected in vivo 115
Figure 20 Inhibition of caspases, but not calpain, inhibits FAK proteolysis
During apoptosis 117
Figure 21 Inhibition of FAK cleavage does not promote cell survival 119
Figure 22 Regulation of apoptosis 135
Figure 23 Apoptotic features associated with cell death in transformed
Rat-1 cells 147
Figure 24 Activation of caspases during apoptosis in transformed Rat-1
xiii
cells 149
150Figure 25 p38 activation during apoptosis in transformed Rat-1 cells 
Figure 26 Apoptotic features associated with induction of apoptosis in
ZVAD.fmk treated cells 151
Figure 27 Biochemical effect of blocking caspase activity 153
Figure 28 Effects of inhibiting p38 activity 155
Figure 29 Verification of reduction in p38 activity in the presence
of SB203580 156
Figure 30 Inhibition of apoptosis in cells with inhibited caspase and
p38 activity 158
Figure 31 Protection from apoptosis by Bcl-2 overexpression 160
Figure 32 Decreased Akt phosphorylation in the absence of v-Src activity 169
Figure 33 Commitment to undergo apoptosis after 2 hours of v-Src
inactivation in serum-starved transformed Rat-1 cells 170
Figure 34 Decreased Akt phosphorylation in the presence of PI 3-kinase
inhibitor 171
Figure 35 Induction of apoptosis in serum-starved transformed Rat-1 cells
after addition of a selective PI 3-kinase inhibitor 173
Figure 36 LY294002 did not induce apoptosis in Rat-1 cells displaying normal
phenotype 174
Figure 37 Akt phosphorylation is decreased in cells treated with inhibitors
of caspases and p38, as well as those overexpressing Bcl-2 176
Figure 38 Variation in MAP kinase activity in serum-starved v-Src
transformed Rat-1 cells induced to undergo apoptosis in the 
absence of v-Src activity or in the presence of PI 3-kinase inhibitor 178
Figure 39 Inhibition of MAP kinase activity does not induce apoptosis in serum-
Starved transformed Rat-1 cells 180
Figure 40 PD98059 was able to inhibit MAP kinase activity but did not affect
Akt phosphorylation 181
Figure 41 Inhibition of MAP kinase activity at the same time as inhibition of 
PI 3-kinase activity does not increase the percentage of cells 
undergoing apoptosis 183
XIV
Figure 42 Pathways involved in mediation of v-Src induced survival 
signalling and the apoptotic pathway it impinges on, in 
transformed Rat-1 cells
List of Tables
Table heading
Table 1 Summary of copy number gains of fak  locus
In lung, colon, and breast tumour-derived cell lines
Table 2 Summary of copy number gains of fak  locus
In BICR lines derived from squamous cell carcinomas 
Of the head and neck
Table 3 Members of the caspase family
Abbreviations
ALV Avian Leukosis virus
AIF Apoptosis inducing factor
AP-1 Activaintg protein-1
BAD Bcl-XL/Bcl-2 associated death factor
CAD Caspases activated deoxyribonuclease
CAS Crk associated substrate
CDKs Cyclin dependent kinases
CE Chick embryos
CEF Chick embryo fibroblasts
CHO Chinese hamster ovary cells
CSF-1 Colony stimulating factor 1
CSK C terminal Src kinase
DAPI Diamidino-2-phenylindole hydrochloride
DIG Digoxigenin
DISC Death inducing signaling complex
DMEM Dulbecco’s modified Eagle’s medium
DMSO Dimethylsulphoxide
DNA Dioxyribonucleic acid
EC Endothelial cells
ECL Enhanced chemiluminescence
ECM Extracellular matrix
EGF Epidermal growth factor
ERK Extracellular regulated kinases
FADD Fas-associating protein with a death 
domain
FAK Focal adhesion kinase
FITC Fluorescein isothiocyanate
FRNK FAK related non kinase
GAP GTPase activating protein
Gly Glysine
GRAF GTPase regulator associated with FAK
GSK-3 Glycogen synthase kinae 3
GST Glutathione S Transferase
HLA Histocompatibility antigen
ICAD Inhibitor of CAD
ICE Interleukin 1|3 converting enzyme
IGF Insulin like growth factor
IL-2 Interleukin 2
ILK Integrin linked kinase
IRS-1 Insulin receptor substrate 1
JNK Jun N terminal kinase
LPA Lysophosphatidic acid
MAP Kinase Mitogen activated protein kinase
MEK MAP kinase kinase/ERK kinase
MEKK MEK kinase
MLC Myosin light chain
MLCK Myosin light chain kinase
NGF Nerve growth factor
OHT 4-hydroxy-tamoxifen
PAF Platelet activating factor
PAGE Polyacrylamide gel electrophoresis
PAK p2 1 -activated kinases
PARP Poly (ADP-ribose) polymerase
Pea Prostate cancer
PDGF Platelet derived growth factor
PDT Photodynamic therapy
PH Plekstrin homology domain
PI 3-kinase Phosphatidyl inositol 3-kinase
PIP Phosphatidylinositol monophosphate
PIP2 Phosphatidylinositol-4,5 bisphosphate
PIP3 Phosphatidylinositol tri phosphate
PKB Protein kinase B
PKC Protein kinase C
PTEN Paxillin and tensin homologue deleted on 
chromosome 1 0
Rb Retinoblastoma protein
REF Rat embryo fibroblasts
RGD Arg-Gly-Asp
RNA Ribonucleic acid
RSV Rous Sarcoma Virus
SAPK Stress activated protein kinase
s e e Squamous cell carcinomas
SEK-1 SAP-ERK kinase-1
Ser Serine
SH2 Src homology domain 2
PTB Phosphotyrosine binding domain
SH3 Src homology domain 3
SRE Serum regulatory element
SREBPs Sterol-regulatory element binding proteins
TdT terminal deoxynucleotidyl transferase
Thr Threonine
TNF Tumour necrosis factor
TRAIL TNF- related apoptosis inducing ligand
TUNEL TdT-mediated dUTP nick end labelling
Ts Temperature sensitive
Tyr Tyrosine
UV Ultra violet
VCAM-1 Vascular cell adhesion molecule
VEGF Vascular endothelial growth factor
xix
Aim
The study detailed in this report is essentially divided into two parts. The first half, 
Chapters 1, 3, and 4, concentrates on the importance and role of focal adhesion 
kinase (FAK) in tumour cells. FAK, as is discussed later in detail, is upregulated at 
protein level in several tumours and tumour cell lines and is also known to be 
important in integrin mediated cell survival and migration- both of which are 
essential for tumour development and progression. Chapter 1 (Introduction 1) 
outlines the role of integrins in focal adhesion signalling, and the importance of Src 
and FAK, two of the kinases known to localise at the focal adhesions, in its 
mediation. Based on studies reporting overexpression of FAK in tumours, initial 
experiments were carried out to determine whether overexpression at protein level 
was accompanied by genetic alterations, which could account for the upregulation at 
protein level (Chapter 3). At the same time, role played by FAK in protecting 
transformed cells from undergoing apoptosis was also investigated (Chapter 4). 
Results indicated that in the model system being studied, FAK proteolysis was not 
required for the induction of apoptosis. Therefore, the focus of the study shifted to 
characterisation of the apoptotic pathway activated in the system being studied, and 
also to investigate the survival pathway impinging on it to protect the transformed 
cells from dying. Chapter 5 reviews the role of some of the key molecules involved 
in mediation of apoptosis and cell survival. Results of the characterisation study are 
outlined in Chapter 6  and Chapter 7. The final chapter discusses the findings of this 
study in a general way and outlines some of the possibilities for future work.
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Chapter 1: Introduction 1
1
1.1 Signalling at the focal adhesions: A role for integrins
Cultured cells attach to the underlying substrate with the help of specialised 
membrane associated structures known as focal adhesions. They were first identified 
in electron microscopic studies of cultured fibroblasts when it was noted that some 
regions of the ventral surface were closer to the substrate than others (Abercrombie et 
al., 1971). They appear as tear shaped plaques at the ends of actin filament stress 
fibres (reviewed in Burridge et al., 1988). Besides providing sites of attachment for 
the membrane to the substrate, focal adhesions also serve the important structural 
role of anchoring and stabilization of the actin cytoskeleton and in mediating signals 
to the cell interior which regulate cell proliferation, differentiation, motility and 
survival (reviewed in Juliano and Haskill, 1993).
Focal adhesions have a complex molecular organisation. On the outside of the 
membrane lies the extracellular matrix (ECM). ECM is composed of glycoproteins, 
proteoglycans and glycosaminoglycans that are secreted and assembled locally to 
which cells adhere (reviewed in Hay, 1982). Thus, fibronectin, vitronectin, laminin, 
collagen, tenascin-C, thrombospondin and fibrinogen, all go to make up the ECM 
(reviewed in Otey, 1996; Boudreau and Jones, 1999). The primary transmembrane 
components of focal adhesions are the integrins (reviewed in Hynes, 1987; Hynes, 
1992). Integrins act as transmembrane receptors for ECM components on the outside 
of the cell, and interact with cytoskeletal and cytoplasmic components of the focal 
adhesions on the inside of the cell (Sastry and Horwitz, 1993; Pavalko and Otey,
1994). Actin binding proteins that co-localize with integrins at focal adhesions 
include, a-actinin, talin, tensin, paxillin, vinculin and tensin along with a diverse 
range of cytoskeletal proteins, protein kinases like focal adhesion kinase (FAK), c- 
Src, protein kinase C and integrin linked kinase (ILK) (reviewed in Kumar, 1998), 
and phosphatases, other signalling molecules, and proteins of unknown functions 
(reviewed in Craig and Johnson, 1996). Integrins interact with the cytoskeleton on 
the inside of the cell through their cytoplasmic domains. Thus, integrins form a 
physical link between the outside environment of the cell, like the ECM or other
2
cells, and the cytoskeleton, and other cytoplasmic proteins found to be concentrated 
at the focal adhesions (Figure 1).
3
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Figure 1 Signalling at the integrins: The diagram  outlin es so m e o f  the pathw ays 
involved  in m ediating integrin sign a llin g  to bring about ce ll proliferation , m igration and 
survival.
1.1.1 Integrins
Integrins are heterodimers of a  and |3 subunits (reviewed in Hynes, 1992). The 
subunits associate non-covalently to produce 22 different receptors (reviewed in 
Kumar, 1998; Aplin et al., 1998). Many integrins are expressed in specific cell types. 
For example, anb|33 is expressed in platelets and a 6 ^ 4  in epithelial cells. Integrins 
contain a large extracellular domain formed by the a  and p subunits, a 
transmembrane segment from each of the subunits and two short cytoplasmic 
carboxy terminal domains (Hogervorst et al., 1990; Suzuki and Naitoh, 1990). 
Extracellular domains bind to proteins of the insoluble ECM or to counter-receptors 
on other cells. Some integrins can also bind to soluble ligands such as fibrinogen. 
Most of the integrins recognise the RGD (Arg-Gly-Asp) sequence in their matrix 
ligands (reviewed in Ruoslahti and Pierschbacher, 1987; Ruoslahti, 1996). They are 
also capable of distinguishing between the different RGD containing ligands such 
that some bind, for example, to fibronectin while others do not (Kumar, 1998).
The interaction of integrin heterodimers with the ECM on the outside and the 
cytoskeleton on the inside, facilitates bi-directional signaling. The binding affinity of 
the integrins for the ligands can be altered by various physiological changes 
accompanying transduction of signals within the cell. For example, soluble agonists, 
such as thrombin or adenine nucleotides, activate platelet and leukocyte integrins not 
through direct interaction with the integrins but by binding to cellular receptors, 
which lead to engagement of classical signal transduction pathways mediated by G 
proteins and tyrosine kinases (Dustin and Springer, 1989). This process adds 
flexibility to integrin function and is indispensable for many of their functions 
(Schwartz et al., 1995).
The assembly of soluble, dimeric fibronectin into soluble fibrils is probably 
important in formation of the ECM (Schwartz et al., 1995). Several lines of evidence 
indicate that integrins also participate in matrix assembly. For example, Chinese 
hamster ovary (CHO) cells lacking asPi assemble a matrix only after reconstitution 
of the integrin by transfection (Wu et al., 1993). Also, overexpression of CX5 P1 
promotes matrix assembly and suppresses the transformed phenotype of CHO cells
5
(Giancotti and Ruoslahti, 1990). However, certain mesodermal structures form and 
cells can assemble a matrix in the absence of asPi (Yang et al., 1993). This indicates 
that although matrix assembly may require integrins in some cases, other receptors 
are able to substitute for particular integrins in other cases. Also, (X5 P1 are the only 
integrins so far implicated in matrix assembly (Schwartz et al., 1995). The finding 
that a number of cell lines expressing only low affinity as Pi did not assemble a 
fibronectin matrix (O’Toole et al., 1994), suggested that fibrillogenesis may be a 
function of high-affinity asPi. A study by Faull et al.} (1994) established that 
cytochalasins, which had been earlier found to reduce the process of fibrillogenesis, 
did not profoundly diminish the affinity of fibronectin binding to asPi. Since 
cytochalasins also inhibit actin polymerisation (Schliwa, 1982), this raised the 
possibility of the involvement of the cytoskeleton in the process (Schwartz et al.,
1995).
1.1.2 Signal transduction through ECM-integrin interaction
Adhesive interactions between cells and the ECM have long been known to play a 
vital role in embryonic development and in regulation of gene expression in adults 
(reviewed in Juliano and Haskill, 1993). Most of these responses are mediated by 
integrins (reviewed in Juliano and Haskill, 1993). Interest in the role of integrins in 
signalling was raised by studies reporting increased levels of tyrosine 
phosphorylation associated with integrin clustering at the focal adhesions. 
Specifically, clustering of integrins causes enhanced tyrosine phosphorylation of a 
120-130 kd protein complex (Kornberg et al, 1991). Another study on mouse 
fibroblasts reported the phosphorylation of ~ 1 2 0  kd protein, now known to be focal 
adhesion kinase (see section 1.3), after adhesion to fibronectin coated substrate 
(Guan et al., 1991). This change in tyrosine phosphorylation of a cellular protein was 
not evident on adhesion to non-specific ligands such as poly-L-lysine.
The ECM, through interaction with integrins, is now known to play an important role 
in regulating growth, differentiation, migration and survival in cells, via signals 
induced at the focal adhesions (reviewed in Hynes, 1992; Ruoslahti and Reed, 1994; 
Vuori and Ruoslahti, 1994).
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1.1.3 Evidence for role of ECM-integrin signalling in cell growth
Much of the evidence for the involvement of integrins in cell proliferation has come 
from studies showing activation of the mitogen-activated protein kinase (MAP 
kinase) pathway (Chen et al., 1994; Miyamoto et a l, 1996; Zhu and Assoian, 1995; 
Schlaepfer et a l, 1994; Wary et a l, 1996). MAP kinase is a major cellular signalling 
pathway that mediates effects of growth factor on cell cycle progression (reviewed 
below; reviewed in Marshall, 1994).
Chen et al, (1994) showed that adhesion of cells to substrates coated with ECM 
proteins, or with synthetic peptide containing the RGD sequence, causes activation of 
MAP kinases in 3T3 or REF52 fibroblasts. This activation of MAP kinases was 
specific to the binding of the integrins to fibronectin or laminin, and not to poly-D- 
lysine, a non-specific adhesion promoting peptide. This suggested that activation of 
MAP kinases was dependent on integrin engagement rather than just cell adhesion 
(Chen et a l, 1994). ERK 1 and ERK2, two conventional MAP kinases, were found 
to be activated by long term adhesion of NIH 3T3 cells to fibronectin, vitronectin or 
type IV collagen coated dishes (Zhu and Assoian, 1995). The stimulation of activity 
was gradual and associated with cell spreading rather than cell attachment.
Studies have also shown that activation of the MAP kinase cascade by some growth 
factors like epidermal growth factor (EGF) and platelet derived growth factor, is 
impaired when cells are held in suspension as compared with cells adhered to a 
fibronectin substratum (Lin et a l, 1997). When NIH 3T3 cells held in suspension 
were treated with either EGF or PDGF, there was only a very modest activation of 
MAP kinases. However, after about lOmin of cell adhesion to fibronectin-coated 
substrata, generic MAP kinases were found to be strongly activated (Lin et a l, 1997). 
Also, in the absence of EGF, adherent cells were again not able to activate MAP 
kinases fully. Specifically, experiments suggested that in non-adherent cells, the 
MAP kinase pathway is attenuated between Ras and Raf kinases (Lin et a l, 1997). 
Another study also showed that activation of the MAP kinase pathway by serum or 
growth factors is strongly dependent on integrin mediated cell adhesion to ECM
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(Renshaw et al., 1997). However, unlike Lin et al., (1997), this study showed that 
this effect occurs at the level of activation of MAP kinase/ERK kinase (MEK) by 
Raf, since endogenous Ras and Raf were found to be maximally activated by serum 
in non-adherent cells, while MEK was not (Renshaw et al., 1997). Integrins have also 
been shown to associate with growth factor receptors directly (Vuori and Ruoslahti,
1994). Insulin stimulation was found to promote association of the a vP3 integrin (a 
vitronectin receptor) with insulin receptor substrate-1 (IRS-1) (Vuori and Ruoslahti,
1994). IRS-1 is phosphorylated by insulin and insulin like growth factor (IGF) and 
associates with other signaling molecules. The interaction between a vP3 and IRS-1 
substantially enhances the growth stimulating effects of insulin and IGF and is 
specific to integrin a vp3 (Vuori and Ruoslahti, 1994).
Rho family GTPases like Rac and Rho, which are important regulators of the actin 
cytoskeleton, are now known to cooperate with Raf-1 to activate the ERK pathway 
(Frost et a l , 1997). These small G proteins have also been implicated downstream of 
integrin signaling as integrins were found to stimulate Rho mediated production of 
PIP2 (Giancotti, 1997).
Some groups have also reported that the activation of cyclins and cyclin-dependent 
kinases (cdk) requires cell adhesion (Fang et al., 1996; Zhu et al, 1996). The cyclin 
E-cdk2 complex, which is required for the Gl-S transition of the cell cycle, was 
activated in the late G1 phase in attached human fibroblasts, but not in fibroblasts 
maintained in suspension (Fang et a l, 1996). Cell adhesion regulates the activity of 
cyclin E-cdk2 by determining the extent of its association with the cdk inhibitors p21 
and p27 (Zhu et a l,  1996). Cell adhesion is also required for the induction and 
translation of cyclin D1 mRNA and the expression of cyclin A mRNA and protein 
(Zhu et a l, 1996).
1.1.4 Mechanism of integrin-mediated activation of MAP kinase pathway
Integrin mediated activation of MAP kinase pathway requires the activity of two 
main kinases known to localise to the focal adhesions (FAK) (Hanks et a l, 1992; 
Schaller et a l, 1992), and Src, which localises at the focal adhesions upon integrin
activation (Horvath et al., 1992; Clark and Brugge, 1993). Clustering of integrins 
causes activation of FAK through phosphorylation (Miyamoto et al., 1995). 
Autophosphorylation of FAK at Tyr 397 (Schaller et al., 1994) facilitates the binding 
of Src by a mechanism involving the SH2 and SH3 domains (Cobb et al., 1994; 
Thomas et al., 1998). Subsequent phosphorylation of FAK Tyr 925 by Src creates a 
binding site for Grb2 to FAK via the SH2 domain (Schlaepfer et al., 1994). Binding 
of FAK to Grb2 provides a link to the activation of the Ras signalling pathway 
(Schlaepfer and Hunter, 1996). Grb2 forms a complex with She, a SH2-PTB domain 
adaptor protein that links various tyrosine phosphorylated signal transducers to Ras 
(Pawson, 1995), and Sos, a Ras specific nucleotide exchange protein which activates 
Ras by converting it to its GTP-bound form (Bowtell et al., 1992). She is also a Src 
substrate (McGlade et al., 1992). Once converted to its GTP-bound form, Ras then 
binds to c-Raf and leads to its localisation to the plasma membrane, followed by 
activation (Jelinek et al., 1996). Activated Raf then phosphorylates and activates 
MEK, that can directly activate ERK1 and ERK2, the conventional MAP kinases 
(Peraldi et al., 1995). These kinases phosphorylate and a number of substrates that 
participate in cell cycle progression, including Elk-1, phospholipase A2 , and p90RSK 
(Renshaw et al., 1997). Phosphorylation of the ternary complex factors Elk-1 and 
SAP-1 regulates the transcription from the fos serum response element (SRE) and 
thus contribute to cell cycle progression (Wary et al., 1996).
In addition, integrin mediated activation of ERK2 can also be mediated by PI 3- 
kinase (King et al., 1997). PI 3-kinase is an enzyme that catalyses the 
phosphorylation of the inositol lipids and associates with FAK through the SH2 
domain of its p85 subunit (Chen and Guan, 1994). PI 3-kinase association with FAK 
is dependent on the autophosphorylation of FAK at Tyr 397 (Chen et al., 1996a). 
Integrin-mediated activation of ERK2, MEK and Raf-1 were about 80% inhibited by 
PI 3-kinase inhibitors LY294002 and wortmannin (King et al., 1997). PI 3-kinase 
was shown to function upstream of Raf-1, but downstream of Ras during integrin 
mediated activation of ERK2 (king et al., 1996).
Other studies have shown FAK to regulate cell proliferation through CAS (Crk 
associated substrate) (Oktay et al., 1999). Binding of CAS to FAK (Polte and Hanks,
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1995) and its phosphorylation by Src (Polte and Hanks, 1997; Vuori et al., 1996) 
leads to the subsequent recruitment of Crk, a SH3 domain-containing adaptor protein 
(Mayer et al., 1988) to the complex, followed by activation of the JNK pathway 
(Oktay et al., 1999). Activation of the JNK pathway was also found to be necessary 
for proper progression through the G1 phase of the cell cycle and thus cell 
proliferation (Oktay etal., 1999).
Inspite of all the evidence implicating FAK in the mediation of MAP kinase pathway, 
a study has shown that in some cases, integrin-mediated activation of MAP kinase 
pathway can be independent of FAK (Lin et a l, 1997). Expression of FRNK, a FAK 
related non-kinase, discussed in section 1.3, as a dominant negative inhibitor of FAK 
phosphorylation, was shown to have no effect on integrin mediated activation of 
MAP kinase suggesting the existence of at least two distinct integrin signalling 
pathways in fibroblasts (Lin et al., 1997).
1.1.5 Role of integrins in cell migration
Cellular migration plays an important role in development, wound healing, immune 
defense and metastasis. It is generally accepted that the driving force for cell 
movement requires re-organisation of the actin cytoskeleton, directing protrusions at 
the front of the cell and retraction at the trailing edge (reviewed in Nobes and Hall, 
1999). Dynamic regulation of focal adhesions is required for making new points of 
attachments at the front and detachment of the old ones at the rear. Also, the ability 
of a cell to form focal adhesions correlates with its ability to assemble an organised 
cytoskeleton, which, in turn, is a prerequisite for cell spreading and migration 
(Dejana et al., 1987).
Binding of the integrins to the ECM components is essential for cell spreading and 
migration (Leavesly et al., 1992). However, binding alone is not enough and the 
integrins are required to cluster at the focal adhesions in order to mediate cell 
spreading and migration (Leavesly et al., 1992). FG human carcinoma cells failed to 
induce migration on vitronectin substrate in spite of expressing one of the vitronectin 
receptors, a vp5 integrin, the defect being in failure to localise to the focal adhesions.
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However, when these cells were transfected with a cDNA encoding the human P3 
integrin subunit and were thus able to express a vP3 , an integrin that binds to 
vitronectin and also clusters at the focal adhesions, the cells were able to migrate on a 
vitronectin matrix (Leavesly et a l, 1992). Thus, the P subunit seems to play an 
important role in cell migration. Mutational analysis of the Pi subunit showed that the 
structural basis for integrin/focal contact formation might depend on three domains 
within the cytoplasmic tail of Pi (Reszka et a l, 1992). Pi and P3 are extremely well 
conserved in each of these regions (Leavesly et a l, 1992).
1.1.6 Mechanisms of integrin-mediated cell migration
Recent studies have shed more light on the molecular mechanisms of cell migration. 
Strength of adhesions between a cell and its matrix, as regulated by receptor affinity, 
organization of focal adhesions and substrate concentration have been implicated in 
cell migration (Huttenlocher et al., 1996). Increase in ligand affinity, decreases cell 
movement. Cells in which the integrins were locked in high affinity state showed 
maximal migration at lower substrate concentrations than cells expressing low 
affinity receptors (Huttenlocher et al., 1996).
MAP kinase pathways have also been shown to be involved cell migration. MAP 
kinase (ERKs) was found to influence cell movement by phosphorylating and, 
thereby, enhancing myosin light chain kinase (MLCK) activity leading to 
phosphorylation of myosin light chains (MLC) (Klemke et a l, 1997). MLC, in turn, 
promotes cytoskeletal contraction necessary for cell movement. Inhibition of MAP 
kinase activity decreased MLCK activity, MLC phosphorylation and cell migration 
on ECM proteins (Klemke et a l, 1997). Thus, integrin-induced MAP kinase activity 
may contribute to integrin-dependent cell motility.
Stress fiber formation and membrane ruffling have been associated with the 
activation of small G proteins like Rho, Cdc42 and Rac (Nobes and Hall, 1994; 
Parsons, 1996). Analysis of Swiss 3T3 fibroblasts has also implicated Rac, Rho and 
Cdc42 in cell motility. Studies found Rac to be essential for the protrusion of 
lamaellipodia and forward movement, Cdc42 was required to maintain cell polarity
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and Rho was required to maintain cell adhesion during movement (Nobes and Hall, 
1999). The Rho family G proteins are also well known for their ability to induce 
rearrangement of filamentous actin, a prerequisite for cell motility (Sells et al., 1999). 
Cells expressing wild type or constitutively active PAK, an effector protein of Rho 
GTPases, were more motile than their normal counterparts (Sells et al., 1999). In 
addition, cells expressing the kinase-defective form of PAK showed reduced 
persistence of movement. Although highly motile, they had defects in directed 
motility (Sells et al., 1999). Expression of constitutively activated PAK was 
accompanied by increased phosphorylation of MLC (Sells et al., 1999).
Two of the most likely regulators of cell motility are the non-receptor tyrosine 
kinases of the Src family and FAK. Rapid turnover of focal adhesion contacts, 
induced by these tyrosine kinases, therefore seems to play a major role in cell 
migration. Transformation of cells by v-Src stimulates not only the phosphorylation 
of FAK but also its degradation in chicken embryo fibroblasts (CEF), causing 
disruption of focal adhesions resulting in cell rounding and detachment (Fincham et 
al., 1995). In this study, impaired morphological transformation was linked to 
inefficient degradation of FAK suggesting that phosphorylation of FAK by v-Src 
stimulates turnover and loss of focal adhesions. More recently, v-Src induced FA 
turnover was shown to be a critical component of motility (Fincham and Frame,
1998). CAS and its adapter protein Crk, also seem to be involved in mediating cell 
migration (Cary et al., 1998; Klemke et al., 1998). As stated before, CAS binds to 
FAK (Polte and Hanks, 1995) and is phosphorylated by Src (Vuori et al., 1996). 
Expression of CAS or Crk in FG cells was sufficient to promote cell migration which 
depended on its anchorage dependent phosphorylation facilitating an SH2-mediated 
complex with Crk (Klemke et al., 1998). Resulting migration could be disrupted by a 
dominant negative form of Rac but not Ras (Klemke et al., 1998).
1.1.7 Role of integrins in cell survival
The role of integrins in cell survival was suggested by a study carried out by 
Meredith et al., (1993). These workers investigated the potential role of ECM as a 
survival factor for human endothelial cells and found that they underwent apoptosis
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in the absence of ECM interactions. Induction of apoptosis was specific to integrin- 
ECM interactions since it was prevented by plating the cells on an immobilized 
integrin Pi antibody but not by antibodies against either class 1 histocompatibility 
antigen (HLA) or vascular cell adhesion molecule-1 (VCAM-1) (Meredith et a l,
1993). A later study termed this type of detachment induced apoptosis as ‘anoikis’ 
(Frisch and Francis, 1994). Disruption of cell-matrix interactions induced apoptosis 
in MDCK epithelial cells. However, normal fibroblasts did not die under similar 
conditions. Myc/Ras or ElA/Ras transformed REF (Rat embryo fibroblasts), 
however, did undergo apoptosis in the absence of matrix adhesion (McGill et al, 
1997). Also, c-Myc induced apoptosis in CEF on serum-withdrawal was suppressed 
by plating the cells on ECM components, collagen and fibronectin (Crouch et al.,
1996). Apoptosis was also prevented by a p i specific integrin antibody (Crouch et 
ah, 1996). The role of different kinases and signaling pathways which lie 
downstream of the integrins in mediating cell survival are introduced in sections 1.2 
and 1.3. Epithelial cells isolated from pregnant mouse mammary gland die by 
apoptosis in culture, but the process of cell death is suppressed by integrin mediated 
cell adhesion to the basement membrane (Pullan et al., 1996). In addition, a 
hormonal signal from insulin or insulin like growth factor was found to be necessary 
to suppress mammary cell apoptosis, indicating an ECM and soluble factor 
cooperation in providing the survival signal (Farrelly et a l, 1999).
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1.2 Src
c-Src, one of the enzymatic components of the integrin-linked focal adhesions, was 
first discovered as the normal cellular homologue of v-Src, the transforming gene of 
Rous Sarcoma Virus (RSV), an acutely transforming avian retrovirus which induces 
sarcomas in chickens (Stehelin et al., 1976). The isolation of c-Src led to the concept 
of the existence of cellular proto-oncogenes from which oncogenes are derived.
Src is a member of non-receptor tyrosine kinases defined by a common modular 
structure (Neet and Hunter, 1996). The Src family is the largest and the best studied 
family of cytoplasmic protein tyrosine kinases. 9 members have so far been placed in 
this group. They are: c-Src, c-Yes, Fyn, c-Frg, Yrk, Lck, Lyn, Hck and Blk (Neet and 
Hunter, 1996). Like Src, Yes and Frg were first described as transforming proteins of 
retroviruses (Kitamura et al., 1982; Naharro et al., 1983). Lck was discovered as an 
overexpression protein in a transformed cell line (Martha et al., 1985). The other 
members of the family were identified by the screening of cDNA libraries. Src, Yes, 
and Fyn are widely expressed proteins whereas, expression of rest of the members of 
the family is restricted, predominantly to the immune system.
1.2.1 Structure of Src
The basic structure of Src is outlined in Figure 2. The first 16 N-terminal amino acids 
form the myristylation domain. The myristylation group is added to the glycine 
residue at position 2 of the protein. Myristylation is a fatty acid modification that is 
determined by the first seven amino acids of the molecule and causes association 
with the plasma membrane (Resh, 1994). Myristylation-defective mutants of v-Src do 
not associate with the cellular membranes and fail to induce cell transformation 
(Cross et al., 1984; Kamps et al., 1986). Myristylation of Src is necessary but not 
sufficient for membrane localisation as there are myristylated variants of v-Src which 
fail to associate with cellular membranes (Stoker et al., 1986). Besides the 
myristylation domain, amino acids 38-111 also seem to be important in membrane
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localisation. Fusion of this region to pyruvate kinase, a cytoplasmic protein resulted 
in its association with the plasma membrane (Kaplan et al., 1990). In addition, 
several of the other Src family members, such as Lck and Fyn undergo palmitylation 
of the cysteine residues near their amino terminus (Resh, 1994; Koegl et al., 1994). 
Unlike myristylation, palmitylation is reversible and is likely to increase membrane 
binding efficiency (Alland e ta l,  1994).
Carboxy terminal to the myristylation domain lies a 50-80 amino acid sequence that 
varies highly among the various family members and is called the unique domain 
(Figure 2). Deletions within this domain have little effect on c-Src kinase activity but 
the deletion of the whole domain can result in kinase activation (Nemeth et al., 
1989). This domain contains a number of phosphorylation sites. Association of 
cellular proteins with the unique domains of Lck and Lyn has been reported (Shaw et 
al., 1989; Turner et al., 1990; Pleiman et al., 1993), perhaps suggesting a role for this 
domain in substrate recognition. In support of this idea, recent studies have found 
that phosphorylation of the NMDA (N-methy D-aspartate) receptor by Src is 
dependent on the Src unique region (Yu et al., 1997). Also, mutation of certain Ser 
and Thr residues within the unique domain, which are phosphorylated upon Src 
activation during M phase, was found to reduce Src activity but not eliminate it 
(Shalloway et al., 1992).
Carboxy terminal to the unique domain is a Src homology 3 (SH3) domain (amino 
acid residues 88-139) followed by a Src homology 2 (SH2) domain (amino acid 
residues 148-250). These domains are shared not only with the members of the Src 
family but also with a variety of unrelated proteins involved in signal transduction 
and mediate specific protein-protein interactions (reviewed in Pawson and Gish, 
1992).
In c-Src, the ligand binding sites of the SH3 domain have been identified by chemical 
shift perturbation studies (Yu et al., 1992). The domain comprises of a hydrophobic 
binding site on the surface of the protein that is lined with the side chains of 
conserved aromatic amino acids (Yu et al., 1992). It has been shown to preferentially
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Figure 2 Structures of c-Src and v-Src: D om ain  structures o f  c-Src and v-Src are 
show n. M yristy lation  dom ain is necessary  for m em brane attachm ent o f  the protein. M yristylation  
group is added to the G ly residue at p o isition  2. T he S H 2 and SH 3 dom ains are required for 
protein-protein  interactions and a lso  regulate c-Src activ ity . M utation o f  L ys295  results in a 
cata lytica lly  in active  protein. T yr416 is a m ajor autophosphorylation  site in Src and its 
phoshorylation  is required for tyrosine k inase function . Apart from  a num ber o f  other point 
m utations, v-Src d iffers from  c-Src in lack ing the regulatory dom ain , the lack o f  w h ich  renders 
it con stitu tively  active.
bind peptides with the consensus sequence RPLPXXP (Alexandropoulos et al., 
1995).
The SH2 domain of v-Src was originally identified as a 100 amino acid noncatalytic 
domain (Sadowski et al., 1986). Crystal structure analysis of v-Src SH2 domain 
complexed with a high affinity phosphopeptide has revealed two binding pockets 
(Waksman et al., 1992 and 1993). One of the two binding pockets interacts with 
phosphotyrosine and contains a highly conserved FLVRES sequence spanning from 
amino acid residues 172 to 177.
The catalytic or the kinase domain of Src family protein tyrosine kinases lies towards 
the carboxy-terminus. The domain encompasses amino acid residues 250 to roughly 
516. It is also known as the SHI domain and is the most highly conserved region 
among Src family members. This domain shows a high degree of homology to the 
catalytic domains of other protein tyrosine and serine/threonine kinases. These 
strictly conserved residues are thought to be important for the binding of ATP and the 
phosphotransfer reaction (Hunter and Cooper, 1985). An invariant lysine residue at 
position 295 in Src is believed to be involved in proton exchange during the 
phosphotransfer reaction (Kamps and Sefton, 1986). Substitution of this residue with 
methionone, glutamic acid, arginine, or histidine results in a kinase dead form of the 
protein (Kamps and Sefton, 1986).
A major site of auto-phosphorylation lies within the kinase domain in a region called 
the activation loop at position 416 (Smart et al., 1981). Autophosphorylation appears 
to occur mainly by an intermolecular mechanism (Cooper and MacAuley, 1988). 
Mutation of the autophosphorylation site leads to decreased kinase activity 
(Schwartzberg, 1998). It has also been speculated that this site might play an 
important role in the regulation of the interaction of Src with its substrates (Superti- 
Furga and Courtneidge, 1995).
At the extreme carboxy terminus of the c-Src molecule lies a regulatory domain. This 
domain corresponds to residues 517 and 531 in c-Src. Phosphorylation of tyrosine
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residue 527 is critical for the regulation of Src family protein tyrosine kinase catalytic 
activity (Cooper et al., 1986).
1.2.2 Regulation of c-Src activity
Evidence for the involvement of phosphorylation in regulation of c-Src came from 
the study which showed that c-Src activity is reduced in the presence of 
phosphotyrosine protein phosphatase inhibitor, sodium vanadate (Courtneidge,
1985). A later study suggested that the difference in the transforming ability and 
kinase activity of c-Src and v-Src was due to the presence of Tyr527 in c-Src, whose 
phosphorylation was responsible for the negative regulation of the molecule (Cooper 
et al., 1986). Substitution of this residue with phenylalanine results in activation of 
the c-Src kinase domain (Kmiecik and Shalloway, 1987). Phosphorylation of Tyr527 
is carried out by another tyrosine kinase, Csk (cellular Src kinase) (Nada et al., 1991; 
Okada et al., 1991). Csk-deficient mice, generated by gene targeting in embryonic 
stem cells were found to exhibit a complex phenotype including neural tube defects 
and these mice die during gestation (Imamoto and Soriano, 1993). Cells derived from 
these embryos showing increase in Src kinase activity and a reduction, but not 
elimination of Tyr527 phosphorylation. This suggests that other protein kinases can 
substitute for Csk or that, as it does to a limited extent in vitro (Cooper and King,
1986), autophosphorylation of this residue takes place in vivo.
The SH2 and SH3 domains are also important in regulating c-Src activity, as 
mutations of either of these domains can lead to c-Src activation (Parsons and Weber, 
1989). These observations lead to the proposal of model in which phosphorylated 
Tyr-527 interacts intramolecularly with Src’s own SH2 domain, leading to the 
distortion or closing of the kinase domain and thus inactivation of the protein. 
According to this model, dephosphorylation of the regulatory phosphotyrosine 
residue releases the SH2 domain and makes c-Src adopt an ‘open’, catalytically 
active conformation. The role of the SH3 domain was though to be aiding in the 
binding of the SH2 domain to Tyr527 by binding to some proline rich sequence 
(Courtneidge et a l, 1993b). Recent crystallographic studies of structure of c-Src and 
other members of the Src family, such as Hck (haematopoietic cell kinase) and Lck,
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provide a more detailed understanding of these interactions (Yamaguchi and 
Hendrickson, 1996; Sicheri et a l, 1997; Xu et a l, 1997). It is now clear that the 
kinase domain remains exposed during interaction between the SH2 domain and 
Tyr527. However, the SH3 domain was shown to interact with the linker connecting 
the SH2 domain to the catalytic domain (Sicheri et a l, 1997; Xu et a l, 1997), as 
shown in Figure 3. The role of the SH2 domain appears to be to position the SH3 
binding site, and it is the SH3 interaction that provides a direct connection to the 
regulation of kinase activity (Sicheri et a l, 1997). It was also shown that elimination 
of the SH3 domain-linker interaction, caused a higher increase in Hck activity than 
did displacement of SH2 domain interaction with phosphorylated Tyr527 (Moarefi et 
a l, 1997). Inactivation of the kinase may therefore result from torsional constraint 
where the dual binding of the SH2 and SH3 domains prevents free movement within 
the kinase domain (Schwartzberg, 1998).
In addition to Tyr527, Tyr416, the presumed autophosphorylation site of Src, may 
also play a role in regulation of Src activity. Autophosphorylation of tyr416 has been 
shown to be required for the efficient transformation by host range mutants of v-Src 
(DeClue and Martin, 1989; Woods and Verderame, 1994). Though, c-Src is only 
phosphorylated at Tyr416 in vitro, and not in vivo (Smart et a l, 1981; Patschinsky et 
a l, 1982), mutation of Try416 to phenylalanine in c-Src was able to eliminate its 
partial transforming activity, suggesting that transient or otherwise restricted 
phosphorylation of Tyr416 is important for c-Src function (Kmiecik and Shalloway,
1987). Also, the mutation did not significantly alter the kinase activity of c-Src.
1.2.3 From c-Src to v-Src
The v-src oncoprotein was created by transduction of c-src by avian leukosis virus 
(ALV), which became RSV (Figure 2). (Swanstrom et a l, 1983). The transduction 
event was accompanied by 19 C-terminus amino acids of c-Src being replaced by 12 
novel amino acids in v-Src (Takeya and Hanafusa, 1983). This included tyrosine 
residue 527, which, as mentioned above, is critical for the regulation of the protein. 
The substitution generated a constitutively activated form of the Src protein. In 
addition, v-src differs from its normal cellular counterpart by a number of point
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Figure 3 Regulation of c-Src activity: (a) (adapted from Thomas and Brugge, 1997) 
In its inactive state, c-Src is phosphorylated at Tyr527 which lead to its binding to the 
SH2 domain. Also, SH3 domain interacts with the linker domain, which lies between 
the kinase domain and the SH2 domain, and regions of the catalytic domain. These 
interactions create conformational changes that prevent the interaction of the 
substrate with the kinase domain, thus regulating the activity of the protein, (b) 
Activation of c-Src requires dephosphorylation of Tyr527 and phosphorylation of 
Tyr416, (c) which results in an ‘open’ conformation, allowing the kinase activity of 
the protein.
Inactive c-Src
N
A ctivation  o f  c-S rc
Phosphorylation
P-527 <  Dephosphorylation
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mutations which it accumulated after the transduction event (Reviewed in Jove and 
Hanafusa, 1987).
Expression of v-Src induces transformation of cells. v-Src localises at the plasma 
membrane (Levinson et al., 1981). Transformation is accompanied by three major 
phenotypic features (reviewed in Jove and Hanafusa, 1987). These include, a change 
in cell morphology to a round, more refractile type, proliferation of cells in low 
serum conditions and anchorage independence. The actin cytoskeleton undergoes 
gross intracellular alteration upon cell transformation (David-Pfeuty and Singer, 
1980) and there is a dramatic reduction in the production of fibronectin matrix 
(Olden and Yamada, 1977). The transforming ability of v-Src, in part, depends on its 
mitogenic action. Cell transformation by v-Src is accompanied by the constitutive 
activation of mitogenic signaling from pathways such as the MAP kinase pathway, 
which is permanently active in fibroblasts transformed by v-Src (Gupta et al., 1992). 
This is thought to lead to the activation of transcription factors like AP-1 (Catling et 
al., 1993), and thus contribute to cell cycle progression.
Temperature-sensitive (ts) mutants of v-Src have proven valuable in many studies 
investigating the signal transduction pathways modulated by v-Src to confer 
transformation. Many of these mutants were obtained by random isolation of single 
foci of transformation produced at the permissive temperature by mutagenised virus 
(Wyke, 1973; Wyke, 1975; Wyke, 1976). The mutants are generally classed into two 
groups, C and T. Class T mutants are defective only in transforming properties at the 
non permissive temperature while class C mutants have a coordinate lesion in both 
cell transformation and viral replication. All the mutant were found to be 
transforming at 35°C and selected for inability to transform at 41°C (Wyke and 
Linial, 1973). One of these mutants, ts LA29 v-src, was used in the experiments 
reported in this thesis and is described in detail in the following section. Generation 
of a c-Src temperature-sensitive mutant has also been described (Koegl et al., 1993). 
Mutation of Gly 478 to Asp rendered both wild type c-Src and its activated allele c- 
Src (Y527F) temperature sensitive. Rat-1 fibroblasts infected with the temperature- 
sensitive mutant of c-Src (Y527F) displayed a transformed phenotype when grown at 
34°C but not at 39°C (Koegl et al., 1993).
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1.2.4 ts LA29: A v-Src mutant
ts LA29 v-src belongs to the T class of temperature sensitive mutants and thus, as 
mentioned before, its defective only in transformation ability at the non permissive 
temperature (Wyke, 1973). The kinase activity of the protein was found to decrease 
more than five folds on being shifted from the permissive to the non permissive 
temperature (Stoker et al., 1984).
ts LA 29 v-src differs from the wild type v-Src at three amino acid residues. (Welham 
and Wyke, 1988). All three of these mutations lie within the kinase domain. The 
alterations include a change at residue 351 from lys to arg, at 375 from ala to thr and 
at 507 from pro to ala. A mutation in the 3’ terminal 100 nucleotides of the coding 
region for ts LA29 v-Src had been shown to confer temperature sensitivity (Fincham 
et al., 1982). Studies with chimeric proteins showed that only one of the mutations at 
residue 507 accounts for all the temperature sensitive characteristics (Welham and 
Wyke, 1988). However, cells infected with the chimeric virus encoding only the 
alanine substitution at 507 were found to have a fusiform morphology suggesting that 
this mutation also has other effects on the function of v-Src and that other mutations 
somehow compensate for these effects (Welham and Wyke, 1988). A mutation at 
residue 427 was found to restore the wild type phenotype. The mechanism by which 
temperature sensitivity is conferred is not known. It can be speculated that upon shift 
to non permissive temperature, a conformational change (perhaps analogous to that 
found in c-Src) mediated by residue 507, restricts the kinase activity of the protein.
The transformed phenotypes of ts LA29 v-Src is similar to that wild type v-Src 
(Wyke and Linial, 1973; Stoker et al., 1984). At the permissive temperature, 50% of 
ts LA29 v-Src protein was found in the membrane in contrast to 80% of the wild type 
protein but was sufficient for cell transformation (Stoker et al., 1986). Shift to non 
permissive temperature did not change the ability of the mutant protein to incorporate 
myristic acid but only 15% of the protein localises to the membrane (Stoker et al.,
1986). Also, like the wild type protein, transformation by ts LA29 v-Src mutant also 
reduces production of fibronectin matrix and causes redistribution of actin and a- 
actinin.
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Studies using ts LA29 v-Src mutant have revealed the importance of mitogenesis in 
v-Src transformation of cells (Wyke et a l, 1993; Johnson et al., 1998). Experiments 
with ts v-Src mutant have shown that v-Src activity is required at two points in the 
cell cycle- at the G0/G1 transition and at the Gl/S transition (Wyke et al., 1993). 
Activity of AP-1 transcription factor is required for the mitogenic function of 
tsLA29 v-Src (Frame et a l, 1994; Wyke et al., 1995). The transformed Rat-1 cells 
traverse the G1 phase of the cell cycle more rapidly and fail to exit cycle efficiently in 
response to serum starvation and cell confluence (Johnson et al., 1998).
1.2.5 Role of c-Src in Growth factor signalling
The protein tyrosine kinase activity of c-Src has been found to be important in 
signaling from certain tyrosine kinase growth factor receptors, like platelet derived 
growth factor (PDGF) and colony stimulating factor-1 (CSF-1) (Gould and Hunter, 
1988; Courtneidge et a l, 1993a). On binding to their respective ligands, the receptors 
activate their own intrinsic tyrosine kinase activity. This leads to the 
autophosphorylation of tyrosine residues within the molecule. One of these 
phosphorylated tyrosines then binds to the SH2 domain of Src and activate it 
transiently (Ralston and Bishop, 1985; Kypta et a l, 1990). Binding and activation of 
c-Src by the PDGF and the CSF-1 receptors is important for their function. Also, 
microinjection of kinase-defective c-Src or injection of antibodies specific for c-Src 
were able to inhibit PDGF induced entry into S-phase of NIH 3T3 cells after serum- 
starvation (Twamley-Stein et al., 1993). There is also evidence that that c-Src may be 
involved in epidermal growth factor (EGF) receptor signaling. Overexpression of c- 
Src in murine fibroblasts results in enhanced incorporation of [ H] thymidine into 
DNA in response to EGF stimulation (Luttrell et a l, 1988). c-Src associates with 
phosphorylated EGF receptor via its SH2 domain (Luttrell et al., 1994). However, a 
recent study has reported that c-Src and other members of the Src family kinases are 
dispensable for PDGF induced signalling (Klinghoffer et al., 1999). Cells lacking 
functional Src, Yes and Fyn were found to be fully competent to respond to PDGF in 
assays for substrate phoaphorylation, myc induction, entry into S phase, cell 
proliferation and chemotaxis (Klinghoffer et a l, 1999).
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1.2.6 Signal-Transduction pathways downstream of Src in mediation of growth 
factor signalling
A study of augmented mitogenic response to EGF in c-Src overexpressing murine 
fibroblasts suggested that increased level of tyrosine phosphorylation of GAP- 
associated proteins, p62 and p i90, resulting in higher levels of active Ras, lie 
downstream of c-Src (Chang et a l, 1993). Other studies have also shown 
requirement of Ras activity for v-Src transformation (Smith et a l, 1986). The 
connection between Src and Ras is an SH2 containing protein called She, which is a 
Src substrate (McGlade et a l, 1992). Phosphorylation of She on tyrosine promotes 
formation of a complex of She, Grb2 (a SH2 and SH3 domain containing adaptor 
protein) and Sos (a Ras specific nucleotide exchange protein), which activates Ras by 
converting it to its GTP-bound form (Egan et a l, 1993; reviewed in Courtneidge,
1994).
c-Myc, another transcription factor activated and growth factor signalling (Armelin et 
a l, 1984) and is important in cell proliferation (Kelly et a l, 1983; Biro et a l, 1993). 
c-Myc has been implicated in c-Src-mediated growth factor signalling (Barone and 
Courtneidge, 1995). The block in PDGF signalling elicited by dominant negative Src 
in NIH 3T3 cells were rescued by injection of c-Myc into the nucleus (Barone and 
Courtneidge, 1995).
Several studies have confirmed the critical role played by its kinase domain in 
transducing mitogenic signals (Wyke et a l, 1993; Johnson et a l, 1998). 
Overexpression of c-Src has also been reported to play a role in regulating mitosis in 
fibroblasts (Chackalaparampil and Shalloway, 1988). The stimulation of the kinase 
activity of c-Src during mitosis was accompanied by phosphorylation of serine and 
threonine residues on c-Src by Cdc2 kinase (Shenoy et a l, 1989; Morgan et a l, 
1989). A 68 kd protein, also known as SAM68 (Src associated during mitosis), has 
also been identified as a protein which is phosphorylated and bound by c-Src 
activated during mitosis (Fumagalli et a l,  1994; Taylor and Shalloway, 1994). A 
study suggesting a role for c-Src in G2/M transition during the cell cycle have
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reported that SAM68 is unlikely to participate at this stage but may be an important 
effector later in mitosis (Roche et al., 1995).
1.2.7 Role of c-Src in integrin-mediated signalling
v-Src localisation to the focal adhesions first suggested the role of v-Src in integrin 
signalling (Shriver and Rohrschneider, 1981; Stoker et al., 1986). Also, translocation 
of c-Src to the cytoskeleton during platelet activation is dependent on the integrins, 
again suggesting functional connection between integrins and c-Src (Horvath et al., 
1992; Clark and Brugge, 1993). Transformation of cells by v-Src results in tyrosine 
phosphorylation of several components of the cortical cytoskeleton and focal 
adhesions (Hirst et al., 1986; reviewed in Thomas and Brugge, 1997). Fibronectin 
stimulated activation of ERK was reduced in c-Src null fibroblasts (Schlaepfer et al.,
1997). However, a truncated Src molecule lacking the kinase domain has been 
demonstrated to restore partial activation of ERK, thus suggesting that at least in this 
case, the role played by Src seems to be more of an adaptor protein rather than that of 
a kinase (Schlaepfer et al., 1997).
c-Src has been implicated in regulation of cell adhesion (Kaplan et al., 1995). 
Fibroblasts derived from src-/- mice were found to be defective in initial cell 
spreading (Kaplan et al., 1995). Defects in phosphorylation of CAS and a decrease in 
MAP kinase activation in response to plating on fibronectin were linked to this 
defect, indicating that Src is critical in pathways downstream of integrin crosslinking 
(Kaplan et al., 1995). However, in the case of regulation of cell adhesion, the kinase 
domain of Src does not seem to be important. In fact, defects in integrin signaling in 
src-/- cells could be complemented, in part, by kinase inactive molecules, generated 
either through point mutations or the truncation of the entire kinase domain (Kaplan 
et al., 1995).
1.2.8 Role of c-Src in integrin-mediated cell migration
Although there have been reports that c-Src is not involved in cell motility (Kundra et 
al., 1994; Rodier et al., 1995), most studies carried out using both v-Src and c-Src
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function have shown its importance in integrin mediated cell migration (Hall et al., 
1996; Fincham and Frame, 1998; Klinghoffer et al., 1999). c-Src is implicated in 
hyaluron receptor RHAMM-induced motility of mouse cells, an effect requiring Src 
catalytic activity (Hall et al., 1996). Cells derived from mice null for c-Src, Yes and 
Fyn were found to have reduced motility in vitro (Klinghoffer et al., 1999). 
Fibronectin-induced tyrosine phosphorylation of focal adhesion proteins, including 
FAK, was nearly eliminated in the absence of Src, Fyn and Yes (Klinghoffer et al.,
1999). Both the kinase domain and the myristylation domain are required for the 
mediation of this function. Binding of Src to FAK through the SH2 and SH3 domains 
(Schaller et al., 1994; Thomas et al., 1998), followed by phosphorylation and 
degradation of FAK by v-Src is though to be important during cell migration 
(Fincham and Frame, 1998).
1.2.9 Role of Src in integrin-mediated cell survival
v-Src has also been implicated in integrin mediated survival signaling. Frisch and 
Francis, 1994, showed that v-Src transformation was able to protect MDCK cells 
from detachment induced apoptosis. Other studies have also linked v-Src to survival 
signaling. Transformation by activated c-Src rendered Myc/Ras or ElA/Ras 
transformed REF cells selectively resistant to adhesion-dependent apoptosis (McGill 
et al., 1997). It has been recently shown that inhibtion of c-Src kinases expression 
activity results in the induction of cell death in DHER14 cells (Kami et al., 1999). 
STAT3, a protein known to play a role in protection from apoptosis, has been shown 
to act downstream of v-Src and is required for cellular transformation by it 
(Bromberg, 1998).
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1.3 Focal Adhesion Kinase
Focal adhesion kinase or FAK was first identified in 1992 by two groups of workers 
at the same time (Schaller et al., 1992; Hanks et a l, 1992). It was identified as a v- 
Src substrate required in oncogenic transformation of chick embryo (CE) cells 
(Schaller et al., 1992). Using a PCR based technique, it was isolated as a cDNA 
encoding a protein, ppl25, which was found to be a major phosphotyrosine 
containing protein in untransformed cells that exhibited an increase in 
phosphotyrosine in v-Src transformed CE cells (Schaller et al., 1992). They proposed 
the name focal adhesion kinase because it was found to localise to the focal 
adhesions. At the same time, it was identified by a homology based cDNA cloning 
strategy (Hanks e ta l,  1992).
1.3.1 Structure of FAK
Immunoflurescence localisation experiments showed that FAK is a component of 
focal adhesions (Hanks et al., 1992). FAK is a non-receptor tyrosine kinase (Figure 
4). The molecular structure of FAK is different from other non-receptor tyrosine 
kinases like c-Src in that it lacks SH2 and SH3 domains. The kinase domain lies in 
the middle portion of FAK and comprises about one third of the FAK protein. A 
region has been identified in the carboxy terminus of FAK, specifically in residues 
856- 1012, that is essential for efficient localization of FAK to adhesion sites 
(Hildebrand et al., 1993). This was determined by the use of FAK variants which 
contained mutations in this region and failed to localise properly to the focal 
adhesions. Also, when this sequence was added to other non-FAK related proteins 
they localised to the focal adhesions. These results were further supported by work 
which showed that FRNK, an alternatively spliced product transcribed from fak gene, 
contains only the carboxy terminus region of FAK and localises efficiently to the 
focal adhesions (Schaller et al, 1993). The carboxy-terminal domain is also involved 
in forming complexes with other focal adhesion proteins such as paxillin and talin 
(Hildebrand et a l, 1995; Chen et a l, 1995). It has been suggested that the paxillin-
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Figure 4 Structure of FAK: Figure sh ow s FA K  structural dom ains and phosphorylation  
sites (adapted from  H anks and P olte, 1997). T yr397  is a m ajor autophosphorylation  site o f  F A K . 
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leads to phosphorylation  o f  T yr925 , w h ich  is a binding site for G rb-2. FA K  is a lso  know n to bind  
to C A S  and G raf through the proline rich regions. T he k inase activ ity  o f  FA K  is e levated  by 
phosphorylation  o f  T yr576  and T yr577, w h ich  lies w ith in  the kinase dom ain . T he foca l adhesion  
targetting (F A T ) dom ain  is required for the loca lisation  o f  the protein at the fo ca l adh esions. 
W ithin the F A T  dom ain  a lso  lies the p ax illin  binding site. FR N K , an alternatively  sp liced  form  
o f  FA K , is h om ologou s to the carboxy term inus region  o f  F A K  and is a lso  targetted to the foca l 
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binding site appears to be distinct from the focal adhesion targeting sequence in FAK 
and is therefore unlikely to be responsible for recruiting FAK to the focal adhesion 
(Otey, 1996). Another study, however, reports that glutathione S- tranferase (GST)- 
FAK fusion proteins, which specifically bind to paxillin, localize to focal adhesions. 
This correlation suggests that FAK is localized to focal adhesions by the direct 
association with paxillin (Tachibana et al., 1995). This controversy still remains to be 
resolved.
The amino-terminal domain of FAK appears to be important for the binding of FAK 
to integrins (Schaller et al., 1995). FAK was found to precipitate efficiently with a 
synthetic peptide, that mimics the cytoplasmic domain of (31 integrin (Schaller et al.,
1995). Furthermore, when expressed in isolation, the amino terminal domain of FAK 
co-precipitated with the integrin peptide, whereas the carboxy terminal domain of 
FAK did not (Schaller et al., 1995). These results suggest that FAK may bind 
directly, through its amino-terminal domain, to a membrane- proximal site in the 
cytoplasmic tail of p i integrin (Schaller et al., 1995), although such an interaction in 
vivo is still uncertain.
1.3.2 FRNK: An alternatively spliced form of FAK
Isolation of a cDNA encoding a carboxy-terminal, non-catalytic domain of FAK has 
been reported (Schaller et al., 1993). The protein has been called FRNK (for FAK 
related non kinase). FRNK is identical in amino acid sequence to the carboxy- 
terminal of FAK and localizes to the focal adhesion (Figure 4). It has been proposed 
that FRNK is generated by alternative splicing and/or utilization of alternative 
transcriptional promoters (Schaller et al., 1993). Two isoforms of FRNK, p41 and 
p43 are observed. It is believed that p41 is phosphorylated on serine and threonine 
residues to generate the p43 isoform (Schaller et al., 1993). FRNK also becomes 
phosphorylated in an ECM-dependent manner with the major sites of 
phosphorylation corresponding to the ones on FAK. Two of the sites of 
phosphorylation are Serl48 and Serl51 (Richardson et al., 1997). Studies have 
implicated FRNK in negative regulation of FAK (Schaller et al., 1993; Richardson 
and Parsons, 1996). This will be discussed in more detail in the following section.
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1.3.3 Phosphorylation sites in FAK and their importance in substrate binding
FAK activity is regulated by phosphorylation (Guan and Shalloway, 1992). 
Immunoprecipitated FAK from fibronectin-adhered cells, with high phosphotyrosine 
content, is 2.5 times catalytically more active as compared to FAK from cells plated 
out on polylysine, which has lower phosphotyrosine content (Guan and Shalloway, 
1992). Six tyrosine residues, 397, 407, 576, 577, 925 and 861 have been identified 
which are phosphorylated ( Schaller et a/., 1994; Schlaepfer et al., 1994; Calalb et a l, 
1995; Schlaepfer and Hunter, 1996; Calalb et al., 1996). Of these, Tyr- 397 is 
thought to be a major site of FAK autophosphorylation, both in vivo and in vitro 
(Schaller et al., 1994) and is a strong binding site for the Src SH2 domain (Schaller et 
a l, 1994). Both v-Src and c-Src have been shown to bind to FAK through the SH2 
domain (Cobb et a l, 1994; Schaller et al., 1994; Xing et a l, 1994). Mutation of this 
site does not abolish the kinase activity of FAK in vitro, but dramatically reduces the 
tyrosine phosphorylation of FAK cytoskeletal substrate paxillin in vivo (Otey, 1996). 
Taken together, these facts raise the possibility that complex formation between c-Src 
and FAK is essential for the phosphorylation and activity of FAK.
Phosphorylation of Tyr 397 is also required for binding of FAK to PI 3-kinase (Chen 
and Guan, 1994; Chen et a l, 1996a). Three other phosphorylation sites, Tyr-407, 
Tyr-576, and Tyr-577 are phosphorylated by c-Src in vitro and to have elevated 
phosphorylation levels in v-Src transformed cells (Calalb et a l, 1995). Tyr-576 and 
Tyr-577 lie within the catalytic domain and their mutation significantly lowers the 
kinase activity of FAK immune complexes (Calalb et al., 1995). Phosphorylation of 
Tyr-925 by Src facilitates binding of Grb2 to FAK thorough the SH2 domain 
(Schlaepfer et al, 1994). In the case of c-Src, this phosphorylation is dependent on 
adhesion of cells to fibronectin while in v-Src transformed cells, phosphorylation is 
independent of cell adhesion to fibronectin (Schlaepfer et al., 1994). Mutation of 
FAK Tyr-925 disrupts Grb2 binding whilst mutation of Tyr-397 disrupts both c-Src 
and Grb2 binding to FAK in vivo (Schlaepfer and Hunter, 1996). In view of the fact 
that FAK is also recognised as a possible substrate for c-Src (discussed earlier), a 
model was proposed whereby Src kinase binding and phosphorylation of FAK at Tyr- 
925 creates a Grb2-SH2 domain binding site and provides a link to the activation of
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the Ras signal transduction pathway (Schlaepfer and Hunter, 1996). Tyr-861 is 
thought to be another major site of phosphorylation by c-Src which may function in 
additional interactions between FAK and SH2-containing proteins (Calalb et al,
1996).
FAK is also phosphorylated in vivo on a number of serine residues (Calalb et a l, 
1995; Schlaepfer and Hunter, 1996), but the functional significance of these is yet to 
be determined (Hanks and Polte, 1997).
1.3.4 Regulation of FAK phosphorylation and activation
Integrins have been implicated in the activation of FAK by stimulating its 
phosphorylation. In 1991, Guan et al, reported that the phosphotyrosine levels in 
FAK increased when integrins were bound to their ECM ligands. Since then, a 
number of groups have confirmed that when cells are grown in suspension, or on 
substrates such as polylysine, phosphotyrosine content of FAK remains low, but if 
cells are allowed to spread on fibronectin or other matrix proteins, the 
phosphotyrosine content of FAK increases dramatically (Burridge et a l, 1992; Guan 
and Shalloway, 1992; Hanks et al, 1992; Kornberg et a l, 1992). Other studies have 
shown that integrin clustering, and not merely their occupation, is involved in 
integrin-dependent phosphorylation of FAK (Guan et al, 1991; Miyamoto et al,
1995). Expression of constitutively acivated form of integrin receptors, in which the 
putative binding site for FAK is altered, does not lead to FAK phosphorylation unless 
occupied by their ligand (Lyman et a l, 1997). Not only the clustering but also the 
conformational state of the integrin might be important in FAK activation (Pelletier 
et al, 1995). Activation of FAK by integrins is independent of focal adhesion and 
stress fibre assembly or the association of integrins with them (Lyman et a l, 1997).
Platelet-activating factor (PAF) induces early phosphorylation in tyrosine residues of 
focal adhesion kinase and paxillin in endothelial cells (Soldi et al, 1996). FAK is 
also activated by the binding of PDGF to its tyrosine-kinase receptor (Rankin and 
Rozengurt, 1994; Knight et a l, 1995; Abedi et a l, 1995). Vascular endothelial 
growth factor (VEGF) caused a rapid increase in tyrosine phosphorylation of FAK in
31
human umbilical vein endothelial cells (Abedi and Zachary, 1997). VEGF 
phosphorylation of FAK was completely inhibited by the actin filament-disrupting 
agent cytochalasin D, showing that it is cytoskeltal dependent (Abedi and Zachary,
1997). Insulin and IGF-1 have also been shown to induce FAK phosphorylation in 
non-attached cells (Knight et a l , 1995; Baron et al., 1998). Thrombin and collagen 
activation of platelets caused an induction of FAK tyrosine phosphorylation (Lipfert 
et a l, 1992). However, FAK was not phosphorylated in platelets deficient in the 
fibronectin receptor and in platelets that were not allowed to aggregate. Also, in 
another study, enhanced tyrosine phosphorylation of FAK by clustering of 
tetraspanins (proteins from the transmembrane 4 superfamily TM4SF which include 
CD9, CD63 etc.) required cell attachment (Berditchevski and Odintsova, 1999). 
Other mitogenic peptides and growth factors such as lysoposphatidic acid 
(Seufferlein and Rozengurt, 1994), bombesin (Sinnet-Smith et a l, 1993, Zachary et 
al, 1993), vasopressin (Zachary et a l, 1993), endothelin (Zachary et a l, 1993), 
bradykinin (Leeb-Lundberg et a l, 1994), and angiotensin 11 (Polte et a l, 1994) have 
also been shown to mediate FAK and paxillin phosphorylation (reviewed in Otey,
1996). In some cases, like that of bombesin, stimulation of phosphorylation requires 
an intact cytoskeleton (Sinnett-Smith et a l, 1993).
Apart from Src itself, another member of the Src family of protein tyrosine kinases, 
Fyn has also been shown to bind directly to FAK and phosphorylate it (Grant, 1996). 
Furthermore, Fyn is responsible for the engagement of CD146 (a transmembrane 
receptor belonging to a group of cell adhesion molecules) in human endothelial cells 
resulting in tyrosine phosphorylation of FAK (Anfosso et a l, 1998).
FAK phosphorylation was found to accompany increase in Ca++ following integrin 
binding to ECM or mechanical deformation by cyclic stretch/ relaxation (Sinnett- 
Smith, 1993). The small GTP-binding protein Rho p21 is thought to play a role in 
cyclic strain mediated phosphorylation of FAK since preincubating the cells with C3, 
a specific inhibitor for rho p21, inhibited tyrosine phosphorylation of FAK (Yano et 
a l, 1996b).
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Other studies have focused on the regulation of FAK dephosphorylation. It has been 
reported that overexpression of Csk, enhanced and prolonged the insulin-induced de­
phosphorylation of FAK (Tobe et al., 1996). Recent studies have also shown that 
PTEN, a known tumor suppressor and a phosphatase, interacts with FAK and reduces 
its tyrosine phosphorylation (Tamura et al., 1998). A decrease in the tyrosine- 
phosphorylation level of FAK by overexpression of FRNK has also been reported. It 
was first suggested by Schaller et al., (1993) that FRNK could function to regulate 
the activity of FAK in cells. A later study then confirmed that FRNK acts as an 
inhibitor of FAK by transiently blocking the formation of focal adhesions on 
fibronectin (Richardson and Parsons, 1996). The inhibitory effects of FRNK were 
found to be reversed by co-expression of FAK suggesting that FAK and FRNK 
compete for a common binding protein whose association with FAK is important for 
signaling by FAK (Richardson and Parsons, 1996). FRNK therefore might compete 
with FAK for localization at the focal adhesions to induce its inhibitory effect. A 
recent study showed that FAK dephosphorylation at Tyr-397 and blocking of FAK- 
mediated cell-migration by expression of FRNK is dependent on its localisation to 
the focal adhesions as the inhibitory effects of FRNK could be reversed by a point 
mutation (Leu-1034 to Ser) which prevented its localisation to the focal adhesions 
(Sieg et al., 1999).
1.3.5 Potential substrates of FAK
Tensin is one of the potential substrates of FAK. Tensin is a 215 Kda protein that 
binds to actin filaments and is concentrated both in cell- matrix and cell- cell 
adhesions (Bockholt et al., 1992; Lo et al., 1994). Tensin is not known to bind to 
FAK directly but it binds to vinculin and a-avtinin, both of which are focal adhesion 
proteins. The evidence supporting the phosphorylation of tensin by FAK came when 
it was shown that the conditions which promote tensin phosphorylation, i.e. an intact 
actin cytoskeleton, clustering of integrins and cell spreading, are the same as that 
required to promote FAK activation (Bockholt and Burridge, 1993). However, this 
does not provide conclusive proof. On the other hand, much more data is available in 
support of FAK mediated activation of paxillin. As mentioned earlier, FAK and 
paxillin have been shown to be directly associated through the carboxy-terminal
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domain of FAK (Tachibana et al, 1995). Furthermore, overexpression of wild type 
FAK in fibroblasts treated with vandate (to inhibit tyrosine phoshatases), lead to a 
significant increase in the level of tyrosine phosphorylation of paxillin (Schaller and 
Parsons, 1995). It was also found that FAK mutants which failed to localize to focal 
adhesions, also failed to induce paxillin phosphorylation (Schaller and Parsons,
1995). In addition, mutation of Tyr-397, the major autophosphorylation site of FAK, 
dramatically reduces the tyrosine phosphorylation of paxillin and tensin in vivo 
(Coorey et al, 1996).
In another approach, expression cloning was used recently to identify cDNAs that 
encode potential FAK binding proteins (Hildebrand et a l, 1996). The study found 
Graf (GTPase regulator associated with FAK), a member of the GAP family of 
GTPase regulators, to bind to the C-terminal domain of FAK in a SH3-dependent 
manner. Graf preferentially stimulates the GTPase activity of RhoA and cdc42 
(Hildebrand et a l, 1996). This finding provides another possible candidate through 
which FAK might mediate integrin signaling. However, in vivo interaction between 
FAK and Graf has not yet been definitively established (Hildebrand et a l, 1996).
Another study has shown the interaction between FAK and CAS (Polte and Hanks,
1995). CAS was first identified as a FAK-interacting protein by two-hybrid screens; 
subsequently, co-immunoprecipitation experiments confirmed that CAS and FAK are 
associated in mouse fibroblasts (Harte et a l, 1996). Association of FAK and CAS is 
mediated by the binding of the CAS SH3 domain to a proline rich sequence at the 
carboxy-terminus of FAK (Polte and Hanks, 1995; Harte et a l, 1996). A region of 
FAK spanning the amino acids 712-718 has been mapped as the binding site (Cary et 
a l, 1998). CAS has been shown to localize to focal adhesions and also bind to FRNK 
(Harte et a l, 1996), and is implicated in FAK-mediated cell motility (discussed 
below).
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1.3.6 Functions of FAK
As stated earlier, the phosphorylation and activation of FAK induced by integrins 
implies that FAK might play an important role in integrin mediated cell-signaling 
which is responsible for regulating cell proliferation, migration and survival.
1.3.7 Role of FAK in cell motility
In normal cells, migration plays a critical role in many biological processes such as 
embryonic development, wound healing and tumour metastasis. The most compelling 
evidence for involvement of FAK in cell motility comes from a study in which cells 
derived from FAK deficient mouse embryos showed reduced mobility in vitro (Ilic et 
al., 1995). A recent study showed that re-expression of epitope tagged FAK is able to 
reverse the morphlogical defects of the FAK-null cells and the cells display 
indistinguishable fibronectin receptor-stimulated migration properties when 
compared to normal fbroblasts (Sieg et al., 1999). In another study, overexpression of 
FAK in CHO cells increased their migration on fibronectin (Cary et al, 1996). 
Loading of glutathione-s-transferase fusion protein (GST-Cterm) containing the FAK 
focal adhesion targeting domain into cells decreased phosphotyrosine content of focal 
adhesions and reduced cell motility (Gilmore and Romer, 1996). However, no 
decrease in the number of focal adhesions was observed implying that FAK activity 
is not required for the formation of focal adhesions (Gilmore and Romer, 1996).
Evidence of FAK involvement in cell migration is also provided by studies using 
malignant tumour cells. FAK expression correlates significantly with mean migration 
rate in the six melanoma lines tested (Akasaka et al., 1995). A study carried out to 
look at FAK mRNA in 49 human tissue samples, including paired normal and 
neoplastic samples, found increased levels of FAK in 1 out of 8  adenomatous tissues, 
17 out of 20 invasive tumours and in all 15 metastatic tumours (Weiner et al., 1993). 
Owens et al, (1995) have also reported the correlation of increased levels of FAK 
with the invasive potential of tumour cells. They found FAK levels significantly 
elevated in 17 out of 17 invasive and metastatic colonic lesions and in 22 out of 25 
invasive and metastatic breast tumours compared with normal tissue from the same
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patient. Furthermore, a study by Tremblay et al, (1996) reported that higher levels of 
FAK protein and mRNA were observed in Pea, prostate carcinoma cancer tissues 
from patients with metastasis, whereas, normal, hyperplastic prostates and localised 
Pea tissues showed undetectable or low levels of both. Additionally, they found that 
FAK associated preferentially with paxillin and Csk in metastatic tissues compared to 
the non-metastatic tissues (Tremblay et a l, 1996).
Some work has also been carried out to determine the molecular signaling pathways 
involved downstream of FAK which play a role in cell migration. It was shown that 
overexpression of kinase-defective FAK, phosphorylated at Tyr397 by endogenous 
FAK, was able to increase migration in CHO cells to the same extent as the 
overexpression of the wild type FAK (Cary et a l, 1996), suggesting that FAK 
catalytic activity was not required for its mediation in cell motility. However, another 
study using FAK mutants has shown that FAK kinase activity is required to promote 
cell migration in FAK-null fibroblasts (Sieg et a l, 1999). Phosphorylation of Tyr-397 
is important in FAK-mediated cell migration (Cary et a l, 1996; Sieg et al, 1999). It 
was also shown that mutation of Tyr-397 abolished its ability to stimulate cell 
migration, whereas its phosphorylation in the kinase defective variant of FAK by 
endogenous FAK led to increased migration (Cary et a l, 1996). A recent study 
involving the expression of FAK mutants with impaired activation loop 
phosphorylation, resulting in lack of catalytic activity of the protein in FAK null 
cells, suggests that FAK activation loop phosphorylation plays an important role in 
mediating activation of FAK/Src complexes by stimulating intermolecular FAK 
autophosphorylation at Tyr-397 (Owen et a l, 1999). Also, the SH3 domain binding 
proline rich region in the carboxy-terminus of FAK, which has also been implicated 
in Src binding to FAK (Thomas et al, 1998), is also required for FAK mediated 
migration (Sieg et a l, 1999).
CAS seems to play an important role in mediating cell motility as a result of 
association with FAK. Cells expressing a FAK mutant, which significantly reduced 
CAS association with FAK, were unable to enhance cell migration (Cary et a l,
1998). Association of FAK with Grb2, on the other hand, is not required in FAK- 
promoted cell migration (Cary et al, 1998). MAP kinases were found to play no
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significant role in migration as no increase in activation of ERKs in the cells showing 
increased cell motility due to the expression of wild type FAK, was observed (Cary et 
al., 1998). Also, MEK inhibitor, PD98059, did not decrease FAK promoted cell 
migration. Association of FAK with PI 3-kinase is also required for its role in 
migration (Reiske et al., 1999).
1.3.8 Role of FAK in cell proliferation
The first evidence of FAKs role in cell growth came from the study carried out by 
Gilmore and Romer (1996). Cells loaded with GST-Cterm fusion protein of FAK 
decreased association of FAK with the focal adhesions and decreased DNA synthesis 
compared with the control cells (Gilmore and Romer, 1996). Binding of FAK to 
Grb2 and PI 3-kinase (Schlaepfer and Hunter, 1996; Chen and Guan, 1994), two 
proteins implicated in the activation of the MAP kinase pathway through Ras 
(Schlaepfer and Hunter, 1996; King et al., 1997). Combined activity of c-Src and 
FAK, after fibronectin stimulation, promotes signalling via the MAP kinase pathway 
(Schlaepfer et al., 1998).
A recent study has proposed a role for FAK in the activation of another MAP kinase 
pathway- JNK (Jun NH2-terminal kinase; Oktay et a l, 1999). Integrin mediated 
stimulation of JNK required the association of FAK with c-Src and CAS, and also 
phosphorylation of CAS and the subsequent recruitment of Crk, the adapter protein. 
Activation of the JNK pathway is necessary for proper progression through the G1 
phase of the cell cycle and thus regulates cell proliferation (Okay et al., 1999).
1.3.9 Role of FAK in survival
FAK undergoes degradation during c-Myc induced apoptosis in CEF after serum 
withdrawal, and has thus been implicated in this process (Crouch et al., 1996). 
Furthermore, integrin signalling has been shown to suppress apoptosis induced by c- 
Myc transformation (Frisch et al., 1996b) and was found to suppress FAK cleavage 
(Crouch et al., 1996). Constitutively activated forms of FAK were able to rescue two 
established epithelial cell lines from anoikis (Frisch et al., 1996b). It was also found
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that both the Tyr-397 site and the kinase activity of FAK were required for this effect 
(Frisch et al., 1996b). This suggested that once initiated, apoptosis requires the 
inactivation of FAK, possibly through degradation. Another study suggested that 
calpain mediated FAK cleavage and the subsequent down regulation of its autokinase 
activity and cytoskeletal localization may be responsible for its signal termination 
(Cooray et al., 1996). Furthermore, when a FAK peptide, containing the integrin 
binding sequence of FAK was micro-injected into CEF, these cells underwent 
apoptosis (Hungerford et al., 1996). The peptide most likely acted as a dominant 
negative and presumably did not allow FAK’s association with the p i integrin, again 
suggesting that FAK-integrin association is required for the suppression of apoptosis. 
Treatment of tumour cell lines known to express high levels of FAK with different 
antisense oligonucleotides to FAK in order to attenuate FAK expression, caused the 
cells to undergo apoptosis (Xu et al., 1996). This study provides further evidence of 
FAK’s importance in cell survival. However, this effect of attenuation of FAK 
expression was found to be specific to overexpressing tumour cell lines. Normal cells 
did not undergo apoptosis on being treated similarly (Xu et al., 1996).
FAK is also upstream of the PI 3-kinase-Akt survival pathway in hydrogen peroxide 
induced apoptosis in T98G cells, a glioblastoma cell line (Sonoda et al., 1999). 
Hydrogen peroxide causes oxidative stress in vitro. FAK is phosphorylated and 
associated with PI 3-kinase after hydrogen peroxide stimulation. Inhibition of PI 3- 
kinase with wortmannin accelerated apoptosis in the cells suggesting that signal 
transduction from FAK to PI 3-kinase and Akt exerts an anti-apoptotic effect 
(Sonoda et al., 1999). In another recent study, expression of exogenous PTEN, a 
phosphatase for FAK, in glioblastoma and breast cancer cells lacking PTEN caused 
the cells to undergo apoptosis (Tamura et al., 1999). Overexpression of FAK in these 
PTEN transfected cells was able to partially rescue PTEN induced apoptosis, again 
suggesting FAK’s role in PI 3-kinase mediated cell survival pathway (Tamura et al.,
1999).
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1.3.10 PYK2: A FAK homologue
Another protein tyrosine kinase related to FAK, with a molecular weight of 113 kd, 
has also been identified. Its also referred to as CAK|3, RAFTK, FAK2 or PYK2 
(Sasaki et al., 1995; Avraham et al., 1995; Herzog et al., 1995; Lev et al., 1995). 
PYK2 shows an overall identity of about 42% to the amino acid sequence of FAK 
(Herzog et al., 1996). PYK2 isolated from the rat brain is about 60% identical to the 
catalytic domains of mouse and human FAK (Sasaki et al., 1995). Comparison of the 
amino acid sequences of human and murine PYK2 revealed 95% homology 
(Avraham et al., 1995). It has all the characteristic of a non-receptor protein tyrosine 
kinase (Sasaki et al., 1995). PYK2 does not have myristoylation sites, a 
transmembrane region or SH3, SH2 domains (Avraham et al., 1995). Comparison of 
the amino acid sequence of FAK and PYK2 also reveals that there exists a 60-70% 
homology in the FAT region.
However, despite belonging to the same family of protein tyrosine kinases, FAK and 
PYK2 show different pattern of expression. PYK2 is found to be expressed mainly in 
brain, intestine, kidney, spleen and epididymis and is only weakly expressed in the 
cerebellum, testis, and adrenal glands- organs where FAK is expressed in abundance 
(Sasaki et al., 1995). Confocal analysis showed PYK2 at the cell-cell contacts instead 
of the focal adhesions (Sasaki et al., 1995). Other studies have reported PYK2 to 
localize to the perinuclear region (Sieg et al., 1998) and diffusely in the cytoplasm 
(Zheng et al., 1998). There have also been conflicting reports as to the regulation of 
its phosphorylation or activation. Studies have suggested that PYK2 is not found to 
be activated in response to cell interaction with fibronectin (Sasaki et al., 1995). In 
contrast, PYK2 has been shown to display integrin-dependent phosphorylation in B 
lymphocytes, CMK cells, and transfected COS cells (Zheng et al., 1998). In cells 
overexpressing endogenous PYK2, integrin mediated cell adhesion produced only a 
small increase in PYK2 phosphorylation. A significantly higher increase in PYK2 
phosphorylation was observed when cells were stimulated with soluble factors such 
as angiotensin II, PDGF and sorbitol (Zheng et al., 1998). PYK2 has also been shown 
to be rapidly phosphorylated on tyrosine residues in response to various stimuli that
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elevate intracellular calcium concentration as well as protein kinase C activation (Lev 
et al., 1995).
Like FAK, PYK2 has been found to interact with paxillin, that is also known to bind 
to FAK (Zheng et al., 1998). A recent study has shown that PYK2 associates with 
active Src family members after plating on fibronectin in murine fibroblasts lacking 
FAK (Sieg et al., 1998). PYK2 tyrosine phosphorylation is also enhanced by 
fibronectin stimulation in these cells. However, PYK2 was unable to fully restore the 
migrating capacity of the fak  -/- cells (Sieg et al., 1998). PYK2 has also been 
reported to have an opposing effect to FAK during the process of apoptosis (Xiong 
and Parsons, 1997). Overexpression of PYK2, unlike FAK, was found to induce 
apoptosis in rat and mouse fibroblasts (Xiong and Parsons, 1997).
Chapter 2: Materials and Methods
41
2.1 Materials
2.1.1 General Chemicals and Reagents
Chemical/Reagent Suppliers Name
P Glycerophosphate Fisher
X Hindlll GIBCO
c|)XHaeIII markers GIBCO
10% Block solution Boehringer Manneheim/Roche
2  mercapto ethanol Sigma
Acrylamide (30:0.8) Severn Biotech Limited
Agar Beckton Dickinson
Agarose GIBCO
ALLN Sigma
Ammonium per sulphate (APS) Fisher
Ampicillin Sigma
Aprotinin Sigma
Anti-sheep donkey texas red Jackson Immuno research
Avidin-FITC Sigma
BamHI GIBCO
Benzamidine Sigma
Biotin labelling nick translation kit Boehringer Manneheim/ Roche
Biotinylated anti-avian D Vecta Labs
Biotinylated dUTP Roche
Boric acid Fisher
Bromophenol blue Sigma/BDH
BSA Sigma
BSA (For TUNEL analysis) Sigma
Cacodylic acid Sigma
Calcium chloride (CaCl2) Fisher
Chick Serum GIBCO
Chick tryptose phosphate GIBCO
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Chromosome Medium A GIBCO
Cobalt chloride Sigma
Colcemid GIBCO
Cow Gum BDH
DAPI Sigma
Dextran sulphate Sigma/Pharmacia
DH5a competent cells GIBCO
Diaminethanetetra-acetic acid (EDTA) Fisher
DIG labelled centromeric probe for Appligene Oncor
chromosome 8
DIG labelled c-Myc FISH probe Appligene Oncor
Dimethyl Sulfoxide (DMSO) Fisher
Disodium phosphate (Na2P0 4 .2 H2 0 ) Fisher
Dithiothreitol (DTT) Sigma
DNA ladder lkb GIBCO
Donor Calf Serum Sigma
DOTAP Roche
Dulbecco’s Medium (10XDMEM) Sigma
ECL reagents Amersham
EcoRI GIBCO
Ethanol Hayman Limited
Ethidium bromide Sigma
Ethylene glycol tetraacetic acid (EGTA) Fisher
Fetal Calf Serum Seromed
FICOLL (Type 400) Sigma
FITC-Avidin DCS Vecta Labs
Formaldehyde Fisher
Formamide Sigma
G-418 (Geneticin) GIBCO
Glacial acetic acid Fisher
Glycerol Fisher
Glycine Fisher
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Hepes
Hexanucleotide mix (10X)
Hindlll
Human Cot-1 DNA
Hydrochloric acid (HC1 S.G.I.16 32%)
Hydrocortisone
Insulin 200u/ml
Isopropanol
Kanamycin
Klenow polymerase
Leupeptin
L-Glutamine
LY294002
Maleic acid
Methanol
Milk
New Born Calf serum 
NP-40
Nucleotides (dNTPs)
PBS tablets 
Penicillin 
Pepsin 
Phenol
Phenyl methyl sufonyl fluoride (PMSF) 
Plasmid Prep kits 
Polyvinyl pyrolidine (PVP)
Potassium acetate 
Potassium chloride (KC1)
Potassium hydroxide 
Propidium iodide
Protein rainbow molecular weight markers 
Proteinase K
BDH
Boehringer Mannheim
GIBCO
GIBCO
Fisher
Sigma
Sigma
Fisher
Sigma
Kramel
Sigma
GIBCO
Calbiochem
Sigma
Fisher
Marvel
GIBCO
Calbiochem
Promega
Oxoid
Sigma
Sigma
Rathburn
Sigma
Qiagen
Sigma
Fisher
Fisher
Sigma
Sigma
Amersham
Roche
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Rnase A Sigma/Kramel
RPMI medium GIBCO (Cat no. 31870-025)
Salmon Sperm DNA Sigma
SB 203580 Calbiochem
Sheep anti-digoxigenin Boehringer Manneheim
Sodium acetate (NaAc) Fisher
Sodium bicarbonate Sigma
Sodium chloride (NaCl) Fisher
Sodium dodecyl sulphate (SDS) BDH
Sodium fluoride (NaF) Sigma
Sodium pyrophosphate Fisher
Sodium pyruvate Sigma
STF (Post fix) Alpha labs/MBF
Streptomycin Sigma
Taq Bioline
TdT Roche
TEMED Sigma
Tris base GIBCO
Tris-Sodium Acetate Fisher
Triton X100 Sigma
Trypsin GIBCO
Tween 20 Sigma
Vecta shield Vector Labs
ZVAD-FMK Calbiochem
2.1.2 List of Antibodies
Antibodies Suppliers
FAK (Monoclonal) Transduction Labs
c-Myc Provided by David Gillspie, Beatson
Institute, Glasgow, UK
ERK Provided by Anne Wyke, Beatson Institute,
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PYK2
Phospho ERK 
P38
Glasgow, UK 
Affinity, Cambridge 
Biolabs
New England Biolabs
Phospho p38 (Rabbit) (Against Thrl80, New England Biolabs 
Tyrl82
Akt
Phospho Akt (Ser473)
New England Biolabs 
New England Biolabs
2.1.3 Solutions
2.1.3.1 General Solutions
Blocking buffer with BSA
3% BSA
0.2% Tween 20
Make up with PBS or IX TBS
Blocking buffer with milk
5% Milk
0.1% Tween 20
Make up with PBS or IX  TBS
Block Solution 10% (For FISH)
!0% Boehringer Mannheim blocking reagent in maleic acid buffer
Microwave until solution becomes yellow and turbid and then autoclave to dissolve
Cacodylate buffer
For 10 tubes
200pl (0.2M) 0.5M Potassium cacodylate (pH 7)
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50[il (2.5mM) 25mM Tris-Hcl pH6 . 6  
50pl (2.5mM) 25mM Cobalt Chloride 
50pl (0.25mg/ml) 2.5mg/ml BSA 
150pl dH20  
2pl TdT 
5(utl b-dUTP
Calpain Buffer
50mM Hepes pH 7.5 (with NaOH)
2mM EDTA 
3mM CaCl2
Denhardts solution (50X)
1% FICOLL (Type 400)
1% PVP 
1% BSA
Make up in dH20  
FDE
lOOmM EDTA
20% FICOLL
0.05% Bromophenol blue
Fix Solution (For FISH)
3 volumes methanol: 1 volume acetic acid
High stringency wash
0.2XSSC 
0.1% SDS
Hybridisation solution (50%)
50% Formamide
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2XSSC
!0 % dextran sulphate 
500ug/ml salmon sperm DNA
Hypotonic solution
0.075M KCL
ICE Buffer
25mM Hepes 
10% Glycerol 
5mM DTT
L Broth-Agar
500ml L Broth 
2% Agar
Autoclave to dissolve agar
Add 1 mg/ml Ampicillin after cooling the Broth down 
Pour in petri dishes (Sterlin) and allow to set
Low stringency wash
2XSSC 
0.1% SDS
Malaic acid buffer
0.1M Malaic acid 
0.15M NaCl 
0.35M NaOH 
pH to 7.5 with NaOH
NP40 Buffer (without inhibitors)
For 500ml:
1% TritonXlOO
0.5% NP40
150mM NaCl
lOmM Tris pH 7.5
ImM EDTA
ImM EGTA
lOmM NaPPi (add solid)
(Store at 4°C)
NP40 +Inhibitors
TolOml NP40 buffer: 
lOpil 200mM PMSF 
lOpl lOOmM Na Vanadate 
10pl lOmg/ml Leupeptin 
lOpl lOmg/ml Benzamidine 
lOpl 0.5M NaF 
lOpI Aprotinin
lOmM p Glycerophosphate (add solid) 
lOpil 1M DTT 
(Store at -20°C)
200mM PMSF was made up in propanol. For Sodium vanadate, it was first converted 
into pervanadate by dissolving in 100ml of water and adjusting the pH to 10. At this 
point, the solution (orange in colour) was boiled in the microwave till it was 
colourless. It was then cooled and aliquots stored at -20°C.
PI (For PAC clone isolation)
15mM Tris, pH 8
lOmM EDTA
lOOpg/ml RNaseA
Filter sterilise and store at 4°C
P2 (For PAC clone isolation)
0.2N NaOH
49
1% SDS
Filter sterilise and store at room temperature
P3 (For PAC clone isolation)
3M KOAc, pH 5.5
PBS
For 2 L of distilled water add 20 tablets of PBS (Dulbecco 4 A ’) formulated tablets
Pepsin solution
0.01% Pepsin 
lOmM HC1
Prehyb solution
For 500ml:
125ml 20XSSC
12.5ml 20% SDS or 12.5ml of 10% SDS 
50ml of 50X Denhardts solution 
500mg Total Yeast RNA 
Make up with dH2 0
Sample Buffer (2X)
1.3ml dH20  
1.3ml Tris pH 6 . 8  
2ml Glycerol 
5ml 10% SDS
800pl 2  mercapto-ethanol (add this in the fume hood)
Bromophenol blue
SDS-PAGE gels
15% 9% 10% 7.5% 12% Stacking
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13.3ml 10ml 16ml
15ml 15ml 15ml
10.9ml 15ml 8.2ml
0.4ml 0.4ml 0.4ml
375^1 375^1 375[xl
2 0 pl 2 0 pl 2 0 pl
SDS-PAGE gel running buffer (10X)
For 2L:
60g Tris 
288g Glycine 
20g SDS 
pH should be 8.3
SSB (10X)
50% Gycerol
0.25% Bromophenol blue
(make up in water)
SSC (10X)
3M NaCl
0.3M Tris-sodium citrate 
pH to 7.0 with NaOH
Acrylamide 20ml 12ml
(30:0.8)
1M Tris pH 8 . 8  15ml 15ml
dH20  4-2ml 12.3ml
10% SDS 0.4ml 0.4ml
1M Tris pH 6 . 8
10% APS 375pi 375pl
TEMED 20pl 20pl
3.2ml
14ml
0 .2 ml
2.5ml
2 0 0 pl
2 0 pl
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SSC-TB (4X)
4XSSC
0.05% Tween 20 
0.5% Block solution
4XSSC-T Wash Solution
4XSSC
0.05% Tween 20
SSPE (20X)
175.3g NaCl
31.2g Na2P0 4 .2 H2 0  (or monohydrate 27.6g)
7.4g EDTA
pH should be around 7.4 or else pH with 10M NaOH and make up to 1L with dH2 0
Stain buffer (for TUNEL analysis)
For 10 tubes:
lml 4XSSC+ 0.1%Triton X-100 
50mg (5%) Milk
lp l (5pg/ml) 5mg/ml Avidin-FITC
Strip Buffer (for western blots)
1% SDS
0.2M Glycine (pH 2.5)
TBE (IX)
89mM Tris 
89mM Boric acid 
2.5mM EDTA
TE
lOmM Tris pH 8
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ImM EDTA pH 8
TNE
lOmM Tris pH 8.2 
400mM NaCl 
2mM EDTA pH 8
Tris Acetate gel running buffer (10X)
For 1L:
60.5g Tris Base 
16.4g Sodium Acetate 
7.4g EDTA 
5.8g NaCl
Tris Borate (10X)
For 1L:
55g Boric Acid 
108g Tris Base 
9.3g EDTA 
pH should be about 8.5
Western Blot transfer Buffer (10X)
600mM Tris 
500mM Glycine 
16mM SDS 
For use (500ml):
100ml Methanol
50ml 10X Western Blot Buffer
350ml dH20
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2.1.3.2Tissue Culture Solutions and Medium
Solutions made by the central services
Distilled H2O 
PBS
PE (PBS+EDTA)
L Broth
DMEM- Medium for Rat-1, ts v-Src transformed Rat-1, BT474, LS277, HT29, 
CALEB
For 1L: To 800ml dH20  add 
10X DMEM 
200mM L-Glutamine 
Sodium Bicarbonate 7.5% 
lOOmM Sodium Pyruvate 
New Born Calf Serum
New Born Calf Serum 
New Born Calf Serum
1.12M HC1
Streptomycin 10,000 pg/ml 
Penicillin 10,000 unit/ml 
(Antibiotics made up in PBS)
1 0 0 ml
1 0 ml
50ml
1 0 ml
100ml (10% serum for BT474, LS277, HT29, 
CALU3)
50ml (5% serum for Rat-1 fibroblasts)
2ml (For 0.2% serum)
6 ml 
5 ml 
5ml
10H- Medium for BICR and HEK cell lines 
For 1L: To 800ml dH20
Penicillin 5ml
Streptomycin 1 ml
200mM L-Glutamine 1 0 ml
IN HC1 4ml
lOOmM Sodium Pyruvate 1 0 ml
Sodium Bicarbonate 40ml
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Top up to 900ml with dK^O. Then add
10X DMEM 100ml
Remove 100ml of 1XDMEM and add 
Fetal Calf Serum 100ml
Hydrocortisone (Diluted) 1ml
10C- Medium for Swiss 3T3 feeder cells 
For 1L:
Same as for 10H except add 30ml Sodium Bicarbonate, 100ml of Donor calf serum 
instead of Fetal Calf serum, and no hydrocortisone.
Standard Chicken Medium
For 500ml
dH20 450ml
10X DMEM 50ml
Na Pyruvate 5ml
L-Glutamine 5ml
New Born Calf Serum 25 ml
Chick serum 5ml
Chick Tryptose phosphate 50ml
Penicillin 5ml
Streptomycin 5ml
Medium for AA/C1 and AA/C1/SB10 cells
For 500ml:
1XDMEM 500ml
Fetal Bovine Serum 1 0 0 ml
L-Glutamine 5ml
Insulin 200units/ml 0.5ml
Hydrocortisone 100(ig/ml 5ml
Streptomycin 5ml
Penicillin 5 ml
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Freezing medium for Rat-1 fibroblasts
For 100ml:
10XDMEM 10ml
L-Glutamine 1ml
Na Pyruvate 1ml
Na Bicarbonate 5ml
New Born Calf Serum 20ml
DMSO 7.5ml
dH20  54.9ml
HC1 0.6ml
(Store at -20°C in 10ml aliquots)
RPMI- Medium for COLO320, ALT1, MDA231 
IX RPMI 500ml
L-Glutamine 5ml
Fetal Calf Serum 50ml
Penicillin 5ml
Streptomycin 5ml
Hydrocortisone (diluted)
5mg/ml stock:
O.lg Hydrocortisone 
20ml 95% EtOH 
Store at 4°C 
Diluted: 
lml stock
11.5ml 10C medium
Filter and store lml aliquots at -20°C
Trypsin
1/10 0.25% trypsin in PBS
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2.2 Methods
2.2.1 Isolation of fak PAC clone
2.2.1.1 Random primed labelling of FAK cDNA
20 pg of FAK cDNA (A gift from A lan Richardson and Tom Parsons) was restriction 
digested using HINDIII restrictive enzyme to generate a 558bp fragment. The DNA 
fragment was isolated from 1 % agarose gel using the protocol outlined in the 
manufacturers protocol (Qiaquick gel extraction kit, Qiagen). The approximate yield 
was calculated to be about lpg  using the following reasoning:
Total length of plasmid = 6200bp 
Total length of fragment = 558bp
Expected Yield (if 100%) = 558/6200 = 1/12 of 20\ig = 1.6pg
Taking into account loss during extraction procedure, approximate yield = lpg
200ng of the isolated DNA was used for radioactive labelling. DNA was diluted in 
dH2 0  to give a total volume of 8 pi and transferred to a screw cap microfuge tube. In 
order to denature the DNA, the tube was boiled for lOmin, buried in ice for 5min, 
and then flashspun in the microfuge. To the denatured DNA, 5pl of random 
hexamers/cold dNTPs (2pl Hexamers, lp l of lOmM dATP (0.5mM), lp l of lOmM 
dGTP, lp l of lOmM dTTP), 5pl of a 32PdCTP (1.85 Mbq/50pC), and 2pl of Klenow 
polymerase were added quickly to prevent DNA from re-annealing. The tube was 
then incubated for 30min at 35°C. Following incubation, labelled DNA was 
separated from unincorporated label using Biospin columns (Biorad) following 
manufacturer’s protocol. Prior to use, the probe was denatured by boiling for lOmin 
and then placed in ice for another 5min.
2.2.1.2 Probing a library
The DNA library filters (obtained from UK HGMPR) were prehybridised in 200ml 
of prehyb solution at 65°C overnight. For this the 7 filters were placed in a plastic 
box, which was then put in a 65°C waterbath (Grant) and weighed down using heavy
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lead blocks. Next day, the prehyb solution was poured off and replaced by 70ml of 
fresh prehyb containing 200ng of the denatured, radioactively labelled probe. Again, 
probing was carried out overnight at 65°C. Following incubation, the filters were 
washed once at high stringency for lOmin and then at low stringency for 20min. They 
were dried on 3mm paper, wrapped in DOW Saran wrap, and exposed to Fuji RX 
medical X-ray film overnight in large film cassettes with intensifying screens at - 
70°C. The film was developed in Kodak X-OMAT 480 RA processor. For the 
purpose of orientation, tape with radioactive markings was stuck on the cassette.
2.2.1.3 Confirmation of the fak  PAC clone
To select out the right clone, PCR was carried out on the clones using primers 
designed from the 5’ and 3’ UTR (untranslated region) of the known fak  mRNA 
sequence. The primers were designed using the chick fak  mRNA sequence that has 
>90% homology to the human sequence. They were chosen to be from the 
untranslated region since it is the most conserved amongst different species. 
Following were the sequences of the primers used:
From the 5’ UTR-
5a (6 ) 5’- ACTGTGAGCCCGCGGCGTGA-3’
5b (229) 5’- AATAATGGCAGCTGCTTACCTTGA-3’
Primer- 5 ’ - TCAAGGTAAGCAGCTGCCATTATT-3 ’
5c (187) 5’- TAACGGAAGGGAGAATATGACAGA-3’
Primer- 5’- TCTGTCATATTCTCCCTTCCGTTA-3’
From the 3’ UTR-
3a (3717) 5’- GGGATGGCCAAGGGGTGACATCTT-3’
Primer- 5’- AAGATGTCACCCCTTGGCCATCCC-3’
3b (3369) 5’- TTGGGCAGACGAGACCACAC-3’
3c (3444) 5’- TTCCACCAGCAGCGAGGAATTAAC-3’
Concentration of the primers was worked out using the OD reading. Following 
formula was used:
(Concentration X OD at 260 X 40)/1000= x jig/iil
Final concentrations of the primers were:
3a- 3.67p,g/pl 
3b- 2.12pg/pl 
3c- 1.5pg/pl 
5a- 1.83pg/pl 
5c- 1.7p,g/pl
PCR reactions were carried out using the primers to determine the PAC clone for fak. 
Following PCR reagents and conditions were used.
PCR reaction mix:
Total volume- 50pl 
IOXNH4 buffer- 5 pi 
50mM Mg++- 2.5 pi 
lOOng/pl forward primer- 5 pi 
lOOng/pl reverse primer- 5 pi 
Taq- 0.2-0.5pl 
DH20 - 26 pi 
Target DNA- lp l
PCR conditions:
5min- 95°C
Cycle X 30: 
lmin- 91°C
lmin- 55°C
lmin- 72°C
5min- 72°C 
Soak- 4°C
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The completed reactions were run on a 1.5% agarose gel.
2.2.1.4 Isolation of DNA from PAC clones
Clones obtained were streaked onto LB agar plates containing 25pg/ml kanamycin 
and incubated overnight at 37°C. A single bacterial colony was isolated the next day 
and inoculated into 2ml of L Broth supplemented with 25 fig kanamycin. It was left 
overnight at 37°C for incubation with shaking (225-300rpm). Following incubation, 
the bacteria were spun down at 3000rpm in a bench top centrifuge (MSE) for lOmin 
at room temperature. After discarding the supernatant, the bacterial pellet was re­
suspended in 0.3ml of PI solution. 0.3ml of P2 solution was added to the re­
suspended pellet and the tube was shaken gently to mix the contents and left for 5min 
at room temperature. 0.3ml of P3 was slowly added to the mix with gentle shaking 
and then the tube was placed on ice for 5min. To remove the thick white precipitate 
formed after the addition of P3, the tube was centrifuged at 10,000rpm for lOmin at 
4°C in Sorvall RC-5B refrigerated superspeed centrifuge. The supernatant was 
transferred to a 1.5ml eppendorf tube containing 0.8ml of ice cold isopropanol. The 
tube was inverted to mix the contents and left on ice for 5min. To precipitate the 
DNA, tube was centrifuged at maximum speed in a microfuge for 15min at 4°C. 
Supernatant was removed, taking care not to dislodge the pellet. The pellet was 
washed with 0.5ml of 70% ethanol, spun for 5min and then left to air dry. The pellet 
was re-suspended in 40fil of TE.
2.2.2 Fluorescent in situ hybridisation (FISH)
2.2.2.1 Preparation of chromosomes from Lymphocytes
Chromosomes were prepared using a small amount of fresh blood from a volunteer 
and ‘chromosome medium 1A\ 200fil of blood was added to each 5ml tube of 
medium and incubated for 72 hours at 37°C. Tubes were agitated daily to prevent 
setting of the contents. 71 hours after the blood had been seeded, colcemid was added 
to each tube to a final concentration of O.lg/ml. Tubes were then agitated gently and 
left for 1 hour at 37°C. Following this incubation, the blood was transferred to 15ml 
Falcon tubes, spun down in benchtop centrifuge (MSE) (2500rpm for 5min), and the 
supernatant was poured off. Cells were re-suspended in small amount of remaining
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medium and 10ml of warmed (37°C) hypotonic solution added slowly. Tubes were 
incubated at 37°C for lOmin before being spun, as detailed before. The hypotonic 
solution was poured off, leaving a very small amount remaining above the cell pellet 
in which the cells were re-suspended. At this stage it was crucial that cells were well 
suspended and not clumped. 1 0 ml of fix was added to the cell suspension very slowly 
drop-wise, with the tube constantly being agitated with the fingers. Once the fix was 
all added, the cells were left at room temperature for 15min. Tubes were then spun as 
before. The fix was poured off, leaving a small amount remaining, in which the cells 
were re-suspended and 10ml of the fix solution was added for the second time. Cells 
were spun immediately this time.
This process of fixing and spinning samples was continued till the re-suspended 
solution became clear and there was no trace of haemoglobin from the lysed red 
blood cells, usually 5-6 repetitions. A sample of the fixed cells was then dropped 
onto a slide to check for the presence of metaphase spreads and also for 
determination of cell density. Final lymphocyte preparations were stored in fix at - 
20°C.
2.2.2.2 Preparation of chromosomes from the BICR cell lines and HEK cells
Since these cells were grown on feeders, the first step was to remove the feeders a 
day before preparing the chromosomes from the keratinocytes. To do this, medium 
was removed and 4ml of warmed up (37°C) PE was added to the 90mm tissue 
culture dish (Falcon) and left for about 30 seconds. The feeder cells were removed by 
vigorous pipetting. After removing the PE, the remaining keratinocytes in the dish 
were washed three times with 5ml of PBS and the medium replaced.
Chromosomes were prepared from 90mm tissue culture dishes of sub-confluent 
(70%) cell lines. Colcemid was added at a concentration of 1/100 to the medium and 
left for 3 hours. After the incubation period, medium was removed from the plate 
into a 15ml falcon tube. The cells were washed with 2-3ml of PBS and added to the 
falcon tube. They were trypsinised as usual and neutralised using the medium poured 
out earlier into the falcon tube. They were then spun down at 600rpm for lOmin and 
the supernatant was poured off. The tube was flicked gently to loosen the pellet and 
2ml of the warmed up (37°C) hypotonic solution was added dropwise with constant 
flicking of the tube using the fingers. The re-suspended cells were incubated at 37°C.
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Following incubation, 2ml of fresh fixative was added and mixed by inverting the 
tube a few times. The tube was spun at 600rpm for 5min in a benchtop centrifuge. 
After the spin, supernatant was poured off and 2ml of fresh fixative was added 
dropwise as described before. This time, the tube was left at room temperature for 
30min and then spun down as before. The re-suspension, incubation at room 
temperature and the spinning down steps were repeated once more before finally re- 
suspending the cells in a volume of fixative which would not result in highly 
concentrated spreads.
2.2.2.3 Preparation of chromosomes from other cell lines
Chromosomes were prepared from 75cm tissue culture flasks (NUNC) of sub­
confluent (70%) cell lines. 1/100 concentration of colcemid was added to the medium 
and then incubated for 3 hours at 37°C. Medium was then removed, cells were rinsed 
with PBS and trypsinised. Cells were washed in PBS, spun down (2500rpm for 5min) 
in a benchtop centrifuge and the PBS poured off, leaving a small amount covering 
the cells. The pellet was re-suspended in this small amount of PBS and 10ml of 
warmed hypotonic solution added as for the lymphocyte and keratinocyte 
preparations. All cell lines were incubated for 15min with hypotonic solution at 37°C 
and then spun, as before. The chromosome preparation was continued as outlined for 
lymphocytes with fix and spin steps being repeated 4-5 times.
2.2.2.4 Fixing chromosomes on slides
A small volume of chromosomes in the fixing solution were dropped onto a slide 
from a height and the area of spread marked on the slide using a diamond pen. The 
slide was fixed for an hour at room temperature and air-dried. The dried slide was 
incubated for an hour in lOOpg/ml RNase in 2XSSC at 37°C. After rinsing the slide 
in 2XSSC, it was incubated in pepsin solution for lOmin at 37°C. The slide was 
rinsed in water once and post-fixed for lOmin in STF at room temperature. Finally, it 
was dehydrated 2X2min in 70% ethanol and then 2X2min in 100% ethanol.
2.2.2.5 Biotin labelling for fak  probe
Nick translation reaction was carried out using lpg  of isolated FAK fragment and 4pi 
of biotin labelling mix, made upto 2 0 pl with dF^O and incubating for one and a half
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hours at 16°C. 5(xl of sodium acetate, lOOpl Human Cot-1 DNA, and 300pl of 100% 
ethanol were added to the mix and then kept at -20°C overnight. The next morning, 
the tube was spun at 13,000- 15,000rpm in a microfuge for 15min and the 
supernatant was removed. Precipitated DNA was washed in lOOpl of 70% ethanol 
and then re-spun for 5min at 13,000- 15,000rpm. Ethanol was removed and the DNA 
was left to air dry before being re-suspended in 60pl of 50% hybridization mix.
2.2.2.6 Chromosome denaturation
In order to denature the chromosomes after they have been being fixed onto the slide 
(as described in ‘chromosome preparation’), 30pl of 70% formamide (made up in 
2XSSC) were pipetted on the marked section on the slide and covered with 22mm X 
32mm glass cover slip. The chromosomes were then denatured for 5min at 80°C 
using the Hybaid Omnislide system, dehydrated first in 70% and then 100% ethanol, 
and were finally dried by placing on a slide drying rack.
22.2.1 Probe denaturation
For FAK probe
The labelled probe was heated at 75°C for 5min, placed briefly on ice and then spun 
down. After spinning down, the probe was placed at 37°C for half an hour.
For centromeric probe
The digoxigenin labelled probe was heated at 75°C for 5min.
For c-Mvc probe
The digoxigenin labelled probe was incubated for 5-10min at 37°C.
2.22.8 Hybridisation of slides
After denaturing the chromosomes and the probe, 12 pi of denatured probe was added 
to the slide, covered with a coverslip making sure that there were no bubbles, and 
then the edges of the coverslip were sealed with Cow Gum, rubber adhesive using a 1 
or 2ml syringe. The slide was incubated in the Hybaid omnislide system overnight at 
37°C. Where double hybridisations were performed, using a centromeric probe and a 
single copy (like FAK) probe, 3pl of the centromeric probe and 9pi of single copy
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probe were added. For doubles with two single copy probes (FAK and c-Myc), 5pi of 
each was applied.
2.2.2.9 Probe detection
After the overnight incubation, the slides were first washed and blocked before 
proceeding to the detection steps. The wash and block procedure was the same for 
single or double hybridisations. For washing, the coverslips were removed by 
pouring a small volume of 2XSSC over them and then peeling off the Cow Gum. The 
slides were then washed first in 50% formamide in 1XSSC at 42°C for 20min 
followed by a wash in 2XSSC at 42°C for 20min in Hybaid wash module. After 
washing, the slides were rinsed in 4XSSC-T for 3min in a Hybaid wash sleeve and 
then blocked in 4XSSC-TB by squirting it onto the slides and covering with parafilm 
for lOmin.
The following is the procedure for the detection of both biotin and digoxigenin 
labelled probes in a double hybridisation reaction. For single label detections, biotin 
or digoxigenin, only antibodies against either of the labels were used at the 2nd and 
3rd layer detection step.
For the 1st layer detection, FITC-Avidin DCS was used at a concentration of 1:200 in 
4XSSC-TB. lOOpl of the dilution were added to each slide, covered with parafilm 
and the slides were then incubated at room temperature in a dark Hybaid humidity 
chamber for 1 hour. Following incubation, the slides were washed in 4XSSC-T at 
room temperature for lOmin using Hybaid wash sleeve.
For the 2nd layer detection, biotinylated anti-avian D was used 1:100 and sheep anti- 
digoxigenin was used at 1:200. Both were diluted in 4XSSC-TB and lOOpl of the 
dilution of each was applied to the slides and covered with parafilm. As before, the 
slides were incubated at room temperature for an hour in the dark Hybaid humidity 
chamber and then washed in 4XSSC-T for lOmin at room temperature.
3rd layer detection involved incubating the slides with FITC-avidin DCS (1:200) and 
anti-sheep donkey texas red (1:300). lOOpl each of the dilutions (made in 4XSSC- 
TB) were applied to the slides and covered with parafilm. Following incubation at 
room temperature for an hour in the dark Hybaid humidity chamber, the slides were 
washed with 4XSSC-T for 20min. They were then dehydrated first in 70% ethanol 
and then 100% ethanol and dried on a slide drying rack. A drop of vectashield with
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DAPI was added to each slide, covered with a glass coverslip and sealed with nail 
varnish. Slide were viewed using Axioskop (Zeiss) fluorescent microscope and 
photographed with the fitted camera and detector controller (Princeton instruments 
Ltd).
2.2.2.10 Cutting and storage of frozen sections
5mm thick frozen sections from tissue blocks were removed from liquid nitrogen and 
placed on aminopropyltriethoxysilane (APES)-treated slides and air-dried. Each slide 
was then wrapped in parafilm to protect from condensation and stored at -20°C until 
use.
2.2.2.11 Preparation of frozen sections
The slides were allowed to come down to room temperature before removing the 
parafilm. The sample region was marked using a diamond pen and the slides were 
rinsed in PBS. After being rinsed, they were fixed for 10-20min and then incubated 
for 1 hour in lOOpg/ml RNase in 2XSSC at 37°C. Following this, the slides were 
incubated with 0.02% pepsin in lOmM HC1 at 37°C for 20min. They were then post­
fixed in STF for lOmin at room temperature after being rinsed in water. Finally, the 
slides were dehydrated twice in ethanol for 2min each and then air-dried.
2.2.2.12 Probe detection for frozen sections
Probe detection for the frozen sections was carried out in the same way as outlined 
before for chromosomal preparations from cell lines.
2.2.3 Protein analysis
2.2.3.1 Cell Lysis
For immunoprecipitation or western blot analysis requiring protein quantification, 
cells were lysed in NP40 buffer (with inhibitors). For this purpose, an appropriate 
volume of the buffer was added to the plates that had been washed with PBS, and 
spread around so that all the cells were covered. Frozen plates were first allowed to 
thaw on ice (These had been washed twice in PBS, snap frozen on dry ice and then 
stored at -70°C). The plates were left for 15-30min on ice to let the cells lyse. After
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the incubation, cells were scraped off using a cell scraper (Costar) and the lysate 
transferred to a microfuge tube. The tubes were spun at 14,000rpm for 20min in the 
Sorvall RC-5B centrifuge and the supernatant was transferred to fresh eppendorf 
tubes. The lysate was then either used straight away or stored at -70°C.
For all other western blot analysis, cells were lysed straight in appropriate volume of 
2XSB and scraped off using cell scrapers. The viscous lysate was sonicated giving 4, 
5-10 second pulses. The lysate was then either loaded on to a gel or stored at -70°C.
2.2.3.2 Protein assay
Protein assays were carried out using Micro BCA protein assay reagent kit. For 
calibration, 7 standards containing 0, 5, 10, 15, 20, 25 and 30pg of BSA were 
prepared in lml of dH20  and lm l of assay reagent mix (prepared according to 
manufacturers guidelines). 7.5pi of the lysis buffer were also added. For the samples, 
7.5pl of the lysate were added to lm l of dH20  and lml of assay reagent mix. The 
standards and the samples were incubated for 45min at 60°C in a waterbath. After 
incubation, the contents were transferred to plastic cuvettes (Elkay). Protein was 
quantified using Beckman DU 650 Spectrophotometer at the wavelength of 562X. 
Standards were then plotted as a graph and protein concentration for the samples 
determined.
2.2.3.3 Immunoprecipitation
Protein A-sepharose beads were re-hydrated by incubating with PBS on ice for 1 
hour, washed twice with PBS and taken up in the same buffer to give a 50% w/v 
protein A sepharose slurry.
Aliquots of cell lysate containing about lmg of protein (as determined by protein 
assays) were incubated with lOpl of normal rabbit serum on ice for 15min to pre­
clear. 50pl of protein A sepharose slurry was added to each of the aliquots and the 
tubes were rotated on a spiramix (Denley) at 4°C for half an hour. They were then 
flashspun in the microfuge to precipitate the beads. The supernatant from each tube 
was removed and incubated with 5 pi of anti-FAK antibody on ice overnight. As 
before, 50pl of protein A sepharose slurry was added and the tubes rotated on the 
spiromix for half an hour to precipitate the protein. After precipitation, the beads
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were spun down at 14000rpm in a microfuge, washed 3 times with NP40 buffer 
(without inhibitors), and kept on ice for western blot analysis or cleavage assays.
2.2.3.4 Calpain and ICE cleavage assays
Immunoprecipitated FAK was washed with either lml of calpain or ICE buffer 
without any DTT. After spinning at 14000rpm, the supernatant was removed and the 
beads re-suspended in 30[il of either calpain or ICE buffer, this time containing DTT. 
For calpain cleavage assays, lp l of 1:10 diluted calpain I was added to the re­
suspended immunoprecipitates and the reaction carried out in a 30°C waterbath. For 
ICE cleavage assays, lp l of S/M extracts (a gift from Prof. Earnshaw, Edinburgh; 
Lazebnik et a l , 1994) was added to each immunoprecipitate and the reaction carried 
out in a 37°C waterbath.
2.2.3.5 SDS polyacrylamide gel electrophoresis
SDS-PAGE gels were set using ATTO gel casters and formers. Protein samples were 
mixed with equal volumes of 2XSB (sample buffer) first or in cases where the cells 
had been lysed in it, they were boiled directly for lOmin on the heating block before 
loading on the gel. Gels were run using Pharmacia electrophoresis power supply- 
EDS 600. Protein molecular weight standards were used for determination or 
verification of the molecular weight of the proteins investigated.
2.2.3.6 Western blotting analysis
Proteins separated in SDS polyacrylamide gels were transferred to a nitrocellulose 
membrane by semi- dry blotting. For this purpose 12 pieces of 3mm Whatman 
chromatography paper and a piece of nitrcellulose membrane, all the same size as the 
gel, were soaked in transfer buffer. The membrane and the gel were placed between 
stacks of six pieces of soaking paper on either side after being soaked themselves, 
and put on the blotting apparatus. After transfer for 1 hour, the membrane was 
incubated for one hour or overnight with blocking buffer. Incubations with primary 
antibodies, and subsequent washes were carried out as per the instructions supplied 
with each antibody. For anti-FAK antibody, the blocking buffer was made up with 
BSA, incubation with primary antibody was for 1 hour and three 15mins washes 
were done with PBS+0.2% Tween-20. For other antibodies, overnight incubation
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with the primary antibody was carried out at 4°C. After the washes following 
incubation with primary antibody, the membrane was incubated with 1:3000-5000 
dilution of horseradish peroxidase-linked sheep anti-mouse or anti-rabbit antibody in 
blocking buffer for 1 hour at room temperature on the shaker. After three more 
washes with the wash buffer, the proteins were detected by ECL following 
manufacturer’s instructions. The nitrocellulose membranes were dried briefly on 
Whatman chromatography paper, wrapped in DOW Saran wrap and put into a film 
cassette with intensifying screens. Chemiluminescence was recorded on Fuji RX 
medical X-ray film. Films were developed in Kodak X-OMAT 480 RA processor. In 
some cases the amount of staining was quantified using a pdi Arcus II scanner and 
pdi Quantity one software. To reprobe the blot with another antibody, membrane was 
stripped in strip buffer for 30min at room temperature. After stripping, the membrane 
was washed twice in wash buffer for lOmin each followed by repetition of the 
western blot protocol starting from blocking.
2.2.4 DNA analysis
2.2.4.1 Bacterial transformations
20pl of competent DH5a bacterial cells were aliquoted into chilled microfuge tubes, 
lp l of diluted DNA was added to the cells and shaken to mix. The tube was then 
placed on ice for 30min, heat shocked for 40 seconds in a 42°C water bath, then 
placed back on ice. 80pi of L Broth was added to the cells and the microfuge tubes 
were left to shake at 225 rpm for 1 hour at 37°C. Afterwards, the cells were all plated 
onto a LB agar plate containing the antibiotic for which the resistance gene is carried 
by the transfected DNA.
2.2.4.2 Extraction of Plasmid DNA
DNA extraction was carried out using Qiagen plasmid prep kits.
2.2.4.3 Calculation of DNA concentration
The concentration and purity of solutions of isolated DNA fragments or plasmids was 
determined spectrophotometrically as described in Sambrook et ah, 1989 using a 
Beckman DU 650 Spectrophotometer.
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2.2.4.4 DNA agarose gel electrophoresis and isolation of DNA fragments from 
agarose gel
Agarose gels were prepared by boiling a solution of 50ml lXTris acetate buffer 
mixed with the appropriate percentage of agarose (normally ranging from 0.8 to 
1.2%). 5pl of lOmg/ml ethidium bromide solution was added to the gel mix before 
poring it into an LKB agarose gel former. Before loading into the set gel, equal 
volume of 2XSSB buffer was added to the samples and the gel run at 100mA in a 
LKB 2012 Maxiphor electrophoresis unit using a Consort Flowgen electrphoresis 
power supply, lp l of XHindlll or (j)X Hae III DNA markers were run alongside the 
samples after adding 2XSSB. The DNA bands were visualised on a UV light box and 
video image prints of the gels were taken using an Appligene Imager video camera 
and control unit and Seikosha VP-1500 printer.
DNA fragments were isolated from the agarose gel using the Qiaquick gel extraction 
kit (Qiagen) following manufacturer’s instructions.
2.2.4.5 DNA extraction from cells for DNA laddering analysis
Trypsinized cells were collected in 50ml Falcon tubes and washed in PBS by being 
spun for 5min at lOOOrpm and then re-suspended in PBS 2-3 times. After the final 
spin, PBS was removed and the cells re-suspended in 200pl of TNE and transferred 
to microfuge tubes. lOpl of 10% SDS (l/10th volume) was added to the re-suspended 
cells and mixed gently but thoroughly in order to lyse them. The viscous mix was 
then incubated with 5pl of lOmg/ml proteinase K at 37°C overnight. Following 
incubation, an equal volume of water saturated phenol was added to the tubes and 
mixed gently. The tubes were spun for 5min at 13000rpm in a microfuge and the 
upper layer was removed using a broad tip as the mix is very viscous at this stage. 
Addition of water saturated phenol and removal of the upper layer was repeated 
again. After this, an equal volume of chloroform was added, the mix shaken gently 
and the spun as before. The upper layer that contains the DNA, was removed to a 
fresh tube. To this, added 1.5 to 2 volumes of 100% ethanol and mixed. The 
precipitated DNA was spun for 5mins in a microfuge at room temperature and the 
supernatant poured off. The DNA pellet was then washed in lm l of 70% ethanol, 
vortexed, and re-spun for 2min at room temperature. All ethanol was removed and
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the pellet re-disolved in 50-100pl of TE. lul of lOmg/ml DNase free RNase A was 
added and heated at 37°C for 30min with the cap open to get rid of all ethanol. To 
run the DNA on a 2% tris-borate gel, an equal volume of gel loading buffer (FDE) 
was added and the mix heated for 10-15min at 65°C, leaving the cap open. The gel 
was run at about 50V, 100mA for 2-3 hours.
2.2.4.6 Sub-cloning the constitutively active form of pllO
The construct for the constitutively active form of p i 10 was originally contained 
within the pEF-BOS vector which does not carry the gene for neomycin resistance. 
Since neomycin selection was required for stable transfections, the p i 10 construct 
was sub-cloned into another vector, pcDNA3.1 (+), which is resistant to neomycin. 
Restriction digests were carried out in order to cut out the p i 10 construct from pEF- 
BOS. BamHl and Sail were used for restricting 5pg of DNA in a total reaction 
volume of 50pl. Digests were run on a 0.8% agarose gel and the required DNA 
fragment, of 4kb length, was extracted. 3pg of pcDNA3.1 (+) was also cleaved using 
BamHl and Xhol. Following the restriction digestion of pcDNA3.1 (+), phosphatase 
reaction was carried out to prevent the restricted fragments from ligating back. For 
the ligation of p i 10 into the pcDNA3.1 vector, ligation reactions with approximately 
lOOng of vector DNA and 200ng of p i 10 DNA were carried out at 4°C overnight, in 
a total reaction volume of 20pl. Ligation reactions with just pllODNA and vector 
DNA were also set up as controls. Following ligation, the reaction mix was used for 
bacterial transfection, and plated out on ampicillin minus agar plates. After 
incubation overnight at 37°C, ampicillin resistant clones were picked up and DNA 
was extracted. Restriction digests were carried out on extracted DNA to confirm that 
the required construct comprised of pcDNA3.1 with p i 10 as the insert.
2.2.5 TUNEL assay
2.2.5.1 Fixing the cells
Medium from the tissue culture dishes was transferred to universal tubes. The cells 
were washed once in PBS and then trypsinised. Medium in the tubes was used to 
neutralise trypsin and the cells transferred back to the tubes. The tubes were spun at 
HOOrpm for 5min in a benchtop centrifuge. After removing the medium, the cells
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were fixed in lml 1% formaldehyde in PBS (stored at 4°C) for 15min on ice. 
Following fixation, they were centrifuged at 2000rpm for 5min. Formaldehyde was 
removed and the cells were re-suspended in 200pi of PBS and then lm l of 70% 
ethanol in PBS (stored at -20°C) was added and the cells transferred to eppendorf 
tubes. The cells were stored at 4°C till ready to stain.
2.2.5.2 Staining the cells
Fixed cells were centrifuged at 5000rpm for 5min in a microfuge and re-hydrated in 
PBS on ice for 30min. After re-hydration, they were again centrifuged for 5min at 
5000rpm, resuspended in 50pl of cacodylate buffer and incubated at 37°C for 30min. 
Following incubation, lml of PBS was added to wash the cells and then the tubes 
were centrifuged at 5000rpm for 5min. The cells were re-suspended in lOOpl of stain 
buffer and incubated in the dark for 30min at room temperature. For the final wash, 
lml of PBS containing 0.1% Triton X-100 was added and the cells were spun as 
before. They were then re-suspended in 500pl of PBS containing lOmg/ml propidium 
iodide.
2.2.5.3 Flow cytometric analysis
Flow cytometric analysis was carried out on Becton Dickinson FACScan using the 
Cell Quest programme. The cells were collected at 0% compensation for FITC 
labelling because the analysis was done on two dimension plots where the propidium 
iodide labelled red cells were distinguishable. The forward scatter (FSC) was set at 
E-l. Green fluorescent cells (FL1) were collected in the log phase at the voltage of 
528. The voltage for the collection of cells labelled red (FL2) was set at 430. These 
values were adjusted from time to time depending on the intensity of signals from 
sample to sample. Labelled cells were visualised using a dot plot of FL2-W (width of 
the signal) against FL2-H (height or the intensity of the signal) to gate single cell 
population. Percentage of FITC labelled cells was determined from this gated cell 
population.
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2.2.6 Caspase assay
2.2.6.1 Cell preparation
Medium from the tissue culture dishes was transferred to 50ml Falcon tubes. The 
cells were washed once in PBS and then kept at 37°C for a few minutes after 
addition of 10ml PE. Attached cells were then detached by vigorous pipetting of PE 
and then transferred to the Falcon tubes. Tubes were centrifuged at llOOrpm for 
5min. The supernatant was removed and the cells washed three times in lm l of PBS 
and finally re-suspended in lOOpl of PBS. The cell suspension was transferred 
directly to eppendorf tubes chilled in liquid nitrogen for snap freezing.
2.2.6.2 Caspase assay
The assay to detect the presence of active caspases was carried out using a biotin 
labelled peptide called zEKD-amok which binds to the active site of the caspases and 
was detected in a western blot analysis using streptavidin conjugated horse radish 
peroxidase antibody. The assay was carried out as described in Martins e ta l, 1997.
2.2.7 Tissue Culture
2.2.7.1 Recovering frozen cells
Cells contained in freezing ampules (NUNC) were recovered from liquid nitrogen 
and thawed in warm water (37°C). The cells were then transferred to universals 
containing fresh medium and centrifuged for llOOrpm for 5min. They were re­
suspended in fresh medium and added to tissue culture flasks for culturing.
22.1.2 Preparing CEF from chick embryos
Primary CEF were prepared from 10 day old embryos obtained from Wickham 
Laboratories Ltd., Wickham, Hampshire, England by the method outlined in Tato et 
a l , 1978. Cells were counted using a Neuber haemocytometer and the cell
n
suspension diluted to a cell density of 10 cells/ml. lml were then stored in liquid 
nitrogen as described below or cultured in tissue culture flasks.
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2.2.7.3 Cell culture
All cells were cultured in tissue culture flasks and dishes and cultured at appropriate 
temperatures in humid incubators with 5%CC>2 levels. Confluent cultures were 
trypsinised and split for passaging. All manipulations were carried out in Class 2 
Microbial Safety Cabinets.
2.2.7.4 Trypsinisation
For Rat-1 fibroblasts:
Medium was removed from confluent culture flasks or dishes. 10ml of diluted trypsin 
(in PE) was added, spread around to wash all the cells and then all but lml of it was 
removed. The cells were left for a couple of minutes at room temperature to let them 
detach and then 10ml of fresh medium was added to neutralise trypsin. Cells were 
then spun at llOOrpm for 5min, the medium replaced with fresh medium and then 
appropriately plated out in flasks or dishes containing medium.
For CEF:
Medium was removed from the flasks and the cells were washed once with PBS. 
10ml of trypsin diluted in PBS was added to the flask and spread around till the cells 
started to detach. Trypsin was then removed immediately and 10ml of fresh medium 
was added to neutralise trypsin and collect the detached cells. The cells were then 
spun down at llOOrpm for 5min, and plated out in new flasks containing fresh 
medium.
For Feeder cells:
Cells were washed in 7ml of PBS before adding lm l of diluted trypsin (in PBS). 
They were then left for a few minutes at 37°C to allow them to detach from the base. 
Trypsin was neutralised by adding 4ml of medium, collected in a universal tube 
(Sterilin) and spun down at llOOrpm for 5min. They were then counted and 105 cells 
were plated out in each dish. The rest were irradiated as described below.
For the BICR cell lines grown on feeders:
Medium was removed and the cells washed with PBS. Then to remove the feeders, 
about 5ml of PE was added and pipetted vigorously a few times. After removing PE, 
10ml of PBS were again added to remove all feeder cells. The keratinocytes were 
themselves trypsinised by adding lm l of diluted trypsin (in PE). Trypsin was
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neutralised by 4ml of fresh medium, the cells were spun down at llOOrpm for 5min 
and counted as described for the feeder cells. 3X 105 cells were then mixed with 106 
of feeder cells and re-plated.
For all other cell lines:
Same as the BICR cell lines after the removal of feeders.
2.2.7.5 Freezing the cells
Following trypsinisation, the cells were cenrifuged for 5min at llOOrpm and re­
suspended in freezing medium, lml aliquots were transferred to freezing ampules 
(NUNC). The freezing ampules were kept for a few days at -70°C and then stored in 
liquid nitrogen.
22.1.6 Irradiating feeder cells
Feeder cells were irradiated using the Alcon II Teletherapy unit containing a 222 TBq 
(6000 Ci) Co-60 source.
22.1.1 Counting cells
400pl of the cell suspension was added to 19.6ml of PBS and the number of cells per 
ml of the solution determined by using Casyl cell counter and analyser systems 
(Scharfe system).
2.2.7.8 Cell transfection
Semi-confluent (50%-70%) cell cultures plated out in 80mm2 tissue culture flasks or 
60mm tissue culture dishes, were transfected with plasmid DNA using DOTAP 
transfection reagent (Boehringer Mannheim) following manufacturer’s protocol.
For transfections using c-Myc RCAN (Provided by David Gillespie, Beatson 
Institute, Glasgow, UK), fresh medium was added the day following the transfection. 
The cells were then cultured and split like normal cells.
For transfection with vectors carrying the neo gene for G418 resistance, the cells 
were trypsinised upon reaching confluence. Two days following trypsinisation, fresh 
medium containing lmg/ml G418 was added to select for the transfected cells. Fresh 
medium containing G418 was added every other day to remove the dead cells. When 
single transfected clones had grown to a visible size, they were picked up and plated
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out in 30mm tissue culture dishes. To pick up clones, each colony was marked using 
a marker pen. Medium was then removed and the colonies picked up by detaching 
the cells through vigorous pipetting of a very small amount of medium. Care was 
taken to pick up well isolated colonies so that cells from neighbouring colonies did 
not get picked up. Each clone was maintained in medium containing G418.
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Chapter 3: Results 1 
Increased dosage and amplification of FAK in human cancer
3.1 Introduction
There are certain characteristics that differentiate cancer cells from their normal 
counter parts. Tumour cells need to be able to proliferate in a deregulated way, they 
need to be able to invade surrounding tissues and then finally be able to survive in an 
anchorage-independent manner to colonize distant organs. Tumour development is a 
multistage process and may result from the action of any one or a combination of 
chemical, physical, biologic or genetic insults to the cell (Weinberg, 1989; Pitot, 
1993). The development of a tumour involves a number of complex genomic 
changes. Two predominant categories of genes influencing this process are, the 
oncogenes and the tumour suppresser genes. Proto-oncogenes (cellular genes having 
a viral counterpart) or cellular oncogenes (genes that have the capacity to cause 
cancer but no viral counterpart has been found) require to be activated in order to 
drive the unrestricted growth or survival of a tumour cell (Pitot, 1993). On the other 
hand, the growth promoting effects of oncogenes are counter balanced during normal 
cell proliferation by the effects of tumour suppressor genes. Development of a 
tumour thus requires the silencing of such genes.
3.1.1 Importance of overexpression of proteins in tumours
Tumour progression in spontaneous or experimentally induced cancers is 
accompanied by genomic instability. Multiple chromosomal abnormalities have been 
reported in a variety of human cancers including small cell lung carcinoma (Birrer 
and Minna, 1989), and colonic adenocarcinoma (Vogelstein et al., 1988). These 
genomic alterations can lead to overexpression of oncogenes and reduced expression 
of the tumour suppresser genes involved in tumour progression.
Of particular relevance to this study is the overexpression of some known oncogenes 
in tumour cells, and the genetic changes which cause overexpression. In a study done 
to analyse global profiles of gene expression in human cancer cells, 108 out of a total 
of 289 differentially expressed transcripts, were expressed at higher levels in the 
colon cancers than in normal colon tissue (Zhang et al., 1997). The study also
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suggested that the genes exhibiting the greatest differences in expression are likely to 
be the most biologically important. Two examples of proteins that are often 
upregulated during tumour development are given below.
The myc family of cellular oncogenes is an example of the oncogenic effects being 
projected through overexpression. The myc family consists of three protein members, 
c-Myc, N-myc , and L-myc, all of which encode related nuclear phosphoproteins 
(reviewed in Prins et al., 1993). The proteins appear to play a central role in the 
control of cell proliferation and differentiation. c-Myc is a DNA binding transcription 
factor. Tumour cells expressing higher levels of the protein show a reduced growth 
factor requirement and a shorter Gl-phase of the cell cycle. In some cases, c-Myc has 
also been known to promote immortalization of cells (reviewed in Prins et a l, 1993). 
Overexpression of L-myc is observed in SCLC specimens or cell lines and in some 
human leukaemia cell lines (reviewed in Prins et a l, 1993).
Telomerase, an enzyme required to maintain the length of the chromosomal ends, 
known as telomeres, is another example of a protein whose altered expression has 
been implicated as having a role in tumour formation (Soder et al., 1997). 
Telomerase is inactivated before or soon after birth, as a result of which telomeric 
attrition is experienced by all normal cells and is thought to be a mechanism by 
which cells limit their clonal proliferation (Soder et al., 1997). Thus, reactivation of 
the enzyme is thought to contribute to immortality in tumour cells. Telomerase is 
often, but not always, found to be overexpressed in immortal human cells and 
tumours.
3.1.2 Mechanisms of protein upregulation
The mechanism/s by which overexpression of any gene is achieved in a cell are 
varied. Generally, they can be divided into two categories:
1. Genetic: These changes occur in the genome and lead to an increase in the copy 
number of the gene in question. More copies of the gene could, in theory, lead to 
more protein. For example, a study has shown the correlation between the gene
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copy number of DNA topoisomerase 1, an enzyme that catalyses the breakage 
and rejoining of DNA during replication, and protein expression (McLeod and 
Keith, 1996). This analysis was carried out in breast and colon cancer cell lines, 
which showed an altered gene copy number for the enzyme that correlated with 
altered protein expression. Gene amplification, isochromosome formation and 
gain of whole chromosomes are genomic changes which could lead to an increase 
in the gene copy number. Increase in protein level can also be achieved through 
deregulation of transcription control. Point mutations in the promoter region or 
translocation of the gene to another region in the genome can facilitate more 
efficient transcription. For example, c-myc activation in B cells involves its 
translocation to the Ig locus which lies on chromosome 14 (Haluska et al., 1986).
2. Post transcriptional and post translational: Increased mRNA or protein 
stability can lead to more efficient translation of the protein and thus to increased 
protein levels. An increase in protein stability can also enhance the level of 
detectable protein in the cell.
Since this study deals with the genetic mechanisms that might contribute to increased 
levels of proteins, the process that leads to the development of these changes is 
described.
3.1.3 How amplicons arise
Amplification is defined as the production of additional copies of a chromosomal 
region occurring as tandem repeats. Numerous hamster cell line models have been 
used to investigate the mechanism involved in the creation of these regions. Some of 
these models have been reviewed by Stark (1993). The primary events of 
amplification do not involve over replication of the DNA region, but are based on 
recombination followed by unequal distribution of the recombined DNA into the two 
daughter cells. How an initial duplication may eventually give rise to an amplicon 
containing several copies of that region is outlined in Figure 5.
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Three possible ways by which recombination between two sister chromatids can lead 
to duplication of a region of DNA are shown in Figure 5. The process involves 
unequal sister chromatid exchange followed by bridge-break-fusion cycles 
(Wintersberger, 1994). As is shown, two of the possible mechanisms involved, a and 
b, require the creation of a dicentric chromosome which will break at the next round 
of replication to produce one chromosome with two copies of the defined DNA 
region (in black). The third mechanism, c, involves the formation of the duplication 
following non-homologous recombination. This mechanism does not require any 
subsequent breakage as both the chromatids are monocentric.
3.1.4 Mechanism of formation of isochromosomes
Isochromosomes are defined as chromosomes in which the two arms, on either side 
of the centromere, are mirror images of each other. In other words, isochromosomes 
carry the duplication of one of the chromosome arms. A possible mechanism behind 
the formation of isochromosomes is shown in Figure 6. The process is thought to 
initiate during DNA replication as the chromosomes line up at the equator to 
segregate to the daughter cells. The process starts when the chromosome in question 
(shown in red), fails to line up correctly at the equator, i.e. instead of lining up along 
the plane of the equator, it lines up perpendicular to the plane. This would lead to the 
segregation of the two parts of the chromosome at the centromere, but the daughter 
cells would have only one arm of the chromosome each. An isochromosome would 
thus be formed.
3.1.5 Mechanism for gain of chromosomal copies
Most cancer cells are aneuploid, i.e., they carry extra or are missing chromosomes 
compared to the normal complement. Non-disjunction of sister chromatids during 
replication can be one of the mechanisms giving rise to aneuploidy. Non-disjunction 
of sister chromatids during anaphase, involving separation of the centromeres, leads 
to the gain of a chromosome by one of the daughter cells, leaving the other without a 
full complement. Expectedly, this means that the cell gaining an extra copy of the 
chromosome would gain extra copies of the genes on this chromosome, and might
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Figure 5 Mechanism for regional duplication: (adapted from Wintersberger, 1994) 
The diagram shows the currently accepted model for gene/regional duplication on a 
chromosome. The two sister chromatids are represented in red and light blue, dark 
blue circle represents the centromere and the region to be amplified is coloured 
yellow. There are three possible ways by which the depicted region can be amplified. 
According to pathway a, the process can start by a break at the telomere creating 
frayed chromosome ends followed by sister chromatid fusion. As a result, a dicentric 
chromosome is formed which breaks during mitosis to produce one chromosome 
with two copies of the region while the other ends up without any copies. The second 
pathway, b, again involves fusion of the sister chromatids at the telomere following 
unequal sister chromatid exchange. Thus resulting in a dicentric chromosome leading 
to duplication of the region. Pathway c starts by non-homologous sister chromatid 
exchange, resulting in the formation of two chromosome, one with no copy of the 
region and the other with a duplication of the region.
Three different m echanism s for regional duplication
/ \
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A
M echanism  for am plification o f an initial duplication
Figure 6 From duplication to amplification: (a) F o llow in g  initial duplication  o f  a region  
on the ch rom osom e, subsequent am plification  can arise in su ccess iv e  rep lication  cy c le s . A s is 
sh ow n  in the figure, h o m ologou s, but unequal sister shrom atid exch an ge  during m itosis can  result 
in on e ch rom osom e aquiring 3 co p ies  o f  the reg ion  w h ile  the other being le ft w ith  just one.
(b) R epeated unequal sister chrom atid  exch an ges can u ltim ately lead to the am plification  o f  the region .
thus express a higher level of the proteins encoded by genes on the gained 
chromosomes.
As stated earlier, FAK has been implicated to play a role in cell migration and cell 
survival. Since the expression level of FAK maybe a determinant of the rate of cell 
movement, and since elevated FAK may also enhance tumour cell survival, it is 
perhaps not surprising that a number of groups have found FAK to be up-regulated at 
the protein level in cancer cells. In particular, FAK is elevated in cell lines derived 
from the human melanomas, with FAK levels correlating with the rate of migration 
on fibronectin (Akasaka et al, 1995), in cervical carcinoma cell lines (McCormack et 
a l, 1997); in prostatic carcinoma tumours and cell lines (Tremblay et al., 1996), and 
in colon and breast tumours and cell lines (Owens et al., 1995). The latter study also 
inferred a link between FAK expression and tumour invasiveness. However, despite 
the mounting evidence that the expression of FAK is elevated in tumour-derived cell 
lines, the mechanism of upregulation has not been addressed.
The work now presented in the following section identifies genetic changes 
associated with FAK upregulation. An important factor which influenced this study 
was the finding that the tip of the q-arm of chromosome 8, where the fak  gene is 
thought to localize, was amplified in the lung adenocarcinoma cell line, CALU3 
(Hoare et al., 1997). The study found c-myc to be one of the oncogenes amplified 
within the region, but the length of the amplicon suggested that other genes within 
the region might be co-amplified.
3.2 Isolation of a fak  genetic probe
To isolate a PAC clone containing the sequence coding for fak  protein, nylon filters 
supporting a total of human genomic DNA library were obtained from UK MRC 
Human Genome Mapping Project Resource (UK HGMPR).
In order to screen the library, chicken fak  cDNA sequence contained within the 
Bluescript vector was used. 20pg of the cDNA was digested using Hind III restriction 
enzyme. The enzyme cuts the cDNA at four sites; 0, 1782, 2340, and 3211 bases
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generating three fragments sized 1782 bp, 558 bp and 871 bp respectively. Since the 
558 bp fragment lies within the ideal size range for a probe to screen a genomic 
library, it was selected as the optimal probe. The fragment was recovered by excising 
from the gel and isolating it from agarose using the gel recovery kit (Qiagen). The 
approximate yield was calculated to be about l\ig  using the reasoning described in 
Materials and Methods. The recovered DNA was resuspended into lOpl of TE to 
give a final concentration of O.lpg or lOOng/pi. lul of this was then run on a 1% 
agarose gel alongside 0.5pg of the Hae III markers to check the concentration and the 
size of the recovered fragment. The size of the fragment was confirmed to be 558 bp 
long and the yield to be approximately correct (Figure 7a).
Thq fak  cDNA fragment was then radiolabelled with [a32P]- dCTP using the random 
priming procedure. The nylon filters supporting the human PAC library were then 
incubated overnight with the radiolabelled probe for hybridization. Filters were 
washed and exposed to film. Hybridization of the probe to clones containing 
corresponding sequence generated positive signals (Figure 7b). True positive signals 
appear as doublets since each clone is fixed twice onto the filter (Figure 7b). 22 
positive signals were picked up in all from the library. Identity of the clones was 
determined by using the manufacturers guidelines supplied along with the filters. 17 
of these signals were confirmed as false positives on checking up against a list of 
false positives provided by the UK HGMPR. 5 clones, 4 1 16, 231 C 7, 305 A 3, 307 
J 23, and 316 G 19 were finally selected.
To confirm that the selected clones were indeed positive for fak, PCR reactions 
required to be carried out using primers designed from the 5’ and 3’ UTR 
(untranslated region) of the known fak mRNA sequence. The primers were designed 
using the chick fak  mRNA sequence that has >90% homology to the human 
sequence. They were chosen from the untranslated region since it is the most 
conserved amongst different species. To check if the primers were functioning as 
expected, a test reaction was carried out using genomic DNA isolated from the 
human fibroblast cell line, SUSM-1 (lmg/ml). 4 reactions were set up with different 
combinations of the primers, i.e. 3ab, 3ac and 5ac, and a negative control reaction 
with no DNA added. The completed reactions were run on a 1.5% agarose gel.
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Figure7 Isolation of fa k  PAC clone: (a) A 558bp fragment was isolated by 
restrictive digestion of FAK cDNA and run alongside (J)HaeIII markers to confirm 
size and yield (the product runs between markers sized 603bp and 3210bp). (b) The 
isolated fragment was radiolabelled and used as a probe to isolate PAC clones 
positive for fak from a human PAC library (provided by the UKHGMPR). The 
positive signals appeared as duplicates on the filter and their identity was determined 
following the guidelines provided along with the filters, (c) Primers generated from 
the 3’ or 5’ untranslated region (UTR) were first tested on DNA from whole genome 
to confirm the size of the products (run alongside (|)HaeIII markers; products run 
between markers sized 603bp and 310bp) and to see if they work (described in more 
detail in Materials and Methods), (d) Two of the primer pairs from the 3’ region, 3ab 
and 3ac, were found to be suitable for the task of identifying the PAC clone 
containing fak. DNA was isolated from 5 possible PAC clones and following PCR 
analysis using the primer pairs from 3’UTR, clone 307 J 23 was identified to be 
positive for fak.
a Isolation o i fa k  cD N A  fragment h Possible PAC clones positive for fak
'  N
PCR products o f  d ifferent prim er pairs cl Identification  o f  c lo n e  307 .1 23  to be p ositive
for fak
Primer combinations 3ab and 3ac worked well whereas 5ac did not yield any 
products (Figure 7c). Therefore, 3ab and 3ac were used for future experiments to 
confirm the fak  positive clone. PCR reactions confirmed clone 307 J 23 to be 
positive for fak (Figure 7d).
3.3 Localisation of the fak  probe to the human chromosome 8q24
Having isolated a PAC probe for fak, it was important to confirm its genomic 
localisation. The gene encoding FAK had previously been mapped to mouse 
chromosome 15 and to human chromosome 8 (Fiedorek and Kay, 1995). Its synteny 
with mouse chromosome 15, and the previously known linkage of fak  to the proto­
oncogene c-myc in the mouse, suggested that human 8q24, where human c-myc is 
located, was the likely site for fak localization.
Previously prepared chromosomes from lymphocytes were used. The chromosomes 
were fixed on a slide as described in Materials and Methods. The PAC probe was 
biotin labeled using the nick translation kit (Boehringer Mannheim). DIG labelled 
centromeric probe for chromosome 8 was also used to confirm that fak resides on the 
long arm of chromosome 8. The double hybridization procedure confirmed that the 
human fak gene mapped to the q arm of chromosome 8 and that normal lymphocytes 
had two copies of the gene (Figure 8).
3.4 fak  gene copy number gain in cell lines from a variety of human epithelial 
tumour types
Various studies have shown FAK protein levels to be upregulated in a variety of 
human epithelial tumour types. To test the generality of fak copy number gains, FISH 
analysis on archived chromosome preparations from cell lines derived from lung, 
breast, and colon tumours was carried out. Protein analysis for a few selected cell 
lines with high number of fak gene copies from amongst the ones used for FISH 
analysis, was also carried out to determine if the increase in gene dosage of fak  was 
accompanied by high levels of FAK protein expression. A probe with high efficiency 
is necessary for accurate mapping by FISH and is essential for quantitative analysis
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Figure 8 Localisation of fa k  to chromosome 8q: Chromosomes were prepared from 
lymphocytes that were arrested in metaphase using colcemid and probed with both a 
DIG-labelled centromeric probe for chromosome 8 (visualised as red) and biotin 
labelled fak  probe (visualised in green), fak  was confirmed to localise to the 
telomeric end of chromosome 8q.
Localisation o f  fa k  probe in chrom osom es derived from human lym phocytes
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of gene copy number (McLeod and Keith, 1996). Since the efficiency of the probe 
was greater than 95% when hybridised to normal lymphocytes, it was suitable for 
further anylysis to determine the gene copy number of fak in other cell lines. For each 
cell line, approximately 50 nuclei were counted and the mode of the signals per 
nuclei was documented.
Out of all the cell lines screened, 8/11 lung cancer cell lines, 5/5 colon cancer cell 
lines and 7/7 breast cancer lines displayed more than 2 hybridization signals in a high 
percentage of nuclei (Table 1). LCPH3 (Milroy et al., 1992), one of the lung cancer 
cell lines, did not show a gain in fak  gene copy number (Figure 9). The figure shows 
a number of interphase nuclei with 2 signals each for fak.
In addition, the fak gene was also amplified in 2 of the cell lines examined, Calu 3 
(lung) and HT29 (colon) (Figure 10a, 10b; Table 1). Isochromosomes carrying the q 
arm of chromosome 8 can also be seen. Figure 10c is the magnified image of a 
chromosome, carrying the chromosome 8 centromere (labeled in red), showing 
amplification of the region containing fak.
For protein analysis, the cells were lysed in NP40 lysis buffer and 50pg of total 
protein was separated by gel electrophoresis. Immunoblotting was carried out using 
anti-FAK antibody. All the epithelial cells examined had readily detectable levels of 
FAK protein. HT29 and Calu3, both of which have an amplication of fak and carry 
more than 10 copies of the gene, did express readily detectable levels of FAK protein 
(Fig. lOd). However, LS277, another lung cancer cell line which has an average of 4 
signals per nuclus, had a higher level of FAK protein as than Calu3 (Figure lOd; 
Table 1). Due to unavailability of normal tissue controls for comparison, it was not 
possible to determine if the difference between the other cell lines was tissue 
specific. Also, three of the cell lines examined, HT29, Calu3 and BT474, had faster 
migrating immunoreactive species, which are presumed to be cleavage products of 
FAK (Figure lOd). The significance of this will be discussed later.
Table 1 Summary of copy number gains of fak  locus in 
lung, colon and breast tumour-derived cell lines
Cell line Origin Signals/nucleus
Calu3 Lung cancer >10
GLC4 Lung cancer 3
LS274 Lung cancer 3
LS277 Lung cancer 4
LS763 Lung cancer 5
H125 Lung cancer 4
LCPH3 Lung cancer 2
LSI 11 Lung cancer 2
LS310 Lung cancer 2
LDAN Lung cancer 5
LSI 06 Lung cancer 4
HT29 Colon cancer >10
Colo320 Colon cancer 3
ALT-F Colon cancer 3
ALT-G Colon cancer 3
ALT-I Colon cancer 3
AA/C1/SB10 Colon cancer 3
BE Colon cancer 3
BT474 Breast cancer 6
MCF-7 Breast cancer 4
MDA436 Breast cancer 4
MDA231 Breast cancer 4
T47D Breast cancer 4
ZR75 Breast cancer 4
Figure 9 No gain in fa k  copy number in a lung cancer cell line: Interphase nuclei 
from LCPH3, a lung cancer cell line, were probed with biotin labelled fak  probe 
(visualised as green) and were found to have the normal i.e. 2 copies of fak.
Interphase nuclei derived  from  LCPH 3. a lung can cer  cell line, 
sh ow in g  norm al num ber o f fa k  gene co p y  num ber
Figure 10 Gain in fak  gene copy number through amplification in some human 
cancer cell lines: (a and b) Chromosomes prepared from Calu3 (a lung cancer cell 
line) and HT29 ( a colon cancer cell line) that were arrested in metaphase using 
colcemid, were probed with biotin labelled fak probe (visualised in green) and 
showed gain in fak  copy number through amplification, (c) Probing Calu3 
chromosomes with both DIG-labelled centromeric probe for chromosome 8 
(visualised in red) and biotin labelled fak  probe showed the presence of an abnormal 
sized chromosome 8 carrying mainly the amplified region, (d) Protein lysates 
prepared by lysing the cells from some selected cancer cell lines were separated by 
SDS-PAGE and probed with anti-FAK antibody to determine the level of FAK 
protein.
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3.5 Increase in gene dosage of fa k  is accompanied by an increase in protein level 
in >70% of the squamous cell carcinoma cell lines
Since it was not possible to quantify increase in FAK protein expression due to lack 
of normal control cell lines for the various colon, lung and breast tumour cell lines 
screened in the previous section, the BICR series of SCC derived cell lines were 
selected to study the relationship between gain in gene copy and protein expression. 
BICR cell lines are malignant keratinocytes derived from squamous cell carcinomas 
of the head and neck (Edington et al., 1995). Primary human keratinocytes, HNK, 
were used as the normal control.
FISH analysis of chromosomal preparations from a number of BICR cell lines 
demonstrated that these generally had more than 2 copies of the fak gene in a high 
percentage of nuclei (Table 2). Two typical examples are shown (Figure 11a and 
lib ). In the examples shown, BICR6 and BICR31 have 6 and 4 copies of the fak 
gene respectively, and some of these are present at both ends of an isochromosome. 
All 9 BICR cell lines screened had a high percentage of nuclei with greater than 2 
hybridization sites for fak (Table 2).
To compare the steady-state levels of FAK protein in the BICR cell lines and the 
normal keratinocytes, HNK, protein immunoblots were carried out. 25pg of cellular 
protein were separated by SDS-PAGE, blotted and probed with FAK specific 
antibody (Figure 12a). The protein levels were then quantified by densitometry and 
plotted as a histogram (Figure 12b), showing that with the exceptions of BICR16 and 
BICR63 (2/9 cell lines), the malignant keratinocyes (7/9 cell lines) displayed steady 
state levels of FAK protein that were elevated above those in normal human 
keratinocytes (HNK). However, although most cell lines had increased levels of 
FAK, there was no direct correlation between fak  gene copy number and protein 
expression. This is exemplified by BICR6 and BICR16 which each had around 6 
copies of fak gene, but which express different levels of FAK protein (Figure 12b). 
As a control for protein loading, p42/ERK2, a protein kinase that is not generally 
regulated by fluctuations in expression was examined and found not to vary (Figure 
12b). Thus, although all the BICR cell lines examined had increased fak  gene copy
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Table 2 Summary of copy number gains of fak  locus in BICR 
lines derived from squamous cell carcinomas of the 
head and neck
Cell line Site Signals/nucleus
(mode)
Signals/nucleus
(maximum)
HNK (human normal 
keratinocytes)
2 2
BICR3 Alveolus 4 4
BICR6 Hypopharynx 5 6
BICR10 Buccal mucosa 6 6
BICR16 Tongue 5 6
BICR31 Tongue 4 5
BICR56 Tongue 4 6
BICR63 Tongue 4 6
BICR78 Alveolus 4 6
BICR82 Maxilla 4 5
Figure 11 Increase in fak  gene dosage in head and neck squamous carcinoma 
cell lines: (a and b) Metaphase chromosomes were prepared from BICR6 and 
BICR31 (two of the head and neck carcinoma cell lines tested) were probed with 
biotin labelled fak probe. Arrows point to the copies of fak gene. Thick white arrows 
point to the presence of the gene at both the ends of an isochromosome.
a  G ain ot fa k  gene co p y  num ber in B IC R 31
b G ain ot fak gen e cop y  num ber and p resence oi 
isoch rom osom e in B IC R 6
/
Figure 12 Variations in expression of FAK in BICR cell lines: (a) 25pig of total 
protein from cell lysates were separated by SDS-PAGE, transferred to nitrocellulose 
and probed with anti-FAK antibody, (b) Quantitation by scanning laser densitometry 
of FAK protein in BICR cell lines is shown relative to the expression in HNK 
control. The immunoblots and quantitation shown are representative of atleast 5 
replicate experiments, (c) Lysates separated by SDS-PAGE were also probed with 
anti-PYK2 (upper panel) or with anti-p42/ERK2 (lower panel).
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number, and this may contribute to elevated protein expressions in some cases, it 
does not necessarily lead to a related increase in protein in all cases.
The expression of PYK2, a FAK homologue was also examined in the head and neck 
squamous cell carcinoma cell lines. It is not yet known if PYK2 is involved in 
cancer, and a recent study has shown that PYK2 is not able to functionally 
compensate for FAK in fak  null cells (Sieg et al., 1998). PYK2 protein levels did not 
vary in the examined cell lines and were the same as in the normal keratinocytes, 
indicating that in these cells lines, PYK2 is not elevated in expression during tumour 
development.
3.6 Evidence for increase in fak  gene dosage also in primary tumour sections
Having shown fak to be present in increased copy number in various cancer cell lines 
tested, it was important to investigate if such was also the case in primary tumour 
sections, since cultured cells, particularly cell lines, do undergo certain changes after 
long term growth in tissue culture. Finding fak  overdose in primary tumours would 
confirm that increase in fak  gene copy number in cell lines was not due to extensive 
passaging in tissue culture, but also occurred in vivo during tumour progression. 
Thus, archived frozen sections of squamous cell carcinomas derived from head and 
neck were subjected to FISH analysis using fak PAC as the probe. A representative of 
the frozen sections examined is shown (Figure 13). It can be clearly seen that several 
of the cells within the tumour contain more than two copies of fak, whilst some 
normal cells within the tumour still have the normal 2 copies of the gene, the latter 
acting as an internal control (Figure 13).
3.7 Increase in fak  gene dosage accompanies the adenoma to carcinoma 
progression in an in vitro model of colon tumour development
To address the stage during tumour progression that fak  was increased, an in-vitro 
system that models the conversion from colonic adenoma to carcinoma was used. In 
this model, a cell line was derived from a large tubular adenoma with mild dysplasia 
(PC/AA). A clonogenic variant adenoma was established (AA/C1) and a fully
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Figure 13 Elevated fak  copy number in squamous cell carcinoma sections:
Frozen squamous cell carcinoma sections were probed with biotin labelled fak  probe 
(visualised here as yellow). The nuclei were visualised as red. Cells within the 
section act as internal controls (arrows point to nuclei with two copies of fak , whilst 
broken arrows point to tumour cell nuclei which contain more than two copies of 
fak).
Elevated fa k  gene copy number in frozen sections o f  squamous cell carcinoma
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tumorigenic and invasive malignant cell line was derived by sequential chemical 
treatment and tissue culture procedures (AA/C1/SB10; model described in Williams 
et al., 1990; Brunton et al., 1997). Both the cellular and molecular changes during 
this in-vitro progression are similar to those that occur in-vivo (Manning et al, 1991; 
Williams et al., 1993), making this a relevant model to study colon cancer 
progression and the changes required for the transition to an invasive phenotype. 
FAK was found to be phosphorylated accompanying EGF induced cell migration of 
the carcinoma cells and was thus implied to regulate focal adhesion turnover and 
tumour cell motility in conjuction with c-Src (Brunton et al., 1997).
FISH analysis on the chromosome preparations derived from the adenoma and the 
carcinoma cell lines show that while the adenoma cell line (AA/C1), has the normal 2 
copies of fak, the carcinoma cell line has three copies (Figure 14a). Thus, acquisition 
of an additional copy of fak occurred during malignant conversion and did not occur 
at an earlier stage of tumour development, at least in this model. This correlates with 
the earlier findings which suggested that FAK was required for acquiring the 
malignant phenotype in this model (Brunton et al., 1997). Co-hybridisation with 
DIG-labelled c-myc was carried out at the same time (reasons and results are 
discussed in section 3.8).
Cell were lysed and cellular protein was separated by SDS-PAGE followed by 
immunoblotting carried out using anti FAK antibody (Figure 14b). Protein levels 
were quantified by densitometry (Figure 14c). Quantification results show that the 
increase in fak gene copy number was coincident with up-regulation of FAK protein 
expression. The several fold increase at protein level cannot, however, be explained 
by the gain of just one extra copy of fak. This suggests that there might be other 
mechanisms of protein upregulation involved in this case.
3.8 Increase in fak  gene copy number is accompanied by an increase in gain of 
c-myc gene copy number
As mentioned in section 3.1.1, c-myc, a known proto-oncogene, also localises to 
chromosome 8q24 in the human genome, the region where fak has also been
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Figure 14 A copy number gain of fa k  gene accompanies increased FAK protein 
expression during colonic adenoma to carcinoma conversion in vitro: (a)
Metaphase chromosome preparations of the AA/C1 colon adenoma cell line and its 
invasive derivative AA/C1/SB10 were probed with biotin labelled fak  probe 
(visualised as green), and DIG labelled c-myc probe (visualised as red). The 
chromosomes were stained with DAPI. (b) FAK expression levels in the early 
colonic adenoma PC/AA, clonogenic adenoma AA/C1 and invasive carcinoma 
carcinoma AA/C1/SB10 cell lines were determined by immunoblotting using anti 
FAK specific serum as probe (carried out by V. Brunton, Beatson Institute, Glasgow, 
UK), (c) Quantitation was carried out by scanning laser densitometry and is 
expressed as ODXmm2 (arbitrary units).
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predicted to lie. There is, thus, some likelihood of c-myc exerting the selective 
pressure for the gain of multiple copies of the region during tumour progression. It 
was therefore important to determine if there was a co-gain of the c-myc locus in the 
cell lines that showed an increase in fak gene copy number.
FISH analysis was carried out on the cell lines that showed an increase in fak copy 
number, fak probe was biotin labelled as before while DIG-labelled c-myc probe was 
obtained commercially (Appligene). Different labelling made it possible to visualise 
both the loci simultaneously. HT29, the colon cancer cell line which had earlier been 
shown to contain an amplification of fak  also displayed c-myc amplification (Figure 
15a). BICR6 along with all the BICR cell lines tested also had the same number c- 
myc gene copies as fak  (Figure 15b). The adenoma to carcinoma conversion in the in- 
vitro colon cancer progression model was also accompanied by a gain in c-myc gene 
copy (Figure 14c).
3.9 Increase in c-myc copy number is not always associated with an increase in 
c-Myc protein level
Results from the previous section raised the possibility that perhaps the gain in fak 
gene copy number was coincidental, given the established oncogenic nature of c-myc. 
If this were indeed the case, one prediction would be an associated increase in c-Myc 
protein levels in the cell lines since that would lead to a selective advantage to the 
cell during tumour progression.
To investigate if c-Myc was elevated and thus potentially responsible for the 
acquisition and retention of the whole region (through amplification, isochromosome 
formation or increased gene dosage) by the cell lines, equal amounts of protein were 
separated by SDS-PAGE, blotted and quantified (Figure 16a). The experiment was 
carried out at the same time as immunoblotting for FAK, and therefore the loading 
control was the same as shown in Figure 12a. The protein levels were quantified and 
plotted (Figure. 16b). The graph shows the comparison between the FAK and c-Myc 
protein levels in the BICR cells and the HNK normal keratinocyte. Amongst the 
BICR cell lines examined, there was considerable variation in c-myc expression.
Figure 15 Gain in fa k  gene copy number in cancer cell lines is accompanied by a 
gain in c-myc copy number: (a and b) Metaphase chromosome preparations of 
HT29, a colon cancer cell line, and BICR6, a squamous cell carcinoma cell line were 
probed with biotin labelled fak  probe (visualised as green) and DIG labelled c-myc 
probe (visualised as red). The chromosomes were stained with DAPI.
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Figure 16 Variation in c-Myc protein levels in BICR cell lines: (a) 25pg of total 
protein from cell lysates were separated by SDS-PAGE, transferred to nitrocellulose 
and probed with anti-c-Myc antibody, (b) Quantitation by scanning laser 
densitometry is shown relative to the expression of FAK in each of the cell lines.
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Only two cell lines BICR 16 and BICR 78 (2/9) displayed more than two fold 
elevated levels of c-Myc when compared to normal keratinocytes. Thus, although fak 
and c-myc genes are both similarly increased in copy number in the BICR cell lines, 
c-Myc protein expression levels are not always coordinately increased, at least in 
vitro.
In addition, unlike FAK, no increase in the expression of c-Myc protein was seen as 
the adenoma cells progressed to become invasive carcinoma cells in-vitro (C 
Paraskeva, unpublished observation).
3.10 Discussion
Linkage of fak  to c-myc in the mouse had suggested that fak  was most likely to 
localize to chromosome 8q24, where c-myc is located and the region has synteny 
with the mouse chromosome 15 where fak  was shown to localize in mouse (Fioderek 
and Kay, 1995). Results obtained through FISH analysis in this chapter confirm that 
fak does indeed localize to the telomeric end of the long arm of chromosome 8.
Several studies have found FAK protein levels to be elevated in different cancer cell 
lines and samples from cancerous tissue. FISH results indicate that one of the 
important mechanisms through which cells are able to overexpress FAK protein is by 
genetic changes. Two of the cell lines examined, CALU3, and HT29 carried 
amplification of fak. Some of the cell lines had isochromosomes involving the q arm 
of chromosome 8. In other cell lines with more than two copies of fak , the gain in 
copy number was accounted for by the gain of extra copies of the chromosome or 
parts of chromosome 8. 100% (5/5 and 7/7) of colon and breast cancer cell lines 
examined showed an increase in the fak gene copy number, while 72% (8/11) of the 
lung cancer cell lines displayed more than 2 hybridization signals in a high 
percentage of nuclei. It was, however, not possible to correlate this gain in copy 
number with an increase at the protein level of FAK due to lack of normal control 
cell lines for colon, breast or lung. A study carried out by Owens et al., (1995) 
reported that FAK was found to be overexpressed at the protein level in 17/17
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metastatic colonic lesions and 22 out of 25 invasive and metastatic breast tumours 
compared to normal tissue in patients from whom the tumour samples were taken. 
This was further confirmed by analysis carried out in the BICR cell lines. FISH 
analysis showed that all the 9 BICR cell lines examined showed greater than two 
hybridization sites for fak. Comparison of protein levels of FAK showed 7/9 (>70%) 
cell lines to have a higher steady state levels of FAK than in normal human 
keratinocytes, HNK. To confirm that genetic alterations involving fak were actually 
involved in the process of carcinogenesis, and not just an artifact of cell culturing in 
vitro, FISH was carried out on primary tumour sections. A vast majority of the cells 
within the section showed more than two hybridisation signals for fak. Some normal 
cells that were also part of the section had the normal two copies of the gene.
Although gain in fak  gene copy number through genetic alterations in the cell was 
generally accompanied by increased levels of FAK protein, there was no direct 
correlation between the two. For example, both BICR6 and BICR16 have around 6 
copies of fak  but they do not express the same level of FAK protein. In fact, BICR16 
was found to express lower levels of FAK as compared to even the normal HNK 
cells which have the normal 2 copies of fak. BICR63 is another cell line that had 
lower level of FAK expression than the normal keratinocytes. Thus there are cases, 
though few, where increase in fak gene copy number is not accompanied by 
overexpression of the protein. This might mean that not all the copies gained by the 
cell are expressed or that they were expressed but the turnover rate for the protein 
was increased. This finding is contrary to the results of another study that established 
positive correlation between copy number and protein expression of the 
topoisomerase 1 gene in colon and breast cancer lines (McLeod and Keith, 1996).
Given the potential role of FAK in cell growth, migration and apoptosis (see section 
1.3), all properties required by a cell to acquire invasive characteristcs, it is not 
surprising that so many of the cancer cell lines show an upregulation of FAK protein 
and gain in fak  gene copy number. Results showing an increase in FAK protein level 
accompanied by gain in fak  gene copy number during conversion from adenoma to 
carcinoma in the in vitro model of colon progression, support this. An earlier study
104
had suggested the potential role for FAK in regulating enhanced cell invasion showed 
by the carcinoma cells upon EGF stimulation (Brunton et al., 1997).
Comparisons between gene copy number gain and protein quantification for FAK 
also showed that in some cell lines, the number of copies gained is not able to 
account for all the elevation at protein level. This is best exemplified in the case of 
the in vitro model of colon tumour development. Here, the progression from the 
adenoma to the carcinoma was accompanied by a gain of one gene copy of fak but 
the increase at the protein level was about 5 fold. Obviously, one extra copy of fak 
cannot account for a five-fold increase in protein expression. There should, thus, 
exist other mechanisms by which some cells might upregulate FAK protein level. A 
mutation in the promoter region or translocation of the gene to a more heavily 
transcribed region of the genome that enhances the transcription of the gene might 
play an important role in enhancing the protein levels. Increase in transcription can 
be quantified using RNA protection assays. These assays involve protection of the 5’ 
end of the mRNA with a radiolabelled probe, digestion of the unprotected part with a 
nuclease, followed by detection of the radiolabelled probe. The intensity of the band 
indicates the amount of mRNA present. Increase in mRNA level could also be due 
increased mRNA stability. The assay to determine mRNA stability would involve 
inhibition of transcription using actinomycin D followed by a time-course detection 
of mRNA levels. Increased protein stability can also account for increased protein 
levels. However, earlier pulse-chase experiments carried out in the lab had indicated 
FAK to be a relatively stable protein (Val Fincham unpublished data), unless 
stimulated to undergo proteolysis during apoptosis or focal adhesion turnover (see 
section 1.3).
The presence of genetic alterations like amplifications and isochromosomes indicate 
a selective advantage conferred on the cells by them. These structures are never 
found in normal cells and won’t be retained by a cell unless their presence is of 
importance to the cell. Cancer cells are under constant selective pressure and only 
those cells that exhibit growth, motility (important in invasion) and survival 
advantages over other cells are allowed to expand further. Thus, genes like fak  that 
localize to these alterations should potentially be able to influence any of the above
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mentioned processes. As suggested earlier, in the case of FAK, one possibility is that 
up-regulated FAK contributes to ECM-dependent tumour growth by mediating 
signaling from fibronectin to the Ras/MAP kinase pathway that is implicated in 
proliferation control (Schlaepfer et al., 1994). Another potential role proposed for 
FAK is in making transformed cells able to grow in an anchorage-independent 
manner (Frisch et al., 1996b). As well as in anchorage-deprived cells, FAK can also 
act as a survival factor for adherent cells (Hungerford et al., 1996; Xu et al., 1996). 
Thus, FAK may contribute to ECM-dependent growth and survival of tumour cells.
As well as tumour cell growth and survival, another likely role for elevated FAK in 
tumour cells is in the acquisition of an invasive phenotype. Cancer cell invasion is a 
complex process that requires cells to adhere and migrate through underlying ECM. 
Since FAK functions as a key regulator of ECM-dependent cell migration (Ilic et al., 
1995, 1996; Gilmore and Romer, 1996; Cary et al., 1996), and since endogenous 
levels of FAK expression can limit the rate of motility in some cell types (Cary et al., 
1996), it seems likely that elevated FAK in tumour cells may release normal 
constraints on the rate of cell motility, thus enhancing invasive potential. Consistent 
with this possibility it was found in this study that the gain of an additional copy of 
the fak  gene, associated with elevated FAK protein level, occurred relatively late in 
an in vitro model of colon carcinoma development and was coincident with 
acquisition of an invasive phenotype (Brunton etal., 1997).
FISH analysis carried out on the cell lines showed that there was a gain in c-myc gene 
copy number along with fak. Indeed, one of the main reasons behind this study was 
the finding that CALU3, a lung cancer cell line was found to carry an amplicon 
containing c-myc (Hoare et al., 1997). The size of the amplicon suggested that there 
might be other genes within the region that could be co-amplified along with c-myc 
and might be responsible for exerting the selective advantage. Finding fak  to be co­
amplified with c-myc, prompted an investigation into which of these two genes was 
selected for in the cells. Comparison of levels of expression of the two proteins was 
carried out in the BICR cell lines. Only 2/9, BICR16 and BICR78, showed an 
increase in c-Myc protein levels when compared to normal keratinocytes, while as 
many as 7/9 of the BICR cell lines showed an increase in the level of FAK protein.
106
Furthermore, although an additional copy of c-myc was gained at the same stage as 
fak during colon carcinoma development in the in vitro model, there was no 
concomitant increase in the expression of c-Myc. An earlier study had shown that 
tumour cells overexpressing c-myc had reduced growth factor requirement and a 
shortened Gl-phase of cell cycle (Prins et al., 1993). Thus, overexpression of c-myc 
is required by the cells for it to confer any growth advantage. However, the data 
implies that fak , at least in some cells, is as strong a candidate as c-myc as the gene 
responsible for the maintenance of increased dosage of this region of the genome. 
However, the possibility of the existence of other gene/s within this region, that 
might be responsible for the retention of the region in increased dosage, still exists.
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Chapter 4: Results 2 
Role of focal adhesion kinase in cell survival
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4.1 Introduction
As stated earlier, FAK has been implicated in cell survival by several studies. Earlier 
work in our lab had raised the possibility of proteolysis of FAK preceding 
commitment to c-Myc induced apoptosis in CEF after serum withdrawal (Crouch et 
a l, 1996). Results of another study by Frish et al, (1996a), showed that 
constitutively activated forms of FAK were able to rescue two established epithelial 
cell lines from anoikis (detachment induced cell death), suggesting apoptosis requires 
the inactivation of FAK, possibly through proteolysis. One of the objectives of this 
study was, therefore, to determine if indeed FAK proteolysis played a causal role 
during apoptosis. Specifically, we tested whether interfering with FAK proteolysis 
blocked apoptosis. To address this, the strategy was to first determine the enzyme 
responsible for FAK cleavage during apoptosis with calpain I and caspases being the 
likely candidates. Having established that, we wished to inhibit FAK cleavage by 
using enzyme-specific inhibitors, and ask whether this correlated with cell survival. 
Finally, if inhibition of FAK proteolysis promoted survival, the strategy would be to 
identify FAK cleavage sites and to generate non-cleavable FAK mutants and study 
their effect of the overexpression on survival.
4.2 FAK undergoes proteolysis in c-Myc induced apoptosis in CEF
Withdrawal of serum has been firmly established as an inducer of apoptotic cell 
death in c-Myc transformed fibroblasts (Evan et al, 1992). Transfer of c-Myc 
transformed CEF to low serum medium induces cell detachment and death in a 
manner analogous to the effects of these conditions in fibroblasts from other species 
(Crouch et al, 1996). This latter study showed proteolytic cleavage of FAK during c- 
Myc-induced apoptosis. The experimental scheme is depicted (Figure 17a). c-Myc 
transformed CEF were deprived of serum leading to the induction of apoptosis within 
two hours of serum withdrawal. Levels of FAK were determined by immunoblotting 
lysates prepared from CEF, or c-Myc transformed CEF at different time intervals 
after serum withdrawal. In comparison to normal CEF, full length FAK diminished
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Figure 17 c-Myc induced apoptosis is accompanied by FAK cleavage: (a) c-Myc 
transformed CEF were induced to undergo apoptosis by serum-withdrawal. (b) 
Levels of FAK were determined by immunoblotting lysates prepared from CEF or c- 
Myc-transformed CEF at various time points after serum-withdrawal (hrs) (carried 
out by V.Fincham, Beatson Institute, Glasgow, UK).
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in c-Myc expressing CEF as cells were induced to detach and die in c-Myc 
transformed cultures (Figure 17b). Loss of full length FAK was accompanied by the 
accumulation of two distinct products of proteolytic cleavage migrating between 60- 
90 Kd (Figure 17b; described also in Crouch et al., 1996).
4.3 Both calpain and caspases can cleave FAK in vitro
In order to determine if inhibiting FAK cleavage could inhibit apoptosis, it was first 
important to determine which enzyme/s were responsible for its proteolysis during 
apoptosis. Calpain was a likely candidate since it is known to localise to the focal 
adhesions (Beckerle, 1986). Calpain has also been shown to cleave various focal 
adhesion proteins like talin, a-actinin, Src and even FAK itself (Beckerle et al., 1986; 
Selliah et al., 1996; Oda et al., 1993; Cooray et al., 1996). Caspases were also likely 
to play a role in FAK proteolysis during apoptosis as they were already known to 
cleave various cellular substrates during initiation and execution of apoptosis 
(reviewed in Harvey and Kumar, 1998).
In vitro cleavage assays with calpain and caspases were carried out using 
immunoprecipitated FAK from CEF. Cleavage reactions with calpain I were set up 
using different concentrations of the enzyme to establish the amount required for 
FAK cleavage. Reactions were carried out at 30°C for 30min, followed by separation 
of proteins by 7.5% SDS-PAGE. Immunoblotting was carried out using anti-FAK 
antibody. Results showed that O.lpg/pl and 1 pg/pl of the protease were able to 
cleave into fragments sized between 60-90 kd (Figure 18a). Earlier studies had also 
shown FAK to be cleaved into two different sized fragments migrating in vivo, 
between 60-90 kd, and it was suggested that the larger fragment was further cleaved 
into the smaller fragment (Crouch et al., 1996).
To establish FAK proteolysis by caspase pro teases in vitro, S/M extracts (a gift from 
Bill Earnshaw, Edinburgh, UK) were used. S/M extracts are cytoplasmic extracts 
made from chicken DU249 cells that become committed to apoptosis as a result of an 
S-phase aphidicolin-induced cell-cycle arrest and are subsequently collected in M- 
phase (Wood and Earnshaw, 1990; Lazebnik et al., 1993). These extracts are
Figure 18 FAK is cleaved in vitro by both calpain I and caspases: (a) To titrate 
calpain I with respect to FAK cleavage in vitro, FAK was immunoprecipitated and 
cleavage reactions were carried out at 30°C for 30min. Proteins separated by SDS- 
PAGE were probed for full length, and cleaved products of FAK. (b) To examine 
FAK proteolysis by caspases, in vitro reactions were carried out at 37°C for 30min. 
As before, immunoblotting was carried out to detect full length FAK and its cleaved 
products.
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enriched for caspases and have been shown to imitate apoptotic events in vitro 
(Lazebnik et al., 1993; Lazebnik et al., 1994). Immunoprecipitated FAK was 
resuspended in ICE buffer and the cleavage reactions carried out at 37°C for 30min. 
As in the case of calpain I, different amounts i.e., 2pl, lpl, l/10pl, and l/100pl, of 
the S/M extracts were used in order to determine the optimal amount required to 
cleave FAK in vitro. Proteins were separated by SDS-PAGE and immunoblotting 
was carried out using anti-FAK antibody, lpl, and 2pi of the S/M extracts were 
found to cleave FAK, generating fragments migrating between 60-90 kd (Figure 
18b).
Thus, both calpain I and caspases were able to cleave FAK in vitro to generate 
products of similar lengths as those generated during apoptosis in c-Myc transformed 
CEF in vivo.
4.4 Caspases, not calpain are most likely responsible for FAK proteolysis during 
apoptosis
In order to determine whether calpain or the caspases were more likely to be 
responsible for cleavage of FAK during apoptosis in vivo, it was important to 
compare the sizes of the in vitro and the in vivo products. Thus, experiments were 
initially carried out to induce apoptosis in c-Myc-transformed CEF after serum 
withdrawal. These experiments were, however, technically difficult to reproduce with 
respect to the apoptotic response induced upon serum withdrawal. The reasons for 
the weak response of the culture observed on many occasions, after serum 
withdrawal from c-Myc-transformed cells, were not clear, but the inconsistency of 
the response was noted by a number of members of the lab (V Fincham, M Frame, M 
Agochiya). One possible explanation for the inconsistency is the culture density, 
which is thought to have an effect on the sensitisation of the cells to c-Myc-induced 
apoptosis. Therefore, another mode of inducing apoptosis, which is outlined below, 
was utilised to study the importance of FAK proteolysis during apoptosis.
The method for inducing reproducible apoptosis was changed to one where apoptosis 
was induced as a consequence of v-Src inactivation in serum-deprived v-Src
transformed Rat-1 cells. This particular method of inducing apoptosis in ts LA29 v- 
src transformed Rat-1 fibroblasts was developed by D. Johnson (Beatson Institute, 
Glasgow, UK). Under these conditions, induction of apoptosis in v-Src transformed 
Rat-1 cells was accompanied by FAK proteolysis producing cleavage products of 60- 
90 kd. The experimental scheme is outlined (Figure 19a). Characterisation of the 
induced cell death to be apoptosis is described in the following chapter (section 6.2). 
This apoptotic response provided a good and reproducible alternative to study 
apoptosis and the role of FAK in cell survival.
In vitro cleavage assays were carried out to compare cleavage products to the ones 
generated in vivo during apoptosis. For this, FAK cleavage products, generated by 
caspase, were compared to the in vivo products. Calpain I cleavage products were not 
compared since earlier experiments had shown that both calpain and caspases 
cleaved FAK to generate similar sized fragments (section 4.3). Immunoprecipitated 
FAK from v-Src transformed Rat-1 fibroblasts was used in reactions carried out at 
37°C for 30min using the S/M extracts (described before in section 4.3). Proteins 
were separated using SDS-PAGE. Lysates from transformed Rat-1 cells undergoing 
apoptosis (harvested 8 hours after induction of apoptosis), were also separated on the 
same gel. Immunoblotting was carried out using anti-FAK antibody. In vitro, FAK 
was cleaved into three different fragments that migrated around 60-90 kd (Figure 
19b). The smaller of the two lower fragments was the same size as that generated in 
vivo during apoptosis. Also, the upper fragment detected in the apoptotic lysates, was 
generated during in vitro cleavage, although, the intensity of the band was weaker 
(Figure 19b). This confirmed that both chick FAK and murine FAK were similarly 
cleavable both in vivo and in vitro and further indicated the possibility of either 
calpain I or caspases to be responsible for FAK proteolysis in vivo.
To determine which enzyme/s were responsible for FAK proteolysis in vivo during 
apoptosis, experiments were carried out to study the effect of inhibiting caspase 
activity on FAK proteolysis during apoptosis. To examine the role played by 
caspases, a broad spectrum cell permeable caspase inhibitor, benzyloxycarbonyl-Val- 
Ala-Asp(0-methyl)-fluoromethy Ike tone (ZVAD.fmk) was used (McCarthy et al., 
1997; Garcia-Calvo, 1998). Also, to investigate if calpain I was responsible for FAK
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Figure 19 In vitro cleavage of FAK generates similar sized fragments as those 
detected in vivo: (a) To induce an apoptotic response in v-Src transformed Rat-1 
cells, they were serum-starved for 24 hours followed by inactivation of v-Src by 
shifting the cells from 35°C to 39.5°C. Cell lysates from dying cells were obtained at 
8 hours after induction of apoptosis and separated by SDS-PAGE. The lysates were 
probed with anti-FAK antibody, (b) To compare the sizes of the in vitro and in vivo 
cleavage products, caspase cleavage products were also separated by SDS-PAGE and 
immunoblotted at the same time.
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proteolysis during apoptosis in vivo, the effects of inhibiting calpain I activity were 
studied. In order to do this, N-acetyl-leucyl-leucyl-norleucinal (aLLN), a modified 
peptide which inhibits the activity of calpain I, calpain II by competing for the active 
site of the enzyme, was used (Wang and Yuen, 1994).
An apoptotic response was induced in transformed Rat-1 fibroblasts as described in 
Figure 19a. The effects of the inhibitors were studied at two different concentrations 
of IOjxM and lOOpM. Both the inhibitors, ZVAD.fmk and aLLN were added an hour 
before inactivation of v-Src. Cells were harvested at different times after induction of 
apoptosis. Cell lysates were separated using SDS-PAGE and immunoblotting was 
carried out.
In the control cells, to which no inhibitor was added, FAK was cleaved, as expected, 
into fragments of sizes between 60-90 kd (Figure 20a). At 2 hours, only the larger of 
the two lower fragments was present, while the upper band was not, but 4 hours after 
v-Src inactivation, both of the lower fragments and the upper fragment were visible. 
At the 6 and 8 hour time points, accumulation of the smaller of the two lower 
fragments was seen, although there was no change in the upper band. There was also 
an increase in the products with increase in time, accompanied by a decrease in full 
length FAK protein.
Addition of lOpM of ZVAD.fmk had no effect on FAK cleavage during apoptosis 
with the cleavage pattern being similar to that seen in the control cells (Figures 20a 
and 20b). However, at the concentration of lOOpM, ZVAD.fmk was able to block 
FAK cleavage completely (Figure 20c). There was no change in the amount of full 
length FAK accompanying progression of apoptosis and no accumulation of the 
cleavage products was evident.
Addition of aLLN, the calpain I and calpain II inhibitor, however, did not have any 
visible effect on FAK proteolysis (Figures 20d and 20e). However, due to lack of a 
control to confirm the inhibitor’s activity, this could not be established beyond a 
doubt. Nevertheless, comparison of in vitro and in vivo cleavage products and
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Figure 20 Inhibition of caspases, but not calpain, inhibits FAK proteolysis 
during apoptosis: (a) v-Src transformed Rat-1 cells were induced to undergo 
apoptosis in the absence of serum and v-Src activity. Cell lysates obtained at different 
time points after v-Src inactivation, were separated by SDS-PAGE and 
immunoblotted with anti-FAK antibody to detect full length FAK and its cleavage 
products. FAK was cleaved into an upper band (indicated by red symbols), and two 
lower bands (indicated by black symbols), (b, c, d, e) At the same time, either 
ZVAD.fmk or aLLN, inhibitors of caspases and calpain respectively, were added to 
other cells an hour before inactivation of v-Src at 10|iM or 100p,M. Lysates from 
these cells were also collected at different time points, saparated by SDS-PAGE and 
immunoblotted for the detection of FAK cleavage products.
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chemical inhibitor data suggest that caspases were most likely to be responsible for 
FAK proteolysis during apoptosis in serum-deprived v-Src transformed Rat-1 cells.
4.5 Inhibition of FAK cleavage does not prevent apoptosis in transformed Rat-1 
fibroblasts
With results indicating that caspases were the likely proteases responsible for 
cleaving FAK, it was possible to investigate whether inhibition of FAK proteolysis 
correlated with suppression of apoptosis. Thus, lOOpM ZVAD.fmk was used in order 
to inhibit FAK cleavage and to study its effects on the induction of apoptosis in 
serum-deprived v-Src transformed Rat-1 cells. The experiment was carried out as 
described in the previous section (depicted in figure 19a), and ZVAD.fmk was added 
one hour before inactivation of v-Src. Cells were harvested at the 0, 2, 4, and 6 hour 
time points and fixed (as described in the Materials and Methods). Terminal 
deoxynucleotidyl transferase (TdT)- mediated dUTP-biotin nick end labelling 
(TUNEL) method was carried out as a measure of cells undergoing apoptosis at the 
different time points. The percentage of cells undergoing apoptosis in the presence 
and absence of ZVAD.fmk was determined (Figure 21). The experiment was 
repeated 3 times and the graph is representative of the results obtained. As is clearly 
shown, blocking FAK cleavage with ZVAD.fmk did not prevent the cell death. The 
percentage of cells undergoing apoptosis with ZVAD.fmk was not substantially 
different from control cells in the absence of ZVAD.fmk (Figure 21). Thus, 
inhibition of FAK had little or no effect on apoptosis (as measured by TUNEL), 
indicating that its cleavage was not a critical determinant of the commitment to 
programmed cell death.
4.6 Discussion
There is a substantial body of evidence implicating FAK in anchorage-independent 
cell survival. Attenuation of FAK signaling at the integrins induces apoptosis in some 
cell types (Hungerford et al., 1997; Xu et al., 1996). A study by Cooray et al., 1996, 
suggested that sequential proteolysis of FAK was perhaps one of the mechanisms 
used by a cell to attenuate its autokinase acitvity and downstream signalling. Work
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C om parison o f  percentage o f  serum -deprived  transform ed Rat-1 ce lls  undergoing  
apoptosis w ith  and w ithout the casp ase  inhibitor, Z V A D .fm k , after inactivation  o f  
v-Src
Z VA D
Time (Hrs)
Figure 21 Inhibition of FAK cleavage does not promote cell survival:
v-Src-transform ed Rat-1 ce lls  w ere induced to undergo apoptosis in the ab sen se  o f  serum  
and after v-Src w as sw itched  off. C ells  w ere fixed  and T U N E L  labelled  at d ifferent tim es  
after inactivation  o f  v-Src. T he T U N E L  lab elled  ce lls  represent the percentage o f  
ce lls  undergoing apoptosis. T he m ean o f  several exp erim ents w as p lotted as control, the error 
bars corresponding to  the standard error. S im ilar exp erim ents w ith  Z V A D .fm k  treated ce lls  
w ere a lso  carried out. T he plotted line is representative o f  3 separate experim ents.
done by our group suggested commitment to apoptosis in c-Myc transformed CEF 
followed proteolysis of FAK (Crouch et al., 1996). Also, suppression of FAK 
proteolysis by a |31-specific integrin antibody promoted cell survival in these cells. 
To further investigate the role of FAK proteolysis in the regulation of apoptosis, we 
first determined which enzymes were responsible for cleaving FAK in vivo during 
induction of apoptosis in c-Myc transformed CEF. Calpain I and caspases were the 
two proteolytic enzymes investigated. Calpain I localises to focal adhesions like FAK 
and cleaves it in thrombin stimulated platelets (Beckerle, 1986; Cooray et al., 1996). 
Caspases were examined because of their well documented role in proteolysis during 
apoptosis (reviewed in Harvey and Kumar, 1998). Comparison of in vitro cleavage 
products of FAK by the two proteases and subsequent inhibition experiments 
confirmed that caspases were most likely the proteases involved in FAK cleavage 
during induction of apoptosis in v-Src transformed Rat-1 cells. A calpain I inhibitor 
was unable to prevent FAK cleavage, although calpain had been able to cleave FAK 
in vitro to produce products of similar but distinguishable size. This, taken together 
with the results of an earlier study which showed prevention of FAK cleavage in 
thrombin stimulated platelets treated with calpain inhibitor-1 (Cooray et al., 1996), 
suggested that calpain I might be involved in FAK proteolysis, but apparently not 
during apoptosis. In other words, calpain I cleavage of FAK might have some role in 
focal adhesion functions like cell migration or growth. FAK proteolysis has been 
observed during cell transformation induced by v-Src (Fincham et al., 1995). 
However, instead of being cleaved into distinct 60-90 kd fragments, as is the case 
during apoptosis in c-Myc transformed CEF and v-Src transformed Rat-1 cells, FAK 
gets completely degraded during transformation. This degradation of FAK is thought 
to play a role in focal adhesion turnover and thus in cell migration.
Proteolysis of FAK by caspases during apoptosis has now been confirmed by another 
study. FAK was sequentially cleaved into two different fragments early in Apo-2L- 
induced (a member of the tumour necrosis family) apoptosis in suspended Jurkat T 
cells (Wen et al., 1997). The first cleavage product (85 kd) appeared after 2 hours of 
addition of Apo-2L, and the second (77 kd) after 4 hours. After 24 hours only the 77 
kd fragment remained. This is in agreement with the results presented in this study 
which also showed that caspase-induced cleavage of FAK generated two fragments
sized between 60-90 kd. The cleavage products were detected after 2 hours of 
induction of apoptosis in the v-Src transformed Rat-1 cells. Also, there was an 
increase in the amount of the smaller sized cleavage product with increased time. 
This suggests that the second fragment is generated through further cleavage of the 
first fragment. It was suggested by Wen et a l, (1997) that cleavage of FAK by 
caspase 6, which is required for the generation of the second fragment (according to 
in vitro results), is only possible after it has been first cleaved by caspases 3 and 7 to 
generate the first fragment (Wen et al., 1997).
It has now been confirmed that FAK is cleaved by the capases at two different sites. 
The cleavage sites in FAK lie within the carboxy terminal half of the protein (Gervais 
et al., 1998). Cleavage of FAK at either or both of the two sites generates a FRNK 
like fragment. Thus, proteolysis of FAK is thought to abrogate FAK mediated 
survival signals by two mechanisms (Gervais et al., 1998). Firstly, it decreases the 
total amount of full length functioning FAK. Secondly, generation of FRNK like 
fragments may lead to competitive inhibition of FAK. As stated earlier, FRNK has 
been shown by other studies before to act as an inhibitor of FAK by competing for 
common binding proteins (Richardson and Parsons, 1996).
In order to investigate the importance of FAK proteolysis during apoptosis in serum- 
starved v-Src transformed Rat-1 cells, ZVAD.fmk, a general inhibitor of the caspases 
was used. Cells were treated with ZVAD.fmk before the induction of apoptosis. 
Results indicated that although, ZVAD.fmk was able to prevent FAK proteolysis by 
the caspases during apoptosis, it was unable to prevent apoptosis. Thus, inhibiting 
FAK cleavage was unable to promote cell survival. This is contrary to the findings of 
another study where a significant increase in cell survival was observed upon 
treatment of Jurkat T cells with ZVAD.fmk before induction of apoptosis by Apo-2L 
treatment (Wen et al, 1997).
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5.1 Apoptosis: Programmed cell death
Apoptosis is a naturally occuring cell suicide programme intrinsic to metazoan cells 
(reviewed in Kerr et al., 1972; Wyllie, 1993). It provides an efficient way for the 
elimination of unwanted cells and is a default pathway which is engaged unless the 
cells receive sufficient signals to negate it (reviewed in Raff et al., 1994). It is 
required in the process of development and maintenance of proper shape and function 
in animals (reviewed in Meikrantz and Schlegel, 1995). Cell death induced in normal 
and tumour tissues exposed to low or moderate doses of chemotherapeutic agents or 
ionizing radiation, also has apoptotic characteristics (Wyllie, 1997). The homeostasis 
of animals is also regulated through apoptosis (Enari et al., 1998). As mentioned 
before, apoptosis is also induced in some cells on disruption of the interactions 
between cells and extracellular matrix (Frisch and Francis, 1994). Anoikis is though 
to prevent tumour cells from anchorage independent growth and may thus protect the 
animal from malignancy. Tumours require anti-apoptotic mutations, in addition to 
inappropriate proliferation, in order to survive and propogate (Evan et al., 1995).
5.1.1 Apoptosis vs Necrosis: morphological distinction
Apoptosis was first recognized by its distinct, stereotyped morphology (reviewed in 
Kerr et al., 1972; Wyllie, 1997). This is an important distinction between apoptosis 
and necrosis, a form of acute pathological cell death resulting from cell injury. 
Morphological changes accompanying apoptosis include dramatic shrinkage of cell 
volume, along with dilation of endoplasmic reticulum and convolution of the plasma 
membrane (Wyllie, 1993; Wyllie, 1997). The cell gets fragmented into multiple 
membrane bound bodies, known as apoptotic bodies, which are engulfed by 
surrounding cells and removed without any inflammation or damage to the 
surrounding tissue. This is in contrast to necrosis where the injured cell swells up and 
the plasma membrane breaks up to release pro-inflammatory components (Cotter et 
al., 1990). Characteristic changes in the organization of the nucleus also 
distinguishes apoptosis from necrosis. Apoptosis is accompanied by condensation of 
the chromatin, which segregates into sharply defined bodies within intact nuclear
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envelope. The DNA is often digested by endonucleases into distinct sized fragments 
(Wyllie, 1993; Wyllie, 1997).
5.1.2 Diverse stimuli can activate apoptosis
Apoptosis can be initiated by a variety of stimuli. Cell damaging stress can cause a 
cell to die by apoptosis. Diverse stress stimuli such as ionizing radiation, osmotic 
shock, oxidative stress or microtubule disruption can all induce an apoptotic response 
(Martin and Cotter, 1990; Payne et al., 1995; Jarpe et al., 1998). This ability of cells 
to undergo apoptosis due to DNA damage induced by ionizing radiation is utilized 
for cancer treatment by irradiation (Jarpe et al., 1998). Also, the chemicals used as 
chemotherapeutic agents induce cancer cells to undergo apoptosis (Lutzker and 
Levine, 1996; Dive et al., 1992; Houghton, 1999; Suzuki et al., 1999). Many of the 
chemothrapeutic drugs induce apoptosis as a result of DNA damage (Houghton, 
1999).
Apart from cellular stress, growth factor deprivation is also known to induce 
apoptosis in some cell types. For example, deprivation of survival factors like IL-2 in 
hematopoietic cells can induce apoptosis (Cohen et al., 1992). Anoikis or cell death 
induced by deprival of survival signals originating from the ECM has been described 
before in section 1.1.7 of this thesis (Frisch and Francis, 1994). During neuronal 
development, apoptosis is required to ensure a definite cell number. Neuronal 
survival is determined by competition for a limited supply of the nerve growth factor 
(NGF; Levi-Montalcini, 1987; Oppenheim, 1991). This is imitated in vitro when 
withdrawal of NGF induces cell death in neuronal PC12 cells (Mesner et al., 1992).
Some oncoproteins such as c-Myc are also known to induce apoptosis in serum 
deprived transformed cells (reviewed in Prendergast, 1999). As mentioned before, 
Evans et al., (1992), discovered that Rat-1 fibroblasts expressing c-Myc 
constitutively, when deprived of serum, underwent apoptosis instead of growth 
arrest. Deregulated expression of c-Myc was also found to accelerate apoptotic cell 
death of interleukin-3 (IL-3) dependent myeloid cells when deprived of the cytokine 
and was required for activation induced death of T-cell hybridomas (Kagaya et al.,
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1997). Since c-Myc expression sensitises cells to a wide range of apoptotic stimuli 
like growth factor withdrawal, p53-dependent response to genotoxic damage etc., it 
has been suggested that c-Myc does not itself induce apoptosis but rather acts to 
sensitise cells to other pro-apoptotic insults (Juin et a l, 1999). Details of c-Myc 
sensitisation to CD95/Fas induced apoptosis is described in section 5.1.3.
Certain specific cell surface receptors belonging to the tumour necrosis factor (TNF) 
receptor family can also induce apoptosis when engaged by their ligands. Two 
ligand-death receptor pairs, FasL-Fas (also known as CD95L-CD95) and tumour 
necrosis factor-a (TNF-a)-TNFRl, are well characterised inducers of apoptosis (Pan 
et al., 1997). Other examples of the receptors belonging to the TNF family include 
DR3, DR4 and DR5. TRAIL (also called Apo2L) is a cytotoxic protein that binds to 
DR4 and DR5 (Sherindan et al., 1997). The receptors contain a stretch of 60 to 80 
amino acids within their cytoplasmic domain, known as the death domain (Pan et al.,
1997). The receptor proximal events have been best characterised for CD95 as it is 
the most widely expressed and its ligation with its ligand induces apoptosis in every 
system studied (Jarpe et al., 1998). Stimulation of CD95 results in aggregation of its 
intracellular death domain, leading to the recruitment of two key signaling proteins, 
FADD (also known as MORT1) and caspase 8, that together with the receptor form 
the death inducing signaling complex (DISC) (Scaffidi et al., 1998). TNFR1, on the 
other hand, binds FADD indirectly through TRADD (Sheridan et al., 1997). 
Activation of caspase 8 leads to the activation of caspase 3 (Stennicke et al., 1998), 
and thus provides a link to the apoptosis execution machinery (as discussed later).
5.1.3 Interaction between different stimuli in the regulation of an apoptotic 
response
Different apoptotic stimuli can sometimes interact functionally to regulate an 
apoptotic response. C-Myc induced apoptosis requires interaction on the cell surface 
between CD95-CD95L (Hueber et al., 1997). Experiments were carried out on Swiss 
3T3 cells expressing a conditional 4-hydroxytamoxifen (OHT)-dependent c-Myc 
protein and that die by apoptosis upon OHT-treatment in low serum. Neutralisation 
of CD95L using monoclonal antibodies reduces and delays c-Myc-induced apoptosis
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in a concentration dependent manner (Hueber et al., 1997). Also, when the effects of 
CD95 ligation were blocked by expression of dominant negative FADD, which was 
unable to interact with caspase 8, similar effects were noticed. Other experiments 
suggested that c-Myc acts downstream of the CD95 receptor by sensitizing the cells 
to the CD95 death signal (Hueber et al., 1997).
5.2 Caspases
Caspases, a family of proteolytic enzymes, were first identified and described in 
nematode worm Caenorhabditis elegans (C. elegans) where cell death was found to 
be dependent on the activation of Ced3, a cyctein pro tease (Hengartner, 1998; Harvey 
et al., 1998). In 1993, Yuan et al., discovered that the product of this death gene was 
similar to human and murine interleukin-lp-converting enzyme (ICE). ICE is an 
unusual cytoplasmic cysteine protease that was first isolated from cells of monocytic 
origin (Shibata et al., 1996). These workers also proposed that since Ced3 acts as a 
cysteine protease involved in apoptosis, cysteine proteases may have a similar 
function in mammals. As predicted, overexpression of ICE in Rat-1 fibroblasts 
caused the cells to undergo apoptosis (Miura et al., 1993). Mutations in the active 
domain of ICE were able to eliminate this effect. In addition, cell death was also 
prevented by CrmA, a poxvirus protein that inhibits ICE (Miura et al., 1993). Since 
then, several ICE homologues have been discovered in mammals and are now 
collectively known as caspases (Alnemri et al., 1996). So far 11 members of this 
family have been discovered and are named as Caspase-1, through to caspase-11, 
where the number is assigned based on its date of publication (Table 3 lists the name 
of all the caspases known and some of the alternate names they are known by) 
(reviewed in Harvey and Kumar, 1998).
Thus, caspases are a family of sytosolic cysteine proteases that are stored in most 
cells as zymogens and play an essential role in the execution of apoptosis (Yang et 
al., 1998). They can be further divided as apical or initiator (Caspases-2, 8, 9, 10) or 
executioner (caspases-3, 6, 7) depending on the role they play during the process of 
apoptosis (Yang et al., 1998). These enzymes act by cleaving on the carboxy-
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Table 3 Members of the caspase family
Caspase Member Alternative names
Caspase-1 ICE
Caspase-2 Nedd 2, ICH-1
Caspase-3 CPP32, Yama, apopain
Caspase-4 TX, ICH-2, ICE-rel-II
Caspase-5 TY, ICE-rel-III
Caspase-6 Mch2
Caspase-7 Mch3, ICE-LAP3, CMH-1
Caspase-8 MACH, FLICE, Mch5
Caspase-9 ICE-LAP6, Mch6
Caspase-10 Mch4, FLICE2
Caspase-11 ICH-3
terminal side of aspartate residues within distinct recognition motifs (Harvey et al., 
1998).
Each caspase is synthesized as a proenzyme and activated by cleavage at specific 
internal aspartate residues, potentially by the same or another caspase class (Harvey 
et a l, 1998). The cleavage processes the caspases to form active heterodimeric 
enzymes. Activation does not require removal of the propeptide but the cleavage 
between the large and small subunits is thought to be an activating event (Yang et a l,
1998). A recent study has shown that caspase-9 can be activated without proteolytic 
processing (Stennicke et al., 1999). In this study it was found that the mutant forms 
that disabled one or both of the interdomain processing sites of caspase-9, were still 
able to activate downstream caspases. The single mutants were only slightly less 
effective than endogenous caspase-9, whereas the double mutants reconstituted 40% 
of the wild type activity (Stennicke et al., 1999). However, the activation still 
required binding to a cytosolic factor, probably Apaf-1, a protein that shares 
homology with with ced 4, the C. elegans death gene (Zou et al., 1997; Stennicke et 
al., 1999).
5.2.1 Function of caspases during apoptosis
Work by several groups has shown that caspases, mainly act by cleaving specific 
proteins, resulting in the irreversible commitment to cell death (Lazebnik et al., 1994; 
Janicke et al., 1996; Enari et al., 1998; Widmann et al., 1998). Various different 
substrates are now known for the caspases whose physiological function helps 
elucidate the role played by the caspases in apoptosis.
The Retinoblastoma protein (Rb), is one of the proteins cleaved by the capases during 
apoptosis (Janicke et al., 1996). Rb is an important cell cycle regulator with a known 
anti-apoptotic function. Phosphorylation of Rb by CDKs leads to the inactivation of 
its growth suppressive function and Rb-deficient mice are more susceptible to 
apoptosis than cells with fully functional protein. Janicke et al., (1996), showed that 
the carboxy-terminal peptide of Rb was specifically cleaved off by the caspases in 
TNF-and staurosporine-induced apoptosis. Cleaved Rb is unable to bind to the
regulatory protein MDM2, which has been implicated in apoptosis (Janicke et al.,
1996).
In contrast to caspase-induced loss of function as with Rb, proteolysis of some 
proteins by caspases leads to their activation (Brancolini et al., 1995). For example, 
Gas2, a member of the growth-arrested-specific genes whose expression is strictly 
coupled to the growth arrest state, was found to be cleaved by caspases in NIH3T3 
cells induced to undergo apoptosis after 48 hours of serum-withdrawal (Brancolini et 
al., 1995). Overexpression of Gas2 deleted in its carboxy-terminal part, similar to the 
peptide generated by caspase cleavage, induced alterations of the actin cytoskeleton 
and of the cell shape in different cell types, resembling the changes normally seen 
during cell death by apoptosis.
As mentioned before, one of the characteristics of apoptotic death is the degradation 
of the DNA into specific sized fragments. A caspase activated-deoxyribonuclease 
(CAD) has been identified in the cytoplasmic fraction of mouse lymphoma cells 
(Enari et al., 1998). CAD is a protein of 343 amino acids which carries a nuclear- 
localization signal and is produced as a complex with ICAD, its inhibitor, which 
seems to function as a chaperone for CAD during its synthesis, remaining complexed 
with CAD to inhibit its DNase activity (Enari et al., 1998). Cleavage of ICAD by 
caspases allows CAD to enter the nucleus and degrade chromosomal DNA (Enari et 
a l, 1998).
Apart from those mentioned above, several other proteins are also known to undergo 
proteolysis by caspase action. These include Poly (ADP-ribose) polymerase (PARP), 
a nuclear enzyme that is recognized as an early event in apoptosis in intact cells 
(Lazebnik, 1994). Caspase 3 cleaves PARP to a specific 85kd form observed during 
apoptosis (Tewari et al., 1995b). A 70kd component of the U1 small 
ribonucleoprotein (Ul-70kd) is a proteolytic substrate for the caspases during Fas and 
TNF induced apoptosis (Tewari et al., 1995a; Casciola-Rosen et al., 1996). DNA 
dependent protein kinase, sterol-regulatory element binding proteins (SREBPs) are 
also specifically cleaved during apoptosis (Janicke et al., 1996). In a study carried out 
by Widmann et al., (1998), Ras, MEKK1 and FAK (as mentioned before) were found
to be cleaved by the caspases in Jurkat cells induced to undergo apoptosis by Fas 
ligation, exposure to ultraviolet-C or incubation with etoposide. Some of the other 
proteins cleaved during apoptosis are, Cbl, Cbl-b, Raf-1 and Akt were cleaved later 
in the apoptotic response (Widmann et al., 1998).
5.3 Role of the Bcl-2 family in cell survival
Bcl-2 was first discovered as an oncoprotein whose deregulated expression through 
translocation is associated with follicular and B cell lymphomas (Yunis et al., 1987; 
Tsujimoto et al., 1985; Cleary et al.} 1986). Since then several other protein 
belonging to this family have been discovered (reviewed in Yang and Korsmeyer, 
1996; Harrington et al., 1994). These proteins contain a carboxy-terminal 
transmembrane anchor sequence that allows them to associate with cellular 
membranes including the outer membrane of mitochondria, endoplasmic reticulum, 
and the nuclear membrane (Krajewski et al., 1993). Inspite of being homologous at 
the level of amino acid sequence, some of the family members suppress apoptosis, 
while the others accelerate it (reviewed in Reed, 1995). For example, while Bcl-2 and 
its homologue Bcl-XL inhibit apoptosis in a wide variety of cell systems, Bcl-Xs , 
Bax, Bak and BAD promote it (reviewed in Reed, 1995). The members of the Bcl-2 
family are able to interact with each other to form heterodimers (Sato et al., 1994; 
Yang et al., 1995). The importance of formation a BAD/Bcl-2 heterodimer in 
regulating Bcl-2 function is discussed later in section 5.7.3.
The earliest findings implicating Bcl-2 in cell survival showed that overexpression of 
Bcl-2 increased the viability of certain cytokine dependent cells upon cytokine 
withdrawal (Nunez et al., 1990; Deng and Podack, 1993). Radiation,
chemotherapeutic drugs, and ceramide, a proapoptotic lipid second messenger that is 
often produced in cells after exposure to y-radiation, have all been reported to 
downregulate Bcl-2 expression in leukemia cells, again implying a role in cell 
survival (reviewed in Reed, 1995). Bcl-2 overexpression also protects the MDCK 
cells during apoptosis induced by disruption of cell-matrix interactions (Frisch and 
Francis, 1994). Studies have also implicated a role for Bcl-2 in mediation of 
suppression of apoptosis in a murine pre-mast cell line by the v-Abl protein tyrosine
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kinase (Chen et al., 1997). Overexpression of Bcl-2 inhibits the activation of 
cytoplasmic caspases after apoptotic stimuli (Krebs et al., 1999). It has also been 
shown to prevent caspase-independent cell death induced by exogenous nitric oxide 
in PC12 and HeLa cells (Okuno et al., 1998). Nevertheless, in another study, 
experiments showed that treatment of Bcl-2 transfected SCC9 cells with anti-Fas 
antibody did not reduce the number of dead cells significantly (Crowe et al., 1998).
Recent experiments have suggested possible mechanisms by which Bcl-2 and its 
homologues are able to participate in cell survival. Some studies suggest that Bcl-2 
acts by preventing the release of cytochrome C (Yang et al., 1997; Kluck et al., 
1997a). Overexpression of Bcl-2 in human acute myeloid leukemia cells prevented 
the initiation of apoptosis induced by staurosporine and also the efflux of cytochrome 
C from the mitochondria, suggesting that Bcl-2 acts upstream of cytochrome C 
release (Yang et al., 1997). On the other hand, in a study carried out by Rosse et al., 
(1998), overexpression of Bcl-2 prevented Bax-induced apoptosis, but did not stop 
cytochrome C release, thus showing that Bcl-2 can prevent apoptosis by acting 
downstream of cytochrome C release. Another more direct approach confirmed that 
Bcl-2 can act downstream of cytochrome C release. Zhivtovsky et al., (1998) 
microinjected high concentrations of cytochrome C into the cytosol and found that 
high levels of Bcl-2 expression were still able to block most of the cell death. A 
recent study has suggested that Bcl-2 might act in part by blocking the activation of 
membrane associated caspases (Krebs et al., 1999). However, other studies have 
shown that overexpression of Bcl-2 prevents CD95 induced apoptosis in SKW6 cells 
but did not block caspase activities (Scaffidi et al., 1998).
5.4 Role of mitochondrial dysfunction and cytochrome C in apoptosis
Mitochondria have been implicated in the process of apoptosis ever since it was 
discovered that the members of the Bcl-2 family of anti-apoptotic proteins, are 
located in the outer mitochondrial membrane (Krajewski et al., 1993). A more direct 
role for mitochondria in apoptosis was demonstrated by the finding that apoptosis in 
Xenopus egg extracts in vitro requires a dense organelle fraction enriched in 
mitochondria (Newmeyer et al., 1994). A later study identified cytochrome C as a
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necessary component for induction of apoptosis in vitro (Liu et al., 1996). 
Cytochrome C is an essential component of the mitochondrial respiratory chain. It is 
a soluble protein that is found in the inter membrane space and is loosely attached to 
the surface of the inner mitochondrial membrane (reviewed in Reed, 1997; Kroemer,
1999). One study used a cell free system based on cytosolic extracts of normally 
growing cells to reproduce aspects of the apoptotic programme in vitro (Liu et al.,
1996). Elimination of cytochrome C from the cytosol diminished the ability of the 
extracts to induce apoptosis; adding back cytochrome C, the apoptotic activity of the 
extracts was restored. Also, cells undergoing apoptosis in vivo showed increased 
release of cytochrome C to the cytosol, suggesting that mitochondria may function in 
the apoptotic process by releasing cytochrome C (Yang et al., 1997; Kluck et a l, 
1997a; Vander Heiden et al., 1997; Bossy-Wetzel, 1998). Another unrelated caspase 
activating factor (AIF) is also released by the mitochondria from the intermembrane 
space into the cytosol and is thought to be capable of processing caspase 3 in vitro 
(Susin et al., 1996; reviewed in Green and Reed, 1998). However, the role of 
cytochrome C in apoptosis has been studied in more detail and is discussed below.
During the apoptotic process, the mitochondrial inner membrane potential is 
frequently disrupted (Vander Heiden et al., 1997). Opening of the megachannel (a 
composite ion channel that traverses the inner and outer mitochondrial membrane at 
sites of contact between them) causes an increase in the matrix volume leading to 
physical disruption of the outer membrane, facilitating the release of cytochrome C 
(reviewed in Green and Kroemer, 1998). However, cytochrome C release can also 
occur independent of mitochondrial transmembrane depolarisation (Bossy-Wetzel et 
al., 1998). Cell free assays have revealed that cytochrome C is an activator of caspase 
3 (Liu et a l, 1996). This activation is dependent on dATP. In addition, another 
cytosolic factor known as Apaf-1 is also required (Zou et a l, 1997). Requirement of 
caspase 9 in cytochrome C mediated activation of caspase 3 was demonstrated when 
it was found that caspase 9 forms a complex with Apaf-1 in a cytochrome C and 
dATP-dependent manner (Li et al., 1997) forming an ‘apoptosome’ (Green and Reed, 
1998). Cleavage of caspase 3 is absent in the cytosolic extracts of caspase 9-deficient 
cells but is restored after addition of in vitro translated caspase 9 (Kuida et al., 1998), 
thus confirming that cytochrome C activation of caspase 3 is mediated by caspase 9.
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5.5 Initiation and execution of apoptosis: caspases vs cytochrome C release
Apoptosis, for sometime, has been considered a consequence of a cascade of caspase 
activation. However, recent studies have shown that the commitment point, as 
measured as the loss of clonogenic potential or loss of viability does not always 
correlate with activation of the caspase proteases (reviewed in Green and Kroemer,
1998). Indeed, there are cases in which activation of caspases is observed at a much 
later time point. For example, during Fas mediated apoptosis in Jurkat and CEM 
cells, cleavage of caspase 3 and caspase 8 is delayed compared to their activation in 
SKW6.4 and H9 cells (Scaffidi et al., 1998). Blocking of all mitochondrial 
apoptogenic activities in these cells by the overexpression of Bcl-2 or B c1-X l , not 
only blocks the process of apoptosis but also blocks the activation of caspases 3 and 
8, showing that caspases activation is downstream of mitochondrial dysfunction, at 
least in these cells (Scaffidi et al., 1998). Other studies have also shown that 
disruption of mitochondrial function leads to cell death without caspase activation, 
and caspase-independent pathways of cell death linked to mitochondrial dysfunction 
also exist (Hirsch et al., 1997).
Inducible expression of Bax, a pro apoptotic Bcl-2 family member, induces apoptosis 
in Jurkat T cells (Xiang et al., 1996). Inhibition of caspase activity by ZVAD-FMK, a 
known caspase inhibitor was unable to block Bax-induced cell death. Inhibition of 
caspase activity was also unable to prevent the fall in mitochondrial membrane 
potential. Thus Bax-induced alterations in mitochondrial function and subsequent 
cell death do not require caspase activity (Xiang et al., 1996). Inhibiton of caspases 
was also unable to prevent cell death induced by the ectopic expression of Bak, 
another pro-apoptotic homologue of Bcl-2, in Rat-1 cells (McCarthy et al., 1997). In 
the same study it was found that cell death induced by c-Myc expression in Rat-1 
cells was also not prevented by inhibition of caspase activity. However, in the case of 
both Bak and c-Myc, the cell death resulting after the inhibtion of caspases did not 
exhibit all of the characteristic biochemical and morphological events associated with 
apoptosis, including cleavage of cleavage of nuclear lamins and PARP, chromatin 
condensation and nucleosome laddering (Xiang et al., 1996; McCarthy et al., 1997).
Characteristics associated with the onset of apoptosis, such as surface blebbing were 
not inhibited. Examples of caspase-independent commitment to cell death can be 
found in several of the other classic models of apoptosis, including glucocorticoid- 
induced death of thymocytes and lymphoid lines, death of haematopoietic cell lines 
induced by cytokine withdrawal and death of target cells of cytotoxic T cells 
(reviewed in Green and Kroemer, 1998).
Most of the studies carried out on caspase-independent cell death conclude that 
although the commitment point is independent of caspase activation, caspases are 
still required for the completion of the process and for the manifestation of certain 
morphological and biochemical features associated with apoptosis, such as cleavage 
of PARP and nucleosome laddering. This led Green and Kroemer, (1998), to suggest 
a mechanism of apoptosis in which caspase activation and disruption of 
mitochondrial function occur in a circular feedback loop. According to their model, 
mitochondrial dysfunction would enable the release of caspase activators such as 
cytochrome C, at the same time as caspases might act on mitochondrial membranes. 
Such a self amplifying system would have several points of entry (mitochondrial 
membranes and caspase cascades), allowing for the activation of apoptotic pathway 
and, at the same time, would be vulnerable to the inhibitory effects of caspase 
inhibitors and of agents that stabilize mitochondrial membranes (Green and Kroemer,
1998). Figure 22 outlines some of the key regulators of apoptosis and shows the two 
points where apoptosis can be initiated.
5.6 Pro-apoptotic signal transduction pathways upstream of commitment
Results of several studies are beginning to reveal the complex integration of signal 
transduction pathways that are involved in the decision of the cell to survive or to 
undergo apoptosis. Certain kinases have been identified that are able to induce 
apoptosis when expressed in cells.
MEKK 1, an upstream kinase activator of the ERK and JNK pathways (reviewed in 
Robinson and Cobb, 1997), has been implicated in the induction of apoptosis 
(Johnson et al., 1996; Cardone et al., 1997; Widmann et al., 1998). A later study
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using MDCK cells demonstrated that the activation of MEKK 1 required caspase- 
mediated proteolysis, generating a fragment that promotes apoptosis (Cardone et al.,
1997). Expression of the cleaved product of MEKK 1 was able to induce apoptosis in 
the cells, while expression of the kinase inactive form protected from cell death 
(Cardone et al., 1997). Cleavage resistant or kinase inactive mutants of MEKK 1 also 
prevent complete activation of caspase 7, suggesting that MEKK 1 lies upstream of 
some caspases. Another study has also reported that the kinase activity of MEKK 1 
stimulates caspase 3-activity in cells (Widmann et a l, 1998).
Involvement of MEKK 1 in apoptosis focused attention on some of its downstream 
effectors. C-Jun N-terminal kinases (JNKs), also known as stress-activated protein 
kinases (SAPKs), are likely to be involved in the process of apoptosis. JNK can be 
activated by various different stimuli such as UV light, y radiation, protein synthesis 
inhibtiors, DNA damaging drugs, chemopreventive drugs, TNF-a and interleukin, all 
implying that JNK may regulate gene expression or other biochemical functions in 
the cell under stressful conditions (Chen et al., 1996b). A direct correlation between 
JNK activation and induction of apoptosis by UV-C and y radiation has been 
observed (Chen et al., 1996b). Also, overexpression of JNK 1 caused cell death in 
transfected Jurkat cells, while the expression of a dominant negative mutant 
prevented UV-C and y radiation induced cell death (Chen et al., 1996b). JNK 
activation has also been reported early after the detachment of the epithelial cells 
from the matrix (Frisch et al., 1996a). Expression of a dominant negative form of 
JNK reduced JNK activation by fourfold and the transfected MDCK cells were 
relatively resistant to anoikis, thus showing that the activation of this pathway is 
linked to anoikis (Frisch et al., 1996a). Inhibition of caspase activity by CrmA 
attenuated JNK activation. Also, blockage of JNK pathway attenuated the activation 
of caspases, suggesting a positive feed back loop between the caspases and the JNK 
pathways (Frisch et al., 1996a). In addition, withdrawal of NGF from PC12 cells also 
leads to sustained JNK activation (Xia et al., 1995). In SHEP cells, a human 
neroblastoma cell line, the expression of JNK1 APF (a mutant for form of JNK) 
inhibited Fas mediated JNK activation and apoptosis, suggesting that JNK is required 
for Fas mediated cell death (Goillot et al., 1997). Some studies have also investigated 
the role of JNK substrates to try to determine the pathway in more detail. JNK is
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known to phosphorylate transcription factors such as c-Jun, ATF-2 and Elk-1 and 
strongly augments their transcriptional activity (Gupta et al., 1995; Whitmarsh et al., 
1995; Karin, 1995). Expression of a dominant negative form of c-Jun blocks 
apoptosis induced by NGF withdrawal in PC12 cells (Xia et al., 1995), suggesting 
that JNK mediated apoptosis might require transcription of other proteins regulated 
by c-Jun.
Despite the findings mentioned above, there have been reports which question the 
role played by JNK activation during the process of apoptosis. Expression of an 
inhibitory mutant of c-Jun did not have any effect on the induction of apoptosis by 
ionizing radiation in SQ-20-B human cells, and the same mutant was found to protect 
the T98G glioblastoma cells against cisplatin induced apoptosis (Jarpe et al., 1998). 
Activation of the JNK pathway also protected HeLa cells from apoptosis following 
photodynamic therapy (PDT) with hypericin and transfection of cells with dominant 
inhibitors of the JNK pathway enhanced PDT-induced apoptosis (Assefa et al.,
1999). Knockout experiments have also shown similar discrepancy (Nishina et al.,
1997). Elimination of an upstream activator of JNK, SEK-1, in ES cells did not make 
any difference to the normal apoptotic response of the cells to anisomycin induced 
apoptosis; instead SEK-1 null thymocytes displayed an increased sensitivity to CD3 
and Fas mediated apoptosis (Nishina et al., 1997).
p38, another stress-activated member of the MAP kinase superfamily, has also been 
implicated in the process of apoptosis. It is the physiological MAPKAP-kinase-2 
activator recruited in response to 11-1 and stress stimuli (Kyriakis and Avruch, 1996). 
MAPKAP-kinase-2, in turn, phosphorylates the heat shock protein Hsp25/HSP27. 
Apoptosis induced by NGF withdrawal in PC12 cells is accompanied by p38 
activation (Xia et a l, 1995). Furthermore, a constitutively activated form of MKK3, 
a p38 MAP kinase kinase, was co transfected along with p38 kinase into cells leding 
to a marked increase in p38 kinase activity and induced a 4.5 fold increase in the 
number of apoptotic cells in the presence of NGF (Xia et al., 1995). Glutamate 
induced apoptosis in the Rat cerebellar granule cells is also accompanied by p38 
activation and inhibition of p38 activity was able to block glutamate-induced 
apoptosis (Kawasaki et al., 1997). However, like the JNKs, there have been
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contradictory reports concerning the role of p38 kinase in apoptosis. For example, 
pre-treatment of HeLa cells with a p38 inhibitor enhances PDT-induced apoptosis 
(Assefa et al., 1999). Thus, the specific role of JNK an p38 stress-activated kinases in 
supression or promotion of apoptosis may be cell-type specific.
5.7 Anti-apoptotic signal transduction pathways
As mentioned before, both integrin signaling and growth factor signaling have been 
implicated in cell survival and protection from apoptosis. The signal transduction 
pathways that act downstream of these signals are just beginning to be described. The 
roles of Src and FAK in cell survival have already been mentioned. This section will 
consider other possible signalling proteins downstream of integrins and growth 
factors that mediate cell survival.
5.7.1 Role of PI 3-kinase/Akt in survival signalling
PI 3-kinase, a known proto-oncogene (Chang et al., 1997; reviewed in Porter and 
Vaillancourt, 1998), is a heterodimer comprising of an 85kd regulatory subunit and a 
HOkd catalytic subunit (Fry and Waterfield, 1993). p i 10 is a dual specificity enzyme 
that acts not only as a lipid kinase but also as protein serine kinase. It is known to 
catalyze the phosphorylation of inositol lipids at the D-3 position of the inositol ring, 
resulting in the formation of phosphatidylinositol 3-phosphate [PIP], 
phosphatidylinositol 3,4-bisphosphate [PIP2] and phosphatidylinositol 3,4,5- 
triphosphate [PIP3] (Liscovitch and Cantley, 1994). These lipid products act as 
secondary messengers that act on several different pathways including cell survival, 
largely through the activation of Akt (also known as protein kinase B or PKB; 
Delcommenne et al., 1998). Akt, a serine threonine kinase, is also a known proto­
oncogene. The lipid products of PI 3-kinase, PIP2 and PIP3, are able to bind to the PH 
domain of Akt (Franke et al., 1997). This binding mediates translocation of the 
kinase from the cytosol to the plasma membrane (Andjelkovic et al., 1997) which 
appears to be required in order to present Akt to upstream activating kinases 
(reviewed in Downward, 1998). Akt becomes phosphorylated at residues Thr308 and
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Ser473 by upstream kinases such as protein kinase-1 (PDK1) (Alessi et al., 1996; 
Alessi etal., 1997).
There is evidence in different cell types demonstrating that cell survival is dependent 
on the PI 3-kinase/Akt pathway. In particular, PI 3-kinase activity is required for the 
survival of serum deprived PC12 cells (Yao and Cooper, 1995). In addition, Ras 
mediated protection of MDCK cells from apoptosis is mediated by PI 3-kinase 
(Khwaja et al., 1997). A constitutively activated form of PI 3-kinase was able to 
prevent apoptosis in the cells while blocking PI 3-kinase activity abrogated protection 
conferred by Ras (Khwaja et al., 1997). Even in non-transformed cells, attachment of 
cells to the ECM leads to rapid elevation of the levels of the PI 3-kinase lipid 
products (Khwaja et al., 1997). Overexpression of EGF growth receptor also 
effectively protects Rat-1 fibroblasts against UV-induced apoptosis (Kulik et al.,
1997), an effect that is inhibited by wortmannin, a PI 3-kinase inhibitor. Also, 
transfection of the cells with constitutively active forms of PI 3-kinase or Akt were 
sufficient to inhibit UV-induced apoptosis (Kulik et al., 1997). The PI 3-kinase/Akt 
pathway is also important in CSF-1 regulated macrophage proliferation, 
differentiation and survival (Hamilton, 1997) and Suppression of c-Myc induced 
apoptosis by insulin like growth factor (IGF-1) is also mediated by Akt (Rohn et al.,
1998). Furthermore, activated Akt suppresses CD95-(Fas) induced apoptosis at a 
point downstream of FADD but upstream of caspase 8 . Thus, there is substantial 
evidence implicating Akt as a survival factor of importance.
5.7.2 Regulation of PI 3-kinase by PTEN
PTEN, a tumour suppressor protein, modulates cell survival by regulating the PI 3- 
kinase/Akt pathway (Sun et al., 1999). PTEN is a phosphatase specific for both 
phospholipids and phosphoproteins. Its substrates include FAK and PIP3 , the lipid 
product of PI 3-kinase (Li et al., 1998). The role of FAK in cell survival has been 
discussed before (in section 1.3). Dephosphorylation of PIP3 negatively regulates the 
PI 3-kinase/Akt signaling pathway. Inactivation of PTEN in ES cells and in 
embryonic fibroblasts results in elevated levels of PIP3 , which in turn increases the 
phosphorylation and activation of Akt and promotes cell survival (Sun et al., 1999).
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Another study has reported that pten heterozygous mice show impaired Fas mediated 
apoptosis (Di Cristofano et al., 1999). T lymphocytes from these mice also showed 
reduced activation-induced cell death. Inhibition of PI 3-kinase activity in these cells 
was able to abolish Fas responsiveness, thus implicating PTEN and PI 3-kinase/Akt 
pathway in Fas mediated apoptosis.
5.7.3 Downstream effectors of Akt that direct cell survival and apoptosis
The mechanism by which Akt protects cells from programmed cell death has been 
the subject of much investigation recently. Akt can phosphorylate the pro-apoptotic 
Bcl-2 family member, BAD (del Peso et al., 1997; Datta et al., 1997), both in vitro 
and in intact cells. The phosphorylation occurs at Serl36 of BAD (Datta et al., 1997), 
creating a binding site for 14-3-3 protein, a family of ubiquitous highly expressed 
adaptor proteins. When BAD is bound to 14-3-3, it is unable to heterodimerize with 
and inhibit the survival activity of Bcl-2 and Bcl-XL proteins (Zha et al., 1996). In 
both haematopoietic precursor cells and fibroblasts, overexpression of BAD induces 
cell death and this effect is reversed by expression of activated forms of Akt. Death 
induced by non-phosphorylatable BAD is not suppressed by activated Akt. However, 
it is not clear if this is the primary way in which the survival signal from Akt is 
mediated (reviewed in Downward, 1997). This is so because BAD is only expressed 
in a limited range of tissues and cell lines and most of the studies carried out to 
investigate its role in Akt mediated survival signal were done using overexpression 
of the protein.
Glycogen synthase kinase-3 (GSK-3) has recently been identified as an important 
downstream element of the PI 3-kinase/Akt cell survival pathway (Pap and Cooper,
1998). GSK-3 is a ubiquitously expressed protein serine/threonine kinase whose 
activity is inhibited by Akt phosphorylation. It is known to phosphorylate a broad 
range of substrates including translation initiation factor eIF2B and several 
transcription factors. Overexpression of a catalytically active form of GSK-3 induces 
apoptosis in Rat-1 and PC12 cells (Pap and Cooper, 1998). Also, a dominant 
negative form of GSK-3 prevents apoptosis induced by the inhibition of PI 3-kinase 
activity. GSK-3 is phosphorylated by integrin-linked kinase (ILK), which is also
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known to suppress suspension induced apoptosis (Delcommenne et al., 1998). 
Phosphorylation by ILK also inhibits GSK-3 activity and is believed to be dependent 
on PI 3-kinase and Akt.
Other substrates of Akt have also been identified which also might mediate cell 
survival. For example, Akt can phosphorylate recombinant caspase 9 in vitro on 
residue Serl96, and inhibit its protease activity (Cardone et a l, 1998). A mutated 
form of caspase 9 with an Ala substitution at position 196, was resistant to Akt 
mediated phosphorylation and inhibition in vitro and in vivo, resulting in Akt 
resistant induction of apoptosis. Akt can also phosphorylate and regulate the activity 
of FKHRL1, a member of the Forkhead family of transcription factors, which can 
induce apoptosis, most likely by inducing the expression of genes that are critical for 
cell death, such as that encoding Fas ligand (Brunet et al., 1999). Akt 
phosphorylation of FKHRL 1 in the presence of growth factors leads to its 
association with 14-3-3 proteins and its retention in the cytoplasm (Brunet et al.,
1999). On the other hand, in the absence of survival factors, FKHRL 1 is translocated 
to the nucleus and targets gene activation (Brunet et al., 1999). There have been 
reports that Akt itself is translocated to the nucleus following stimulation of cells 
with growth factors, suggesting that important substrates could also exist in this 
cellular compartment (Meier et al., 1997).
Another possible downstream target of Akt is p70S6K, a ribosomal protein kinase, 
(Koh et al., 1999). P70S6K also lies downstream of PI 3-kinase (Chung et al., 1994). 
It phosphorylates the S6  peptide of the 40S ribosomal subunit (reviewed in Chou and 
Blenis, 1995). Evidence suggests that p70S6K plays an important role in progression 
through the G1 phase of the cell cycle. It is possible that Akt mediated survival might 
involve the activity of p70S6K since regulation of cell cycle progression is linked to 
cell survival.
5.7.4 Other possible survival pathways
Recent studies have focused attention on another set of proteins known as the signal 
transducers and activators of transcription or STATs. STATs are latent transcription
factors (reviewed in Bromberg et al., 1999). These are activated by phosphorylation 
on a single tyrosine residue in response to extracellular ligands. More than 40 
different ligands can cause STAT activation, including cytokine receptors which 
signal through associated Janus tyrosine kinases (Jaks) or growth factors such as 
EGF, PDGF and CSF 1 (reviewed in Bromberg et a l, 1999). STAT dimers are 
formed by interaction between the SH2 domain of one monomer and the 
phosphorylated tyrosine residue of the other. These dimers can then translocate to the 
nucleus and activate specific genes. They are generally thought to play a role in cell 
growth. However, a recent study showed that cell lines from multiple myelomas that 
have acquired growth factor independence, require constitutively active STAT3 to 
protect against apoptosis (Catlett-Falcone et al., 1999). Another study has 
characterised the role of STAT3 as an oncogene and demonstrated that substitution 
of two cysteine residues within the carboxy-terminal loop of the SH2 domain, causes 
cellular transformation in immortalized fibroblasts (Bromberg et a l, 1999). STAT1, 
3, and 5 have also been implicated in Interleukin-9 (IL-9) signaling. Activation of 
STATs by IL-9 depends on a single phosphotyrosine at position 367 in IL-9R 
(Demoulin et al., 1996). IL-9 protects T cells from glucocorticoid-induced apoptosis 
by a STAT dependent mechanism (Demoulin et al., 1996). Protection from apoptosis 
was observed by activation of either STAT5 or both STAT1 and STAT3, suggesting 
redundancy in these cases (Demoulin et al., 1999).
A subgroup of the MAP kinase family, ERKs, have also been implicated in cell 
survival. The ERKs are activated in response to growth factor stimulation (reviewed 
in Marshall, 1994). Induction of apoptosis in PC12 cells by NGF withdrawal required 
suppression of ERK activity (Xia et al., 1995). In this study, expression of 
constitutively activated forms of MKK1, a protein kinase that activates ERKs, 
prevented apoptosis induced by NGF withdrawal. Another study demonstrated that 
activation of the ERK signaling pathway completely suppressed the FTY720-induced 
apoptosis in T lymphocytes (Matsuda et al., 1999). Furthermore, apoptosis following 
PDT was accompanied by irreversible inhibition of ERK2 in several cancer cell lines 
(Assefa et al., 1999). It has been suggested that ERK may also phosphorylate BAD, 
which is known to play an important role in the induction of apoptosis and its 
phosphorylation correlates with cell survival (Scheid and Duronio, 1998; section
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5.7.3). However, some other studies report that ERK activation does not play any role 
in cell survival. For example, there was no significant change in ERK2 activity 
during the early phase of y or UV induced apoptosis in Jurkat cells (Chen et al., 
1996b), although it did gradually decrease only 5-6 hours after radiation. In Rat-1 
fibroblasts, the ERK pathway does not have a protective effect on UV induced 
apoptosis (Kulik et al., 1997).
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Chapter 6: Results 3 
Characterisation of mediators of apoptosis after removal of v-Src 
induced survival signal: the role of ZVAD.fmk-sensitive caspases
and p38
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6.1 Introduction
Results shown in chapter 5 showed that although apoptosis in serum-deprived v-Src 
transformed Rat-1 cells was accompanied by FAK proteolysis, inhibiting FAK 
cleavage did not prevent apoptosis. Thus, FAK cleavage was not playing an essential 
role in the induction of apoptosis, at least in these cells. For this reason, the planned 
experiments to determine the cleavage sites of FAK followed by generation of 
cleavage-insensitive FAK mutants were not pursued further. Therefore, further 
studies concentrated on examining some of the pathways involved in the mediation 
of apoptosis after attenuation of v-Src induced survival signalling in serum-starved 
Rat-1 cells.
The following chapter gives a detailed description of the characteristics of cell death 
in v-Src transformed Rat-1 cells, and the role of both ZVAD.fmk-sensitive caspases 
and p38 in its induction.
6.2 Characterisation of cell death in v-Src transformed Rat-1 cells
Rat-1 cells expressing a temperature-sensitive mutant (ts) of v-Src, ts LA29, are 
transformed at the permissive temperature of 35°C, and morphologically normal at 
the restrictive temperature of 39.5°C. The mitogenic effects of v-Src have been 
previously characterised by other studies in the group (Wyke et al., 1993; Wyke et 
al., 1995; Johnson et al., 1998). In contrast to normal cells, transformed cells placed 
in 0.2% serum medium (low serum) for 24 hours, continued to cycle at 35°C 
(Johnson et al., 1998). However, after serum-deprivation for 24 hours, when these 
cells were shifted to the restrictive temperature to inactivate v-Src, they became 
loosely adherent or detached and died within a few hours. This was in contrast to 
cells transformed by other oncoproteins such as c-Myc and v-Jun which died upon 
withdrawal of serum (Evan et al., 1992; Clark and Gillespie, 1997).
The type of cell death induced in these cells exhibited characteristics of programmed 
cell death. Specifically, various morphological and biochemical criteria that are 
known to accompany apoptosis, also accompanied cell death induced after v-Src
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inactivation. Experiments were carried out according to the scheme already outlined 
in section 4.4 (Figure 19a). Cells were harvested at 0, 2, 4, and 6  hours after being 
shifted to the restrictive temperature for TUNEL analysis to determine the percentage 
of cells undergoing apoptosis. Figure 23a graphically represents the percentage of 
cells undergoing apoptosis at each time point.
In order to determine if the dying cells were fragmenting their DNA into nucleosomal 
ladders, another characteristic feature of apoptosis (reviewed in Kerr et al., 1972; 
Wyllie, 1997), both detached and adherent cells were harvested separately 6  hours 
after v-Src inactivation and DNA was isolated. lOpg of isolated DNA from detached 
and adherent cells was separated into nucleosomal ladders following electrophoresis 
(Figure 23b). Laddering was more readily detectable in the detached cell DNA 
(Figure 23b).
Also, when viewed by phase contrast microscopy, the cells exhibited a rounded or 
blebbing morphology (Figure 23c) and fragmented nuclei (Figure 23d), which are 
also characteristics associated with cells undergoing apoptosis (reviewed in Kerr et 
al., 1972; Wyllie, 1997).
6.3 Biochemical changes associated with apoptosis induced by inactivating v-Src 
in serum-deprived cells
Apoptosis is frequently associated with the activation of several proteins such as 
caspases (reviewed in Harvey and Kumar, 1998) and the stress activated kinases, 
such as p38 (Xia et al., 1995; Kawasaki et al., 1997).
To investigate whether caspases were activated in v-Src transformed Rat-1 cells that 
were induced to undergo apoptosis after serum-starvation and inactivation of v-Src, 
cells were harvested at the time of serum withdrawal, 12 hours later, and then, 0, 4, 6  
and 8  hours after switching off v-Src. Harvested cells were tested for caspase activity 
by using a biotinylated peptide that binds to the large sub-units of active caspases. 
The cell lysates were incubated with the peptide and then separated by SDS-PAGE.
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Figure 23 Apoptotic features associated with cell death in transformed Rat-1 
cells: (a) To induce an apoptotic response, ts LA29v-Src transformed Rat-1 cells were 
serum starved for 24 hours followed by inactivation of v-Src by shifting the cells 
from 35°C (permissive temperature) to 39.5°C (restrictive temperature). Cells were 
fixed and TUNEL labelled to determine the percentage of cells undergoing apoptosis. 
The mean of several experiments was plotted, with the error bars representing the 
standard error, (b) DNA isolated from detached and adherent cells 6  hours after the 
induction of apoptosis, was separated on a 2 % tris-borate agarose gel and stained 
with ethidium bromide to detect nucleosomal ladders, (c) Cells were viewed under 
the microscope using phase contrast at 6  hours after v-Src inactivation to ascertain 
the morphology of dying cells (arrow points to blebbing cells), (d) At the same time, 
the morphology of the nucleus was also examined by staining with DAPI (carried out 
by D. Riley, Beatson Institute, Glasgow, UK).
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Immunoblotting, using streptavidin-coupled antibody, showed the presence of active 
caspases at 4 hours after v-Src inactivation (Figure 24a). In order to determine more 
accurately the time at which caspases were activated, caspase activity was tested at 
more frequent earlier time intervals between 0 to 4 hours. Immunoblot results 
demonstrated that active caspases can be detected in dying cells around 2.5 hours 
after switching off v-Src (Figure 24b).
To determine whether the stress activated kinase, p38, was active in dying cells, 
lysates were obtained at different time intervals, separated by SDS-PAGE and 
immunoblotted. An antibody, specific for the phosphorylated Thrl80/ Tyrl82 form 
of p38, was used to monitor the amount of active p38. Results indicated the presence 
of active p38 4 hours after the inactivation of v-Src (Figure 25). The same blot was 
stripped and re-probed for total p38 (both activated and non-activated forms) to 
confirm that the observed difference was due to enzyme phosphorylation and 
activation. p38 was present in the cells at all time points in equivalent amounts 
(Figure 25).
6.4 Effects of interfering with caspase activity
To study the effects of inhibiting caspases, which we showed above to be active at
2.5 hours after v-Src inactivation in serum-starved transformed cells, ZVAD.fmk, a 
general caspase inhibitor was used (Garcia-Calvo, 1998). The inhibitor was added 
one hour before inactivating v-Src, at a concentration of lOOpM (Figure 26a). Cells 
were harvested and assayed for TUNEL labelling as before at 0, 2, 4 and 6  hours after 
switching the serum-starved transformed Rat-1 cells to the restrictive temperature. 
We observed there was a steady increase in the percentage of labelled cells with time 
(Figure 26b). The plotted graph represents typical results obtained from a set of 3 
experiments. Thus, inhibiting caspase activity was unable to prevent the cells from 
undergoing apoptosis, at least as measured by TUNEL labelling. However, a 
comparison of the percentage of cells undergoing apoptosis in the presence and the 
absence of ZVAD.fmk, showed that there was a small reduction in the number of 
cells undergoing apoptosis in the presence of the inhibitor (Figure 21). However,
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Figure 24 Activation of caspases during apoptosis in transformed Rat-1 cells: (a)
Serum starved transformed Rat-1 cells were harvested at different time points before 
and after v-Src inactivation. Caspase activity in the harvested cells was tested by an 
assay which involves the binding of biotinylated peptide to the active caspases and its 
subsequent detection following protein separation by SDS-PAGE and 
immunoblotting with streptavidin antibody (carried out in collaboration with Kumiko 
Samejima, Edinburgh, UK), (b) To determine the time of caspase activation more 
accurately, the experiment was repeated with cells harvested at closer time intervals 
after induction of apoptosis.
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Figure 25 p38 activation during apoptosis in transformed Rat-1 cells: Serum- 
starved v-Src transformed Rat-1 cells were induced to undergo apoptosis by v-Src 
inactivation. Cell proteins, obtained at different time intervals after v-Src inactivation 
were separated by SDS-PAGE and immunoblotted using anti-phospho p38 antibody 
to detect the presence of phosphorylated/activated p38 (upper panel). The blot was 
stripped and reprobed for whole p38 to confirm that there was no difference in 
protein loading (lower panel).
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Figure 26 Apoptotic features associated with induction of apoptosis in 
ZVAD.fmk treated cells: (a) Transformed Rat-1 cells were treated with ZVAD.fmk 
to inhibit caspase activity, an hour before the induction of apoptosis. (b) Serum- 
starved cells, induced to die by v-Src inactivation, were harvested at different time 
intervals and TUNEL labelled to calculate the percentage of cells undergoing 
apoptosis. The experiment was carried out 3 times and typical results were plotted, 
(c) DNA isolated from detached or adherent cells 6  hours after induction of the 
apoptotic response, was separated on a 2 % tris-borate agarose gel and stained with 
ethidium bromide to detect nucleosomal laddering, (d) Cells were viewed using 
phase contrast microscopy at 6  hours (arrows point to the cells showing membrane 
blebbing). (e) Cell nuclei were stained with DAPI to detect nuclear fragmentation 
(carried out by D. Riley, Beatson Institute).
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since the percentage of labelled cells lay within the error bars of the controls, it was 
difficult to ascertain whether this difference was significant.
To determine whether the caspase inhibitor affected DNA laddering, cells were 
treated with ZVAD.fmk, as before. Detached and adherent cells were harvested 
separately at 6  hours after switching off v-Src activity. Results showed that, as in the 
cells without the inhibitor, DNA isolated from both adherent and detached cells 
separated into approximately 200bp ladders. As before, the laddering was more 
apparent in the detached cells (Figure 26c and Figure 23b).
When viewed by phase contrast microscopy, more cells were still in the blebbing 
state as compared to the control cells (Figure 26d and Figure 22c). Also, the nuclei 
were fragmented as they were in the cells that had not been treated with ZVAD.fmk 
(Figure 26e and Figure 22d).
Activation of p38 can be triggered by caspases which, in some cell types, cleave and 
activate MEKK 1, the upstream kinase (Cardone et al., 1997). Since p38 was active 
in the cells under study (Figure 25), immunoblots were carried out to determine if 
inhibiting caspases had any effect on p38 activition. Figure 27 shows that although 
the amount of p38 was reduced, when compared to the controls (Figure 25), p38 was 
still activated at about 4 hours after v-Src inactivation (all the samples were run on 
the same gel and are therefore comparable). Thus, p38 activation was largely 
independent of caspase activity.
In order to confirm that ZVAD.fmk was indeed inhibiting caspases, its effect on FAK 
proteolysis, a known caspase substrate (Wen et al., 1997; Chapter 4 of this thesis), 
was examined. The cleavage of FAK was inhibited by ZVAD.fmk (Figure 20c). 
Thus, although ZVAD.fmk was inhibiting caspase-mediated proteolysis, it was 
unable to prevent apoptosis in transformed Rat-1 cells, as measured by TUNEL, 
DNA laddering or p38 activation.
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Figure 27 Biochemical effect of blocking caspase activity: Transformed Rat-1 
cells were treated with ZVAD.fmk to inhibit caspase activity, and then induced to 
undergo apoptosis by v-Src inactivation. Cell lysates obtained at different time points 
after v-Src inactivation were separated by SDS-PAGE and immunoblotted using anti- 
phospho p38 antibody to detect p38 activation (upper panel). Blot was stripped and 
reprobed with antibody against whole p38 (lower panel).
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6.5 Effects of inhibiting p38 activity
To investigate the role played by p38 in the process of apoptosis, 4-(4-fluorophenyl)- 
2-(4-methylsulfinylphenyl)-5-(4-pyridyl)lH-imidazole (SB203580), a chemical 
inhibitor of p38, was used (Saklatvala et al., 1996; Hazzalin et al., 1997).
To study the effects of inhibiting p38 activity in serum-starved transformed Rat-1 
cells, induced to undergo apoptosis after v-Src inactivation, SB203580 was added 
one hour before switching the cells to the restrictive temperature (Figure 26a). To 
determine the percentage of cells undergoing apoptosis, cells, with and without the 
inhibitor, were harvested at 0, 2, 4, and 6 hours after inactivation of v-Src for 
TUNEL labelling. A typical result is shown in Figure 28a. There was an increase in 
the percentage of labelled cells with time. The increase was comparable to that found 
in control cells without inhibitor (Figure 28a). However, the total percentage of cells 
undergoing apoptosis in the presence of the inhibitor was apparently slightly less than 
the control cells, although the significance of this small decrease was not determined.
When viewed at 5 hours, the cells appeared rounded with some clearly in the 
blebbing stage (Figure 28b), morphological features that were indistinguishable from 
the control cells (Figure 23c).
In order to verify the state of p38 activity in these cells, cell lysates were separated by 
SDS-PAGE and immunoblotted using an antibody specific for the phosphorylated 
Thr 180/ Tyr 182 form of p38. Phosphorylated p38 could be found at 2 hours in cells 
to which SB203580 was added, as compared to 4 hours in control cells (Figure 29a 
and Figure 25) and was further increased with time. A possible explanation for why 
SB203580 did not inhibit p38 activation is that the inhibitor acts downstream of p38. 
A study by Hazzalin et al, (1997) showed that SB203580 augmented the activity of 
MKK6, an upstream activator of p38. The increase in MKK6 activity was due to 
ablation of negative feedback influences which originated from downstream kinases 
(Hazzalin et al., 1997). SB203580, thus, does not block the activation of p38, which 
is brought about by the phosphorylation of its Tyr and Thr residues, but inhibits 
activation of its downstream effectors. Phosphorylated p38 was also detected in cells
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Figure 28 Effects of inhibiting p38 activity: (a) Serum-deprived v-Src transformed 
Rat-1 cells were treated with SB203580, a p38 inhibitor, an hour before being 
induced to undergo apoptosis as a result of v-Src inactivation. The dying cells were 
harvested at different time intervals and TUNEL labelled to evaluate apoptosis. The 
experiment was repeated 3 times and typical results plotted. To compare the number 
of treated cells undergoing apoptosis to the untreated ones (control), the two were 
plotted together, (b) Cells were viewed under the microscope using phase contrast to 
look at the morphology of dying cells.
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Figure 29 Verification of reduction in p38 activity in the presence of SB203580:
(a) In order to determine whether p38 activity was inhibited by SB203580, cell 
lysates, obtained from cells harvested at different time points after induction of 
apoptosis in SB203580 treated cells, were separated by SDS-PAGE and 
immunoblotted for the presence of phospho p38. Lysates prepared from serum- 
starved transformed Rat-1 cells, which had been treated with the inhibitor but still 
retained v-Src activity (cultured at 35°C; harvested at the 6 hour time point), were 
also probed for phospho p38. (The apparent mobility shift wasn’t consistently 
observed and was a gel artifact), (b) For in vitro kinase assay, immunoprecipitated 
p38, from cells treated with different concentrations of SB203580, was used to 
phosphorylate ATF-2, a known substrate. Proteins were separated by SDS-PAGE and 
immunoblotted with anti-phospho ATF-2 antibody to detect amount of p38 activity.
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harvested at 6 hours, which had been serum-deprived and treated with the inhibitor, 
but in which v-Src activity had not been switched off (Figure 29a). These data also 
support the possibility that accumulation of phosphorylated p38 was solely due to the 
addition of SB203580.
Since the phosphorylation state of p38 could not be used in this case to verify 
whether p38 activity had been blocked, in-vitro kinase assays were carried out. 
Transformed Rat-1 cells were cultured and serum starved as before. SB203580 was 
added at 3 different concentrations (of 10(iM, 30pJM and 50pM), before inactivation 
of v-Src. Cells were harvested at 6 hours after v-Src inactivation. Cells were lysed 
and immunoprecipitated p38 was used to determine its ability to phosphorylate ATF- 
2, a known substrate of p38. Results showed a several fold decrease in p38 activity 
(Figure 29b).
6.6 Inhibiting p38 and caspase activity simultaneously, reduced the percentage 
of cells undergoing apoptosis
Addition of ZVAD.fmk or SB203580 to serum-starved transformed Rat-1 cells was 
unable to prevent them from undergoing apoptosis in the absence of v-Src activity. 
There was, however, an indication that both these inhibitors might have been able to 
slightly reduce the number of dying cells. Experiments were thus carried out to 
determine if addition of both ZVAD.fmk and SB203580 together had any additive or 
synergestic effect on the apoptotic response.
Cells were harvested at 6 hours after switching off v-Src activity to determine the 
percentage of cells dying by TUNEL labelling. The mean of 4 different values was 
obtained and was compared to that of the cells undergoing apoptosis at 6 hours in 
control cells (with no inhibitor added) and to cells which were treated with 
ZVAD.fmk or SB203580 alone (Figure 30a). The percentage of cells was 
substantially reduced, (about 70% as compared to the control cells), in the cells 
treated with both ZVAD.fmk and SB203580 simultaneously.
Figure 30 Inhibition of apoptosis in cells with inhibited caspase and p38 
activity: Both ZVAD.fmk (ZVAD) and SB203580 (SB) were added to serum-starved 
v-Src transformed Rat-1 cells, an hour before v-Src inactivation, (a) Cells were 
harvested 6 hours after the induction of the apoptotic response and TUNEL labelled 
to calculate the percentage of cells undergoing apoptosis. The experiment was carried 
out twice, each time in duplicate, and the mean of the values was compared to the 
untreated cells (control), and those treated with ZVAD.fmk (ZVAD) and SB203580 
(SB), (b) Cells were viewed using phase contrast microscopy. The arrows point to 
blebbing cells.
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Phase contrast microscopy showed some of the cells in the blebbing state while some 
were rounded (Figure 30b).
6.7 Bcl-2 overexpression prevented induction of apoptosis
As discussed in section 5.3, overexpression of Bcl-2 can inhibit apoptosis under 
certain conditions, though not all (Scaffidi et al., 1998). In this study, it was shown 
that Bcl-2 overexpression inhibited apoptosis only in cells in which caspase 
activation was delayed, indicating that caspases were not involved in the initiation of 
the apoptotic response. Results presented in this thesis also show that inhibition of 
caspases was unable to prevent serum-deprived v-Src transformed Rat-1 cells from 
dying after switching off v-Src activity, and were thus, possibly not involved in the 
initiation of the apoptotic response. Therefore, overexpressing Bcl-2 might be able to 
prevent cell death. To test this, v-Src transformed Rat-1 cells were transfected with 
pSFFV-Bcl-2 (a mammalian expression vector encoding mouse Bcl-2; all the work 
presented in this section was carried out by D. Johnson, Beatson Institute, UK). 
Clones transfected with Bcl-2, or vector alone were isolated after selection for 
neomycin resistance. Immunoblotting with an anti-Bcl-2 antibody was carried out to 
confirm Bcl-2 expression in the clones (Figure 31a). Clones transfected with Bcl-2 
showed varying expression levels of Bcl-2 protein. On the other hand, those, 
transfected with plasmid only, did not show any detectable Bcl-2 expression (Figure 
31a).
Upon serum-deprivation and v-Src inactivation in the transformed Rat-1 cells, the 
percentage of dying cells was determined by TUNEL labelling in cells harvested at 6 
hours (Figure 31b). Results show that whilst a high percentage of cells transfected 
with plasmid only (clones 4 and 10) underwent apoptosis, those expressing high 
levels of Bcl-2 (clones 6 and 27) were prevented from dying (Figure 31b). Also, in 
clones that did express intermediate levels of Bcl-2 (clones 7 and 17), apoptosis was 
partially inhibited. Thus, Bcl-2 inhibited death induced by v-Src inactivation in a 
dose dependent manner.
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Figure 31 Protection from apoptosis by Bcl-2 overexpression: T ransform ed Rat-1 
c e lls  w ere transfected  w ith a p lasm id  construct carrying the gen e for m ou se B cl-2 . (a) C lon es  
transfected w ith B cl-2  and those transfected  w ith vector on ly , w ere isolated . C ells  from  c lo n es  
resistant to G 4 1 8  w ere lysed , the proteins separated by S D S -P A G E  and im m unoblotted  
using an ti-B cl-2  antibody to ch eck  B cl-2  exp ression , (b) C ells  derived  from  the various c lo n es  
w ere serum -starved for 24  hours fo llo w ed  by v-Src inactiva ion  to induce an apoptotic response. 
C ells w ere harvested  after 6 hours o f  v -Src inactivation  and T U N E L  labelled  to calcu late the 
percentage o f  c e lls  undergoing apoptosis. T he experim en t w as carried out several tim es and  
typical results w ere plotted (carried out by D. R iley , B eatson  institute, G lasgow , U K ).
6.8 Discussion
Apoptosis is a naturally occurring cell suicide pathway. Certain oncoproteins, like c- 
Myc, are known to induce apoptosis in transformed cells under low serum conditions 
(Evan et a l, 1992). The aim of the study carried out in this chapter, was to 
characterise the type of cell death induced in serum-deprived Rat-1 fibroblasts that 
had been transformed with v-Src. However, unlike c-Myc transformed cells, v-Src 
transformed cells continued to proliferate in low serum and required inactivation of 
v-Src activity for the induction of cell death in serum-deprived cells. Thus, for the 
purpose of this study, a temperature sensitive mutant of v-Src was used to transform 
the Rat-1 fibroblasts. v-Src activity was then abolished by transferring the cells to 
39.5°C from the permissive temperature of 35°C, leading to apoptosis.
Cells undergoing apoptosis exhibit certain characteristic features that distinguish 
them from cells dying through necrosis. The experiments, detailed in this chapter, 
confirmed that the type of cell death induced in serum-deprived ts v-src transformed 
Rat-1 cells after switching off v-Src activity was apoptotic. The morphology of the 
dying cells, examined after 5 hours of shifting serum-deprived cells to the restrictive 
temperature, was similar to the cells undergoing apoptosis, as recorded by previous 
studies (reviewed in Kerr et a l, 1972; Wyllie, 1997). The cells exhibited membrane 
blebbing, fragmentation of the nuclei and nucleosomal laddering. FACS analysis 
revealed that there was considerable shrinkage in the cell volume of dying cells. 
TUNEL labelling was used to quantify apoptosis in serum-starved transformed cells. 
This assay involves biotin-dUTP labelling of ends of DNA fragments, generated as a 
result of the processs of apoptosis. The labelling is specific to the process of 
apoptosis and had been used by some recent studies to quantify the apoptotic 
response (Okuno et a l, 1998; Huang et a l, 1999).
Biochemical analysis of cells undergoing apoptosis showed the activation of some 
enzymes associated with the process of cell death. Caspases were activated about 2.5 
hours after switching off v-Src in serum-deprived transformed Rat-1 cells. Caspase 
activation is known to play an essential role in the execution and, in some cases, the
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induction of apoptosis (Yang et al., 1998). Although the assay we used here 
recognises the binding of a biotinylated substrate to the active site of the caspases 
that is available only after activation, it cannot be used to distinguish which of the 11 
known members of the caspase family are activated. A more detailed analysis to 
determine which of the caspases was/were activated would provide a better insight 
into the whether caspases are involved in the execution or induction of apoptosis. 
Caspase specific antibodies are now becoming available, which will help in such an 
analysis.
To investigate the role played by the caspases in the commitment to apoptosis and its 
execution in the transformed cells, a known general inhibitor of the caspases, 
ZVAD.fmk was used (McCarthy et a l , 1997). ZVAD.fmk inhibits caspase activity 
by competitively binding to the active site. TUNEL labelling results showed that the 
percentage of ZVAD.fmk treated cells, undergoing apoptosis, was comparable to the 
untreated ones, indicating that inhibiting caspase activity did not prevent the cells 
from dying, as measured by TUNEL labelling. Chromosomal DNA was found to be 
fragmented into nucleosomal ladders and morphologically, the inhibitor treated cells 
were found to be smaller in size and exhibited membrane blebbing. However, more 
cells were still in the blebbing stage as compared to the untreated cells. Despite the 
generally accepted importance of caspase activity in the process of apoptosis, there 
are studies that report that inhibition of caspases by ZVAD.fmk is unable to prevent 
apoptosis (Xiang et a l, 1996; McCarthy et al, 1997). Membrane blebbing in the 
ZVAD.fmk treated cells was also reported by McCarthy et a l, (1997). They used 
membrane blebbing as a characteristic of onset of apoptosis. According to their 
findings, although ZVAD.fmk was unable to block the onset of apoptosis, it inhibited 
the completion of the process. However, McCarthy et al, (1997), reported that the 
cells appeared to die by necrosis rather than by apoptosis. Also, unlike the finding of 
our study, other studies have reported that although unable to prevent cell death in 
some cases, ZVAD.fmk inhibited DNA laddering (Xiang et a l, 1996; McCarthy et 
al, 1997). Indeed, a caspase activated deoxyribonuclease, CAD, has been identified 
(Enari et a l, 1998). Recent studies showed that the production of nucleosomal 
laddering required CAD, although chromatin condensation and nuclear fragmentation 
were independent of CAD activity (Samejima et a l, 1998). Instead, AIF, the
mitochondrial apoptosis-inducing factor, is reported to be responsible for chromatin 
condensation and large-scale fragmentation of DNA (Susin et al., 1999b). However, 
a previous report had stated that the release and function of AIF was biochemically 
distinct from the DNAse activity attributed to the mitochondria (Susin et al., 1999a). 
Thus, there is a possibility that other factors exist that might be responsible for 
caspase-independent nucleosomal laddering of chromosomal DNA. Other results in 
our study also support a mitochondrial-dysfunction-dependent mechanism for 
apoptosis in transformed Rat-1 cells deprived of serum and v-Src activity (discussed 
below).
The caspase-independent nature of cell death reported through the findings of this 
chapter, imply that mitochondrial dysfunction might be involved in the initiation of 
apoptosis. The caspase-independent induction of apoptosis in v-Src transformed Rat- 
1 cells is also implied by the prevention of apoptosis by overexpression of Bcl-2. 
Studies concerning the mechanisms by which Bcl-2 prevents apoptosis also show 
that it involves mitochondrial dysfunction and cytochrome C release (Yang et al., 
1997; Rosse et al., 1998; Zhivtovsky et al., 1998). However, it is possible that 
caspases might still be required for the execution of certain biochemical and 
morphological changes occurring downstream of DNA laddering and membrane 
blebbing. If true, this would explain why the cells were positive for TUNEL 
labelling. To determine if mitochondrial dysfunction is upstream or downstream of 
caspase activation, and thus, whether the type of apoptosis observed in the 
transformed Rat-1 cells is caspase-dependent or independent, it would be important 
to establish if prevention of apoptosis by Bcl-2 is able to prevent caspase activation. 
Also, comparison of the timing of cytochrome C release with that of caspase 
activation would throw more light on the sequence of events followed during the 
apoptotic process.
Apoptosis after switching off v-Src was also accompanied by the activation of p38, a 
stress activated kinase. p38 has been implicated in the induction of apoptosis in PC12 
and Rat cerebellar granule cells (Xia et al., 1995; Kawasaki et al., 1997). MEKK 1, a 
p38 activator, has also been shown to play an important role in apoptosis (Johnson et 
al., 1996). However, the role played by p38 in the process of apoptosis is
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contentious. A study by Assefa et al., (1999), found that inhibition of p38 enhanced 
PDT-induced apoptosis. Results presented here showed that, although, p38 activation 
accompanied the induction of apoptosis in serum-starved transformed Rat-1 cells, 
inhibition of p38 activity was unable to prevent cell death, as measured by TUNEL 
labelling. Also, p38 is known to be required for membrane blebbing during apoptosis 
(Huot et al., 1998), but our results showed that morphological features characteristic 
of apoptosis, including membrane blebbing and cell shrinkage, were not inhibited. 
Besides p38, myosin light chain kinase (MLCK) has also been implicated in 
regulation of membrane blebbing during apoptosis (Mills et al., 1998). Inhibition of 
MLCK decreases membrane blebbing, while, myosin regulatory light chain (MLC) 
phosphorylation increases in blebbing cells (Mills et al., 1998). It is thus, possible, 
that in v-Src transformed Rat-1 cells, MLCK, and not p38, is responsible for 
membrane blebbing, during apoptosis.
Further investigation into the role played by p38 during apoptosis, could be carried 
out using a different approach, such as using antisense oligonucleotides. Using this 
technique, translation of p38 mRNA would be inhibited, ensuring inactivity of p38. 
Also, the action of some inhibitors can be non-specific. Although SB203580 has 
been used in several studies to specifically investigate the effects of inhibiting p38 
activity, it is possible that it might be acting on other proteins too. The antisense 
approach would be able to circumvent this problem too.
Results of our study also showed that, unlike the effects of adding p38 and caspase 
inhibitors separately, adding the two inhibitors together was able to reduce the 
percentage of cells undergoing apoptosis. This suggests that both p38 and caspases 
are most likely involved in contributing to cell death independently, but that 
inhibiting either pathway alone is not sufficient to inhibit cell death. It is possible that 
these two distinct pathways regulate different aspects of apoptosis. Nevertheless, 
since the inhibition of cell death upon inhibiting both these pathways was not 
complete, there is a possibility of the existence of one or more pro-apoptotic 
pathways in the mediation of apoptosis. One likely candidate is the JNK pathway, 
another stress activated kinase. As mentioned before in section 5.6, several studies 
have shown JNK to be involved in the process of apoptosis. Also, work in our lab has
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shown that JNK was activated in serum-deprived transformed Rat-1 cells, by 4 hours 
after v-Src inactivation (D. Riley, unpublished data). JNK activation was partially 
attenuated in cells treated with ZVAD.fmk, while overexpression of Bcl-2 was able 
to prevent JNK activation (D. Riley, unpublished data). Further investigations into 
the role played by JNK in the process of apoptosis could be carried out using JNK 
specific inhibitors or expression of dominant negative forms. Using antisense for 
JNK could also provide useful information.
Chapter 7: Results 4 
Characterisation of survival signalling induced by v-Src in serum- 
deprived transformed Rat-1 cells: a possible role for the PI 3- 
kinase/Akt pathway
7.1 Introduction
It is evident from the results of the previous chapter that inactivation of v-Src induces 
an apoptotic response in serum-deprived transformed Rat-1 fibroblasts. Since these 
cells do not die by apoptosis upon withdrawal of serum, this means that v-Src activity 
induces survival signalling that protects the cells that have otherwise been primed to 
die, perhaps due to lack of integrin-signalling, when they are serum-starved. It was, 
thus, of considerable interest to determine the pathway used by v-Src to protect the 
cells from undergoing apoptosis.
7.2 Role of PI 3-kinase downstream of v-Src
PI 3-kinase is a lipid kinase and a known oncogene (Chang et al., 1997; reviewed in 
Porter and Vaillancourt, 1998). Studies have shown that v-Src binds to PI 3-kinase 
through the SH3 domain (Liu et al., 1993; Haefner et al., 1995) and plays a role in v- 
Src induced cell transformation (Whitman et al., 1985; Fukui and Hanafusa, 1989). 
PI 3-kinase also mediates Ras-induced survival signalling (Khwaja et al., 1997). It 
was, therefore, a candidate mediator of the survival signal downstream of v-Src.
In order to determine whether PI 3-kinase is responsible for survival signalling 
downstream of v-Src, it was necessary to monitor the cellular PI 3-kinase activity, 
and to investigate whether it was altered after v-Src inactivation. To ascertain the 
levels of PI 3-kinase activity, Akt phosphorylation in the cells was used as a measure 
of cellular PI 3-kinase activity. Akt is known to bind to the lipid products of PI 3- 
kinase and this, in turn, facilitates its translocation to the membrane followed by its 
phosphorylation and activation by PDK-1 at Thr308 and Ser473 (Franke et al., 1997; 
Andjelkovic et al., 1997; Alessi et al., 1997).
Cell lysates were prepared from serum-starved v-Src transformed Rat-1 cells before 
and after inactivation of v-Src. Proteins were separated by SDS-PAGE and 
immunoblots carried out using an anti-Akt antibody specific for Ser473 in its 
phosphorylated state. Akt was found to be phosphorylated at all times prior to 
inactivation of v-Src, followed by complete reduction in phosphorylation of Akt at
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Ser473 at 2, 3 and 6 hours after v-Src inactivation (Figure 32a). The blot was stripped 
and re-probed with an antibody specific for total Akt (phosphorylated and non- 
phosphorylated) to ensure that the difference in detection of Akt phosphorylation was 
not due to unequal protein loading or altered protein expression (Figure 32a). In order 
to estimate more accurately the time of decrease in Akt phosphorylation, the 
experiment was repeated with cells being lysed at earlier and more frequent times 
after v-Src inactivation i.e. 0, 15min, 30min, 45min, 1 hour and 1.5 hours after v-Src 
inactivation. The results showed loss of Akt-Ser473 phosphorylation between 30- 
45min (Figure 32b).
The decrease in Akt phosphorylation, and its consequent inactivation, could either be 
a cause or a consequence of activating the apoptotic signal. To investigate whether 
Akt phosphorylation was decreased in the cells before commitment to apoptosis, 
experiments were carried out to determine the point at which cells could not be 
rescued from cell death. Thus, serum was added back to serum-starved transformed 
cells at different times after v-Src inactivation. Cells were harvested 6 hours after 
switching off v-Src activity, and TUNEL labelled to determine the percentage of cells 
undergoing apoptosis. We found that cells could be prevented from undergoing 
apoptosis if serum was added at 2 hours after v-Src inactivation, but by 4 hours, the 
cells were already committed to die, and addition of serum after this time was unable 
to prevent them from death (Figure 33).
These data indicated that inactivation of Akt, through a decrease in its Ser473 
phosphorylation, preceded commitment to cell death. Therefore, activated Akt, 
probably via PI 3-kinase, was a likely candidate for mediation of the survival signal 
downstream of v-Src. In order to determine the role played by PI 3-kinase and Akt, a 
PI 3-kinase specific inhibitor, 2-(4-Morpholinyl)-8-phenyl-4H-l-benzopyran-4-one 
(LY294002), was used (Yano et al., 1995). To confirm that LY294002 inhibited Akt 
phosphorylation, an experiment was carried out as outlined (Figure 34a) except that 
50pM inhibitor was added one hour before v-Src was inactivated (in cells not treated 
with LY294002). This was done to allow the inhibitor time to enter the cells. Cell 
lysates obtained at different times after addition of LY294002 were separated by 
SDS-PAGE and immunoblotted using anti-Akt antibody specific for phospho-Ser473
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Figure 32 Decreased Akt phosphorylation in the absence of v-Src activity: (a)
Cell lysates were prepared from serum-starved Rat-1 cells, before and after v-Src 
inactivation, separated by SDS-PAGE and immunoblotted for the presence of 
phospho and total Akt. (b) For a more accurate estimate of the time of 
downregulation of Akt activity, cell lysates were obtained at earlier time points, 
separated by SDS-PAGE and probed for phospho Akt.
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Figure 33 Commitment to undergo apoptosis after 2 hours of v-Src inactivation 
in serum-starved transformed Rat-1 cells: v-Src transformed Rat-1 cells were serum 
starved for 24 hours followed by v-Src inactivation. Serum was added back to the cells at 
different times after v-Src inactivation and the percentage of cells undergoing apoptosis 
was determined by TUNEL labelling the cells at 6 hours (experiment carried out by D. Riley, 
Beatson Institute, Glasgow, UK).
Figure 34 Decreased Akt phosphorylation in the presence of PI 3-kinase 
inhibitor: (a) LY294002, a PI 3-kinase inhibitor, was added to serum-starved 
transformed Rat-1 cells at a concentration of 50fxM. (b and c) Lysates were prepared 
from LY294002 treated cells at different time intervals, separated by SDS-PAGE and 
immunoblotting was carried out using anti-phospho Akt antibody or anti-total Akt 
antibody (lower panel in (b)).
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as probe. Akt was found to be dephosphorylated even at 0 hours i.e. the one hour pre­
treatment with LY294002 had reduced the phosphorylation of Akt (Figure 34b). We 
next determined the time taken by LY294002 to inhibit Akt phosphorylation. Lysates 
were prepared as before at the time of adding LY294002 (T=0) and then at 15min, 
30min, 45min and 1 hour. We found that LY294002 was able to inhibit Akt 
phosphorylation within 15min of being added to the cells (Figure 34c). Thus, for all 
further experiments, LY294002 was added at 0 hours Le. the same time as v-Src was 
inactivated in control cells.
To determine if the PI 3-kinase inhibitor, LY294002, was able to induce cell death in 
transformed Rat-1 cells in which v-Src remained active, experiments were carried out 
as outlined in Figure 34a. Cells were harvested at different times after the addition of 
LY294002 at 50pM concentration. TUNEL labelling was carried out to determine the 
percentage of cells undergoing apoptosis when v-Src was active and the PI 3-kinase 
inhibitor added. The plotted results are representative of a set of three experiments 
(Figure 35). The percentage of cells undergoing apoptosis increased with time, 
showing that LY294002 was able to induce apoptosis in serum-starved transformed 
Rat-1 cells in the presence of v-Src activity. However, compared to the cells induced 
to undergo apoptosis by v-Src inactivation, the percentage of cells induced to die by 
addition of LY294002 was lower or the rate of cell death was reduced (Figure 35).
7.3 Effect of LY294002 is specific to v-Src transformed Rat-1 cells
In order to confirm that the induction of apoptosis in serum-deprived v-Src 
transformed Rat-1 cells induced by LY294002 was a result of specific inhibition of 
v-Src survival signalling, we compared the effect of drug treatment with that in 
normal Rat-1 cells.
Thus, LY294002 was added to normal Rat-1 fibroblasts, grown at 35°C (R-35) or 
39.5°C (R-39.5), and v-Src transformed Rat-1 cells grown at the restrictive 
temperature of 39.5°C (LA-39.5). The experiment was carried out as depicted (Figure 
36a). v-Src activity in the control cells (LA-35) was switched off at 0 hours, in the 
absence of the inhibitor. Cells were harvested for TUNEL labelling at 0 and 6 hours.
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Figure 35 Induction of apoptosis in serum-starved transform ed Rat-1 cells 
after addition of a selective PI 3-kinase inhibitor: C ells w ere harvested at different 
tim es after the addition o f  L Y 2 9 4 0 0 2  and T U N E L  labelled . T he percentage o f  labelled  ce lls  
w as ca lcu lated  and typical results plotted. T he percentage o f  c e lls  undergoing apoptosis w as 
com pared to the percentage dying in the ab sen ce o f  v-Src activ ity .
Figure 36 LY294002 did not induce apoptosis in Rat-1 cells displaying normal 
phenotype: (a) Transformed and non-transformed Rat-1 cells were cultured at either 
35°C (permissive temperature for ts LA29 v-Src) or 39.5°C (restrictive temperature 
for ts LA29 v-Src). LY294002 was added to transformed and non-transformed Rat-1 
cells cultured at 39.5°C and non-transformed Rat-1 cells cultured at 39.5°C. At the 
same time, v-Src activity was inhibited in transformed Rat-1 cells cultured at 35°C. 
(b) Cells were harvested at the time of LY294002 addition or v-Src inactivation and 
6 hours after, and percentage of cells undergoing apoptosis was calculated by 
TUNEL labelling, (c) Also, cell lysates prepared from cells were separated by SDS- 
PAGE, and screened for the presence of phospho and whole Akt by immunoblotting.
a Diagram atic representation o f  the experim ental protocol to investigate the role o f  FI 3-kinase 
in normal and v-Src transformed Rat-1 ce lls
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The percentage of labelled cells at 6 hours was plotted as fold increase over the 
percentage at 0 hours for each cell type (Figure 36b). For control cells, to which no 
inhibitor was added and v-Src was inactivated, there was a significant increase in the 
percentage of dying cells at 6 hours compared to those at 0 hours (about 7 fold). In 
contrast, the difference in the percentage of TUNEL labelled cells at 0 and 6 hours in 
the drug treated normal Rat-1 cells (including the transformed cells grown at 
restrictive temperature) was much lower. This indicated that the effect of adding 
LY294002 was specific to the inhibition of PI 3-kinase activity downstream of v-Src, 
resulting in death of only the transformed cells.
Also, cell lysates prepared at 6 hours after inactivation of v-Src (in LA-35), or 
addition of LY294002 (in R-35, R-39.5, and LA-39.5), were tested for the presence of 
phospho Akt. The results showed that Akt was in the non-phosphorylated form in all 
cells except for serum-starved LA-35 cells at the time of v-Src inactivation (Figure 
36c).
7.4 Decreased Akt phosphorylation in cells treated with SB203580 and 
ZVAD.fmk and those overexpressing Bcl-2
To determine if the addition of the selective inhibitors of p38 or caspases had any 
effect on Akt phosphorylation, lysates prepared from transformed cells treated with 
ZVAD.fmk (caspase inhibitor) or SB203580 (p38 inhibitor), were also screened with 
the Akt-Ser473 phospho-specific antibody. Akt phosphorylation was decreased in 
cells treated with ZVAD.fmk (Figure 37a). The decrease was evident within 2 hours 
of switching off v-Src activity in transformed Rat-1 cells that had been pre-treated 
with ZVAD.fmk. Also, in cells treated with SB203580, Akt phosphorylation was 
reduced within 2 hours of v-Src inactivation (Figure 37b).
Lysates were prepared from cells transfected with Bcl-2 (cloned into pSFFV) and 
with the pSFFV vector alone, at different times after v-Src inactivation. Screening 
with the antibody specific to phospho-Ser473 of Akt, showed that Bcl-2 did not 
inhibit the decrease in Akt phosphorylation, implying that Bcl-2 blocks cell death 
downstream of PI 3-kinase/Akt (Figure 37c).
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Figure 37 Akt phosphorylation is decreased in cells treated with inhibitors of 
caspases and p38, as well as those overexpressing Bcl-2: (a and b) Transformed 
Rat-1 cells were treated with ZVAD.fmk or SB203580 an hour before v-Src 
inactivation. Cell lysates were prepared at different times after v-Src inactivation, 
separated by SDS-PAGE and immunoblotting was carried out using anti-phospho 
Akt or anti-total Akt antibodies, (c) Transformed Rat-1 cells overexpressing Bcl-2 
were deprived of serum for 24 hours followed by v-Src inactivation. Cell lysates 
prepared at different time intervals after v-Src inactivation were screened for 
phospho and total-Akt (carried out by D.Johnson).
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7.5 Decreased MAP kinase activity in cells undergoing apoptosis
Inhibition of PI 3-kinase activity was able to induce around 50% of the cell death 
induced after v-Src inactivation, suggesting the possibility that another survival 
pathway may operate downstream of v-Src. Among the downstream effectors of v- 
Src transformation is the activation of the MAP kinase (ERK) cascade, which can 
contribute to survival signalling (Xia et al., 1995; Matsuda et al., 1999). Experiments 
were therefore carried out to find if any change in ERK activity was associated with 
apoptosis.
Thus, cell lysates prepared from transformed Rat-1 cells undergoing apoptosis in the 
absence of serum and v-Src activity, were separated by SDS-PAGE and 
immunoblotting was carried out using an anti ERK antibody specific for the 
phosphorylated form of ERK. ERK is activated by phosphorylation on Thr202/ 
Tyr204 by MEK1 (Kyriakis and Avruch, 1996). A rapid decline in ERK 
phosphorylation, and therefore presumably its activity, was noticed within 15min 
after inactivating v-Src (Figure 38a). There was an apparent regain of activity at 
30min, which declined again. ERK activity was detected again at 1.30 and 2 hours, 
which declined at 4 hours and came again at 6 hours. There was, thus, a cyclic gain 
and loss of ERK activity during apoptosis. At the time points where there was a 
regain of ERK activity, it was not to the same extent as that found at 0 hours. Slightly 
different trends were noticed in some other experiments that showed regain of ERK 
activity at 4 hours. However, in all cells, ERK fluctuated.
Similar analysis was also carried out in cells treated with LY294002 (Figure 38b). 
Immunoblot analysis using the anti phospho-ERK antibody showed a decrease in 
ERK activity at 15min, followed by a regain of activity at 30 and 45min. 1 hour after 
the addition of LY294002, no ERK activity could be detected. At 1.5, 2 and 4 hours, 
there was again a gain of ERK activity followed by inactivation again at 6 hours. As 
in the case of control cells, the gain of ERK activity at the later time points was not to 
the same extent as that noticed at 0 hours (Figure 38a and Figure 38b). The cyclic 
trend of activation and inactivation was thus similar to that in the control, although 
the timing of the fluctuations was variable.
Figure 38 Variation in MAP kinase activity in serum-starved v-Src transformed 
Rat-1 cells induced to undergo apoptosis in the absence of v-Src activity or in 
the presence of PI 3-kinase inhibitor: (a and b) Serum-starved v-Src transformed 
Rat-1 cells were induced to undergo apoptosis either by v-Src inactivation or by 
inhibition of PI 3-kinase activity. Cell lysates were prepared at different times after 
induction of apoptosis, separated by SDS-PAGE and probed for the presence of 
phosphorylated p42/p44 (ERK) or total p42 (ERK2).
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7.6 ERK does not play a role in the mediation of survival signals downstream of 
v-Src
To determine whether dephosphorylation of ERK, upon switching off v-Src activity 
in serum-deprived transformed Rat-1 cells, was responsible for induction of 
apoptosis, 2-Amino-3-methoxyflavone (PD98059), a specific inhibitor of MEKK 1 
(the upstream ERK activating kinase; Alessi et al., 1995; Pang et al., 1995), was 
used.
Experiments were carried out as described before for LY294002, the selective PI 3- 
kinase inhibitor. Cells were harvested at different times after addition of 50p,M 
PD98059 for TUNEL analysis. The percentage of labelled cells was plotted as a 
function of time (Figure 39). There was a minimal increase in the number of cells 
undergoing apoptosis from about 2% at 0 hours to about 9% at 6 hours. When 
compared to the number of cells dying after serum-starvation and v-Src inactivation, 
the percentage of cells dying in the presence of the inhibitor was very small (Figure 
39). Thus, inhibiting ERK activation in the presence of v-Src activity was unable to 
induce apoptosis in serum-deprived transformed Rat-1 cells indicting that ERK was 
not a key player in inducing survival downstream of v-Src.
In order to determine if addition of PD98059 had any effect on the Akt survival 
signal induced by v-Src, cell lysates were separated by SDS-PAGE and 
immunoblotted to detect phosphorylated Akt. There was no decline in the levels of 
phospho-Akt up to 2 hours (Figure 40a). At 4 and 6 hours after the addition of 
PD98059, there seemed to be a slight decrease in the amount of Akt activity. After 
one hour, little phospho-Akt was detected. However, probing the same blot with 
antibody against total Akt showed that this could be explained by unequal protein 
loading (Figure 40a).
Effectual working of the inhibitor was confirmed by stripping the blot and reprobing 
it with anti ERK antibody specific for the phosphorylated form. Results showed a 
decline in ERK phosphorylation within 15min of adding PD98059 followed by 
complete dephosphorylation by 30min (Figure 40b).
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C om parison  b etw een  percentage o f  c e lls  undergoing apoptosis in the absence o f  
v-Src activ ity  and those d ying in the presence o f  P D 9 8059
Figure 39 Inhibition of MAP kinase activity does not induce apoptosis in 
serum-starved transformed Rat-1 cells: P D 9 8 0 5 9  w as added to serum -starved  
v-Src transform ed Rat-1 ce lls  in order to inhibit M A P  kinase activ ity . C ells  w ere harvested  
at different tim es to calcu late the percentage o f  c e lls  undergoing apoptosis by T U N E L  
labelling. T he experim ent w as carried out 3 tim es and typical results w ere plotted. T he  
percentage o f  c e lls  dying in the presence o f  the inhibitor w as com pared to those dying  
in the ab sen ce o f  v-Src activ ity .
Figure 40 PD98059 was able to inhibit MAP kinase activity but did not affect 
Akt phosphorylation: PD98059 was added to serum-starved v-Src transformed Rat- 
1 cells, (a) Lysates were prepared from the treated cells at different time intervals 
after addition of the inhibitor, separated by SDS-PAGE and screened for phospho 
and total Akt. (b) cell lysates were also probed for phospho p42/p44 (ERK) and total 
p42 (ERK).
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7.7 Inhibiting PI 3-kinase and ERK activity simultaneously did not increase the 
effect of blocking PI 3-kinase alone
Results from the previous section confirmed that inhibition of ERK activity was 
unable to induce apoptosis in serum-deprived v-Src transformed cells. It was, 
however, possible that inhibiting ERK activity at the same time as PI 3-kinase could 
enhance the effect of blocking PI 3-kinase activity on its own.
Cells treated with both inhibitors, PD98059 and LY294002, were harvested at 
different times for TUNEL labelling. The percentage of cells undergoing apoptosis 
was plotted as a graph and compared to the control cells (with no inhibitor and v-Src 
activity switched off), and cells treated with LY294002 or PD98059 separately 
(Figure 41). The percentage of labelled cells was similar to that after addition of 
LY294002 alone. Therefore, there was no enhanced effect of adding both the 
inhibitors simultaneously.
7.9 Discussion
Results of the previous chapter showed that in the absence of v-Src signalling, 
serum-starved v-Src transformed Rat-1 cells undergo apoptosis. This indicated that v- 
Src was able to provide the serum-starved transformed Rat-1 cells with a survival 
signal. When v-Src activity was switched off, cells were committed to undergo 
apoptosis, possibly because of absence of normal integrin-mediated signalling that 
had been lost as a result of transformation by ts LA29 v-src. In this regard, it is 
known that transformation by v-Src results in reduced production of fibronectin 
matrix and redistribution of actin and a-actinin (Stoker et al., 1986). The possible 
deleterious effect of v-Src on cell viability had been implied by an earlier study as 
well which showed that v-Src transformed cells either died or kept multiplying in low 
serum (Wyke, 1971). This was not surprising since other mitogenic oncoproteins, 
such as c-Myc, E2F-1 and v-Jun, have also been shown to induce apoptosis under 
low serum conditions (Shan and Lee, 1994; Evan, 1992; Clark ad Gillespie, 1997). 
The difference between v-Src and the other oncoproteins, capable of inducing 
apoptosis is, that v-Src, while priming the cells to die, also provides them with an
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C om parison  betw een  percentage o f  c e lls  undergoing apoptosis after the addition  o f  d ifferent 
inhibitors
LY/PD
Figure 41 Inhibition of MAP kinase activity at the same time as inhibition 
of PI 3-kinase activity does not increase the percentage of cells undergoing 
apoptosis: B oth L Y 2 9 4 0 0 2 , the PI 3 -k inase inhibitor and P D 98059 , the M EK  kinase inhibitor  
w ere added together at the concentration  o f  5 0 p M  each  to serum -deprived  transform ed Rat-1 
ce lls . C e lls  w ere harvested  at d ifferent tim es and T U N E L  labelled  to ca lcu la te  the 
percentage undergoing apoptosis. T he num ber o f  c e lls  d ying after being treated w ith  both  
inhibitors w as com pared to the num ber o f  dying ce lls  treated w ith either inhibitor and to  the 
num ber undergoing apoptosis after w ithdraw al o f  serum  and v-Src activ ity .
overriding survival signal, while other mitogenic oncoproteins require co-operation 
from other anti-apoptotic oncogenes (Bissonnette, 1992). Although, our work did not 
focus on investigating further into the mechanisms by which v-Src can possibly 
prime the transformed cells to undergo apoptosis, other studies offer some 
possibilities. For example, v-Src upregulates c-Myc, which has been shown by 
several studies to induce apoptosis in serum-starved cells. It is thus possible that v- 
Src utilises the apoptotic pathway stimulated by c-Myc to induce cell death.
The experiments detailed in this chapter were carried out to determine some of the 
mediators of the survival signal induced by v-Src. Initial experiments showed 
phosphorylation of Akt was reduced within 30-45min of switching off v-Src activity 
in serum-starved v-Src transformed Rat-1 cells. Since commitment to apoptosis was 
shown to occur only after 2 hours of switching off v-Src activity, the decrease in Akt 
phosphorylation preceded commitment to cell death. Further investigation into the 
role of PI 3-kinase and Akt was carried out using LY294002, a selective inhibitor of 
PI 3-kinase (Vlahos et al., 1994). Inhibition of PI 3-kinase activity by LY294002 
induced the serum-starved transformed Rat-1 cells to undergo apoptosis even in the 
presence of v-Src activity, as measured by TUNEL labelling. This was accompanied 
by a decrease in Akt phosphorylation within 15min of adding the inhibitor. The 
percentage of cells undergoing death induced after drug treatment of transformed 
Rat-1 cells was about 50% of that induced by switching off v-Src activity in serum- 
starved transformed Rat-1 cells.
To verify whether the cell death induced by LY294002 was indeed the result of 
inhibition of the PI 3-kinase/Akt pathway or due to some toxic effects of the drug 
itself, control experiments using serum-starved normal Rat-1 cells were carried out. 
v-Src transformed Rat-1 cells, cultured at the restrictive temperature, and thus 
morphologically normal, were also used. Upon treatment with LY294002, the normal 
Rat-1 cells showed a very small increase in the percentage of cells undergoing 
apoptosis at 6 hours after the addition of the inhibitor, as compared to those at 0 
hours. It is possible that the small percentage of cell death, induced in drug treated 
normal Rat-1 cells, might be the result of drug toxicity and not of inhibiting the PI 3- 
kinase/ Akt pathway.
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Some further analysis of LY294002 induced cell death in transformed cells (carried 
out by D.Riley, Beatson Institute, Glasgow, UK) showed that cell death is 
accompanied by activation of both p38 and JNK stress kinases. These biochemical 
events were similar to those induced by switching off v-Src in the transformed cells, 
thus supporting a role for PI 3-kinase in mediating v-Src survival signalling. 
Activation of caspases in the drug treated transformed cells has not yet been 
examined. Also, observation of DNA laddering would provide further support to the 
idea that the cell death induced by LY294002 in transformed Rat-1 cells is indeed 
due to apoptosis.
To confirm the roles of PI 3-kinase and Akt downstream of v-Src, experiments were 
carried out using a constitutively active form of pllO, the enzymatic subunit of PI 3- 
kinase. Results showed that transformed Rat-1 cells, transfected with the 
constitutively active form of p i 10, did not show any resistance to apoptosis in the 
absence of serum and v-Src activity. However, since overexpression of p i 10 could 
not be shown by immunoblot analysis, it was not possible to draw any conclusions 
from this experiment. The experiment, thus, needs to be repeated in order to confirm 
the role of PI 3-kinase and Akt in mediating the v-Src induced survival signal. Also, 
experiments using constitutively active forms of Akt could be carried out for the 
same purpose. Furthermore, the role of downstream effectors of Akt could also be 
investigated.
Results of our study indicate that although Akt phosphorylation decreased within 30- 
45min of inactivating v-Src, caspase activity was not detected until much later i.e. 
about two and a half hours after v-Src inactivation. Inhibition of caspases also did not 
inhibit dephosphorylation of Akt, indicating that activation of caspases lies 
downstream of Akt inactivation due to its dephosphorylation. Similar observations 
were also made regarding inactivation of Akt and activation of p38, suggesting that 
p38 also acts downstream of Akt inactivation upon induction of apoptsis. There are, 
therefore, missing links that exist between the time of switching off the survival 
signal and the time of execution of apoptosis, which need to be established. Results 
of this study also showed that Bcl-2 acts downstream of Akt. Overexpression of Bcl-
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2 in v-Src transformed Rat-1 cells was unable to prevent Akt dephosphorylation, but 
did inhibit the cells from undergoing apoptosis in the absence of serum and v-Src 
activity.
Since inhibition of PI 3-kinase was able to induce only about 50% apoptosis in 
serum-starved v-Src transformed Rat-1 cells (not taking into account possible cell 
death resulting from toxic effects of the inhibitor itself), compared to the percentage 
of cells dying in the absence of v-Src activity, the role of MAP kinase in the 
mediation of v-Src induced survival signal was also investigated. Several studies 
(discussed in section 5.7.4) have reported the involvement of the MAP kinase (ERK) 
pathway in cell survival. ERK phosphorylation was found to be reduced in serum- 
starved Rat-1 cell undergoing apoptosis within 15min after v-Src inactivation or 
addition of LY294002. This raised the possibility of induction of apoptosis being 
related to decrease in ERK activity. However, inhibition of MAP kinase activity, 
using PD98059, in the presence of v-Src, was unable to induce cell death in serum- 
starved transformed Rat-1 cells, although, immunoblot results showed complete 
inhibition of ERK phosphorylation. There was also no change in Akt phosphorylation 
in PD98059 treated cells. It is thus possible that the cyclic loss and gain of ERK 
activity, detected after the induction of the apoptotic stimuli, was more a 
consequence, rather than a cause of apoptosis or was unrelated. The fact that ERK is 
not involved in cell survival was also demonstrated when inhibition of ERK activity 
was unable to further enhance the percentage of cells undergoing apoptosis after 
treatment with LY294002, the PI 3-kinase inhibitor. In support of results of this 
study, other groups have also shown cell survival can be independent of ERK activity 
(Chen et al., 1996b; Kulik et al., 1997).
STAT3 is another likely mediator of the survival signal induced by v-Src (see section 
5.7.4). It is required for v-Src transformation of cells (Yu et al., 1995; Bromberg et 
al., 1998; Turkson et al., 1998). Both c-Src and v-Src have been shown to 
phosphorylate STAT3 on Tyr705, which is required for effective dimer formation 
and transcriptional activity of the STAT molecule (Cao et al., 1996; Cirri et al., 
1997; Schaefer et al., 1999). v-Src also associates with STAT3 both in vivo and in 
vitro (Cao et al., 1996). It is thus possible that STAT3 might be collaborating with
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the PI 3-kinase/ Akt pathway to provide the v-Src transformed cells with a survival 
signal. The role played by STAT3 can be evaluated by examining the effects of 
inhibiting STAT3 activity, possibly through the use of dominant negative mutants of 
STAT3. The role of other STAT molecules, i.e. STAT1, in survival signalling can 
also be investigated by carrying out similar experiments.
Chapter 8: Final discussion, Summary and Future Perspectives
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8.1 FAK upregulation and oncogenesis
Several studies have reported an upregulation of FAK at the protein level in various 
different tumour cell lines (see section 1.3.7). However, the mechanism behind this 
upregulation has not been investigated. Our study revealed that gain of fak  gene copy 
number through genetic alterations is one way by which many cancer cell lines may 
upregulate FAK at the protein level. Furthermore, genetic alterations leading to FAK 
protein upregulation have been found to accompany acquisition of invasive potential 
in an in vitro colon cancer model. Work by several other groups has also shown that 
FAK might play a role in the mediation of cell processes such as cell motility, growth 
and survival (see section 1.3), all of which are likely to be of some importance during 
tumour progression. These findings, although strongly suggesting the importance of 
FAK’s role in tumorigenesis, do not confirm the oncogenic potential of FAK. 
Further investigations are thus needed to determine exactly what aspects, if any, of 
tumour development are influenced by FAK. This can be investigated by combining 
in vivo and in vitro studies. For example, studies involving intervention in the 
functions of FAK, both in cultured cells and in animals, be carried out. In cultured 
cancer cells, overexpression of effective dominant negatives could help determine the 
effects on behavioural properties that are associated with malignancy, like cell 
proliferation, motility and survival.
In vivo studies would require knocking out FAK in animals. Since FAK knockouts 
are embryonic lethal, the strategy would involve conditionally knocking out FAK in a 
tissue specific manner after induction of tumour formation in that tissue. In our 
group, this study is currently underway using transgenic mice carrying ‘loxP’ flanked 
fak  and the gene coding for a fusion protein between a mutated ligand binding 
domain of the human estrogen receptor (ER) and the Cre recombinase (Indra et al., 
1999). The fusion protein can be activated by 4-hydroxy-tamoxifen (OHT), but not 
natural ER ligands (Indra et al., 1999). Upon activation, Cre recombinase will 
facilitate excision of DNA between the two loxP sites. These mice could be induced 
to develop papillomas by chemical treatment and the effects of knocking out FAK at 
different stages of tumour development could be monitored by stimulating Cre 
recombinase using OHT. If the results showed an alteration in tumour development,
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then FAK could be considered a potential therapeutic target. In this respect, several 
drug companies are already showing a keen interest in FAK as a potential target for 
anti-cancer therapy (M.Frame, personal communicaton).
FAK as a potential anti-cancer target
Being a tyrosine kinase, the enzymatic activity of FAK might be crucial in its 
biological functions. However, not much is known about the importance or 
regulation of FAK’s kinase activity. In this regard, overexpression of the kinase dead 
mutant of FAK does not appear to act in a dominant negative manner (V.Fincham, 
unpublished data), perhaps implying that the kinase activity of FAK may not be 
crucial in its function. However, this needs to be further tested. Targetting the kinase 
activity through develpoment of specific small molecular weight inhibitors is a 
possible to approach to test this.
Another possibility is to examine the potential of interfering with FAK’s role as an 
adaptor protein. FAK is known to bind to proteins like Src, PI 3-kinase, CAS and 
Grb-2 (see section 1.3.3). It is thus possible that the binding activity plays an 
important role in FAK’s mediation of intracellular signalling leading to cell survival, 
focal adhesion turnover during cell motility and/or cell proliferation. One way to 
approach this problem could be to observe the effects of mutating the putative 
binding sites and overexpressing these mutants in cells. Analysis of the amino acid 
sequences of FAK and its binding partners that are involved in the binding 
interaction, will help design specific competing peptides, introduction of which 
might interfere with the adaptor function of FAK. Inhibition of the adaptor function 
of FAK through these approaches might provide a useful insight into the role of 
specific binding interactions in various aspects of FAK biological activities.
FAK is phosphorylated on at least six tyrosine residues. Phosphorylation of these 
residues is thought to be important both in activation of FAK and its binding to other 
proteins. Mutation of these sites to phenylalanine residues (work currently being 
carried out in our group) and overexpression of these mutants will also provide 
valuable information regarding which tyrosine phospho-acceptor sites mediate the
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biological responses and might reveal novel ways of intervening in FAK-mediated 
cell survival, motility or proliferation.
8.2 FAK proteolysis is not critical for apoptosis
We examined the role of FAK proteolysis in the apoptotic response induced in v-Src 
transformed Rat-1 cells. FAK is a downstream substrate of Src and is phosphorylated 
by it. If FAK was critical in mediating the survival signalling downstream of Src, 
then inhibiting the attenuation of its activity, induced by its cleavage (Cooray et al., 
1996), should have prevented the transformed Rat-1 cells from undergoing apoptosis 
in the absence of serum and v-Src activity. FAK proteolysis has also been shown to 
accompany c-Myc induced apoptosis in serum-starved transformed fibroblasts 
(Crouch et al., 1996). Our results indicated that although FAK was cleaved upon 
induction of apoptosis in v-Src transformed cells, most likely by caspases, inhibiting 
this proteolysis did not protect the transformed cells against apoptosis. This indicates 
that if at all, FAK retention is not sufficient in mediating the survival signal 
downstream of v-Src. Whether it is necessary or not for survival, can be determined 
by further experiments involving inhibition of FAK activity through the use of 
dominant negative or antisense approaches.
8.3 Switching off v-Src in serum-deprived transformed Rat-1 cells induces 
apoptosis
A major finding of the work presented here was that switching off v-Src in 
transformed Rat-1 cells induced an apoptotic response. The inhibitor studies carried 
out suggested that blocking either caspases or p38 independently did not prevent the 
serum-starved v-Src transformed Rat-1 cells from undergoing apoptosis after 
inactivation of v-Src. However, when caspases and p38 were inhibited 
simultaneously, there was a significant, though not complete, reduction in the 
percentage of dying cells. This implied that the two pathways were redundant and 
independent of each other. These results, although providing significant information 
about the signalling pathways involved in the induction of apoptosis in v-Src 
transformed Rat-1 cells, give rise to many questions that remain to be answered. For
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example, the decrease in the percentage of cells undergoing apoptosis, associated 
with the inhibition of both caspases and p38, was incomplete. This argues that 
another independent pathway is involved in the mediation of the apoptotic signal. 
JNK, another known stress activated kinase that mediates apoptosis, is a possible 
candidate. Studies carried out by our group have shown JNK to be active in the cells 
undergoing apoptosis at about the same time as the activation of p38 (D.Riley, BICR, 
Glasgow). The role of p53, a known tumour suppressor, in the induction of apoptosis 
could also be examined (reviewed in Wang, 1999). Whether the type of apoptosis is 
caspase (those insensitive to ZVAD.fmk inhibition) dependent or independent, also 
needs to be established. Preliminary data from our experiments has suggested that 
caspases are not involved in the induction of apoptosis. They also do not appear to be 
required for DNA laddering, a hallmark of apoptosis. Overexpression of Bcl-2 
protected the cells from undergoing apoptosis. This indicates that mitochondrial 
dysfunction might play an important part in the induction of cell death. To test this, 
the time of release of cytochrome C in cells dying in the absence of serum and v-Src 
activity should be ascertained. This would give some indication as to whether the 
activation of caspases or the release of cytochrome C, is a primary event in the 
decision of cells to commit to apoptosis after switching off v-Src.
The importance of Fas ligands in the induction of apoptosis is well documented. To 
test whether the v-Src induced survival signal supresses the pro-apoptotic pathway 
initiated by CD95 stimulation, it is first important to determine if an intact CD95 
apoptotic signalling pathway is present in the v-Src transformed fibroblasts. Cell 
surface CD95 expression in fibroblast cells can be determined by flow cytometry 
analysis using the method described in Hueber et a l , 1997. If the cells were found to 
express detectable amounts of cell surface CD95 receptors, then these could be 
incubated with CD95 antibody (to stimulate activity)and apoptosis in the presence of 
v-Src activity monitored. Similar experiments could be carried out to test the effect 
of CD95 stimulation in v-Src transformed cells in the presence of serum and v-Src 
activity. If an intact CD95 apoptotic signalling pathway was found to be present in 
the v-Src transformed cells, then its involvement in the apoptotic pathway initiated in 
these cells after switching off v-Src could also be examined. To do this, serum- 
deprived cells, in which v-Src activity had been switched off, would be incubated
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with a monoclonal antibody to CD95L that neutralises CD95 (Hueber et al., 1997). 
Using serum-deprived cells with inhibited v-Src activity and cells with added PI 3- 
kinase inhibitor as controls would enable us to determine whether or not, in the 
absence of v-Src activity, the serum deprived cells underwent apoptosis through the 
Fas L/R initiated pathway. If that was the case, further experiments might reveal how 
v-Src induced survival signals impinge on this apoptotic pathway.
8.4 v-Src mediates survival via PI 3-kinase
Another major conclusion from the work presented in this thesis was that serum- 
deprived v-Src transformed cells are primed to die and are kept alive solely by a 
survival signal induced by v-Src. We also studied some of the possible pathways that 
might lie downstream of v-Src in the mediation of cell survival. These are outlined in 
Figure 42. The data obtained implicated the PI 3-kinase/Akt pathway to lie 
downstream of v-Src in survival signalling. The requirement of FAK for the Src/PI 3- 
kinase mediated survival pathway in the transformed Rat-1 cells has not yet been 
examined. This could be studied by introducing dominant negative mutants of FAK, 
capable of inhibiting the association of FAK with PI 3-kinase, and then observing the 
effect on cell survival that these might have. The in vitro model of apoptosis that was 
used by us has several advantages. It is a tractable model for investigating Src 
survival signalling and is thus, very good for examining the molecular mechanisms 
lying downstream of v-Src. However, since the study was carried out in an in vitro 
model using v-Src, the relevance of the finding with regards to the function of c-Src 
in cell survival is not very clear. In particular, it does not tell us whether the 
endogenous Src family kinases play a role in mediating cell survival in vivo. 
Translating the relevance of our in vitro results to tumour development in vivo is a 
goal for future work. Nevertheless, in advanced cancer cells, the activity of Src 
family kinases, specifically Src itself, is often increased. The role that Src might play 
in the development of malignancy is not well understood but there have been some 
studies that have independently shown c-Src to play an important role in the process 
of cell survival. A recent study has shown c-Src to be required during VEGF-induced 
angiogenesis (Eliceiri et al., 1999). Specifically, c-Src was required for the survival 
of endothelial cells during VEGF mediated angiogenesis. Introduction of a dominant
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Figure 42 Pathways involved in mediation of v-Src induced survival signalling 
and the apoptotic pathway it impinges on, in transformed Rat-1 cells: Mediators 
of v-Src induced survival signalling in transformed Rat-1 cells are shown in blue, 
whereas those mediating the apoptotic response in the absence of serum and v-Src 
activity are shown in pink. Various other candidate pathways that might mediate 
either the survival signal or the apoptotic pathway are also shown.
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negative form of c-Src into cells treated with VEGF for the stimulation of 
angiogenesis, prompted extensive apoptotic response.
The PI 3-kinase/Akt pathway has also been shown by other studies to mediate cell 
survival (see section 5.7.1). Although, the inhibitor experiments, carried out in the 
work presented here, indicated a role for PI 3-kinase and Akt in the mediation of v- 
Src induced survival signal in serum-starved v-Src transformed Rat-1 cells, 
molecular studies using a constitutively active form of PI 3-kinase were inconclusive. 
Further molecular experiments thus need to be carried out to confirm the role of PI 3- 
kinase/Akt in survival signalling. For this purpose, dominant negative mutants of 
both PI 3-kinase or Akt could be used. Another approach could be to study the effect 
of overexpressing PTEN, a known PI 3-kinase antagonist (see section 5.7.2). PTEN 
dephosphorylates PIP3, a product of PI 3-kinase, thus enabling the transfer of Akt to 
the membrane and its subsequent activation.
Resistance to apoptosis or increased cell survival might play an important role in the 
process of metastasis. Recent work in our lab showed that levels of c-Src protein 
were elevated in metastatic cells, as compared to the non-metastatic cells from which 
they were derived (R.Jones, unpublished data). The non-metastatic cell line was 
derived from a primary human colorectal carcinoma (KM12 C), while the metastatic 
cell lines were obtained from metastases resulting after injection of the primary cells 
into the spleen of nude mice (KM12 SM and KM12 L4A; Giavazzi et al., 1986 a and 
b). Levels of phospho-Akt were also elevated in the metastatic cell lines (R.Jones, 
unpublished data). More work needs to be carried out to establish whether there is a 
link between the upregulation of c-Src and phospho-Akt levels. However, it is 
possible that the elevated levels of Src and Akt phosphorylation are indeed linked 
and might be contributing to enhanced cell survival during the metastatic process. To 
address this, Rob Jones and Anne Wyke in our group are expressing a dominant 
negative Src protein in metastatic variants and constitutively activated Src in the non­
metastatic variant. The metastatic cell lines are also being transfected with dominant 
negative Akt, whilst the non-metastatic KM 12 C cells are being transfected with 
active Akt. Once stable transfectants expressing the exogenous proteins are obtained, 
these will then be tested for their ability to survive detachment and growth factor
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deprivation. They will also be tested for their ability to form tumours in nude mice 
and to metastasize to the liver after tail vein injection. These experiments will be able 
to establish whether the survival pathway identified by work described in this thesis 
has any role in tumour cell behaviour, particularly cell survival and metastasis.
Therapeutic potential
It is possible that Src-mediated cell survival signals might be playing a part in 
conferring drug resistance to tumour cells by enhancing their survival potential. For 
example, cancer cells treated with cytotoxic agents, such as apoptosis-inducing anti­
cancer drugs, might be more resistant to cell killing if upstream survival signalling is 
activated. Src inhibitor studies could thus be carried out in conjunction with drug 
treatment to determine if inhibition of Src activity makes the cell more sensitive to 
drug treatment. This possibility could be investigated in the metastatic cell lines 
derived from the model described above and the sensitivity of KM 12 C colon cancer 
transfectants currently being generated, to cytotoxic drugs like 5FU or cis-platin 
examined. Such information would indicate that drugs that specifically target 
components of the survival pathways, such as, Src or PI 3-kinase, might be of 
therapeutic benefit when given in combination with conventional anti-cancer agents.
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F oca l adhesion kinase (p p l2 5 FAK) is present at sites o f  
cell/ex tracellu lar  m atrix adhesion and has been im ­
plicated in the control o f  cell behaviour. In particular, 
as a key com ponent o f  integrin-stim ulated signal 
transduction pathw ays, p p !2 5 FAK is involved in cellular  
processes such as spreading, m otility , growth and 
survival. In addition, a number o f  reports have 
indicated that p p l2 5 FAK m ay be up-regulated in human 
tum our cells o f  diverse origin, and consequently, a role 
has been proposed for p p l2 5 FAK in the developm ent o f  
invasive cancers. H ow ever, to date the m echanism s that 
lead to elevated p p l2 5 FAK expression in tumour cells  
have not been determ ined. H ere we used in situ  
hybridization to confirm chrom osom e 8q as the 
genom ic location  o f  the human fa k  gene and report 
that elevation o f  p p l2 5 FAK protein in cell lines derived  
from invasive squam ous cell carcinom as is accom panied  
by gains in copy number o f  the fa k  gene in all cases  
exam ined. In addition, we observed increased fa k  copy  
number in frozen sections o f  squam ous cell carcinom as. 
Furtherm ore, increased dosage o f  the fa k  gene was 
also observed in many cell lines derived from  human  
tum ours o f  lung, breast and colon, including two cell 
lines C alu3 and H T 29 , in which fa k  w as amplified. In 
addition, in an in vitro  m odel for human colon cancer 
progression there was a copy number gain o f  the fa k  
gene during conversion from adenom a to carcinom a, 
which w as associated  with increased p p l2 5 FAK protein  
expression . T hus, we show for the first tim e that many  
cell lines derived from invasive epithelial tum ours have 
increased dosage o f  the fa k  gene, which m ay contribute 
to the elevated protein expression com m only observed. 
A lthough other genes near the fa k  locus are co ­
am plified or increased in copy number, including the 
proto-oncogene c-m yc, the b iological properties o f  
p p l2 5 FAK in controlling the growth, survival and 
invasiveness o f  tumour cells, suggest that it m ay  
contribute to  the selection  pressure for m aintaining  
increased dosage o f  the region o f  chrom osom e 8q that 
encodes these genes.
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protein  expression; cancer; F A K
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Introduction
F oca l a d h esion  k inase (p p l2 5 FAK) is a tyrosin e  kinase  
that loca lizes to  cellu lar foca l ad h esion s and associa tes  
w ith a num ber o f  o ther proteins such as integrin  
ad hesion  receptors (review ed in R ich ard son  and  
P arsons, 1995), focal ad h esion  co m p o n en ts, such as 
paxillin  and talin  (T urner and M iller 1994; Schaller and 
P arsons, 1994; T ach ibana et al., 1995; H ild eb rand  et 
al., 1995; C hen et al., 1995), and sign allin g  proteins  
includ ing  p rotein  tyrosine k inases o f  the Src fam ily  
(C ob b  et al., 1994; X in g  et al., 1994; C ary et al., 1996; 
F in ch am  and  F ram e, 1998), p h osp h atid y l in o s ito l (PI) 
3-k inase (C hen  et al., 1994), the R h o  G T P ase  
activatin g  protein  G ra f (H ildebrand  et al., 1996) and  
ad aptor m o lecu les, includ ing  G R B 2  (S ch laepfer et al., 
1994; K h arban da et al., 1995) and p l3 0 CAS (H arte et 
al., 1996; P o lte  and H an k s, 1995). A lth o u g h  the precise 
regulation  and b io log ica l function  o f  p p l2 5 FAK rem ain  
to be determ ined , its d iverse range o f  b ind in g  partners 
places it at a crossroads betw een ad h esion  and  grow th- 
regulatory signal transduction .
Studies addressing  the role o f  p p l2 5 FAK in cell 
ad h esion  suggest that it can  con trib u te to  b o th  focal 
ad h esion  assem b ly  (R ich ard son  and P arson s, 1996; 
R ichardson  et al., 1997) and foca l a d h esion  turnover  
(F in ch am  et al., 1995; Uic et al., 1995; F in ch am  and  
F ram e, 1998). P p l2 5 FAK is ex ten sively  regu lated  by 
tyrosine p h osp h o ry la tio n , w hich  m ight, in turn, con tro l 
the p rocesses o f  focal adhesion  assem b ly  and d isas­
sem bly that con trib u te  to cell m otility . In k eep in g  w ith  
this, there is stron g  evidence that p p l2 5 FAK is a key 
regu lator o f  cell m igration . Specifically , cells derived  
from  p p l2 5 FAK —/ — m ou se em bryos exh ib it reduced  
m igration  as a result o f  im paired  a d h esion  turnover  
(Ilic et al., 1995, 1996). M oreover, d isp lacem en t o f  
p p l2 5 FAK from  focal ad h esion s reduces cell m igration  
(G ilm ore and R om er, 1996), w hilst overexp ression  o f  
p p l2 5 FAK in C H O  cells stim u lates m igration  (C ary et 
al., 1996), su ggestin g  that the level o f  p p l2 5 FAK protein  
m ay lim it cell m ovem en t in som e cell types.
Since the expression  level o f  p p l2 5 FAK m ay be a 
determ inant o f  the rate o f  cell m ovem en t, and since 
elevated  p p l2 5 FAK m ay a lso  enhance tu m ou r cell 
survival (F risch  et al., 1996; X u  et al., 1996), it is 
perhaps n o t surprising that a num ber o f  grou p s have  
fou n d  th at p p l2 5 FAK is up-regulated  in cancer cells. In 
particu lar, p p l2 5 FAK is elevated  in cell lines from  
hum an m elan om as, w ith  p p l2 5 FAK levels correlating  
w ith the rate o f  cell m igration  on  fib ronectin  (A k asak a  
et al., 1995), in cervical carcinom a cell lines
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(M cC orm ack  et a l., 1997), in prostatic carcinom a co lon  and breast tum ours and cell lines (O w ens et al.,
tum ours and cell lines (T rem blay et al., 1996) and in 1995), the latter study inferring a link betw een
Localisation o f f a k  gene to human chromosome 8q
Cell lines derived from squamous cell carcinomas have elevated 
copies o f  fa k  gene
BICR3 BICR6
Elevated fa k  gene copy number is also evident in sections from 
squamous cell carcinomas
Figure 1 Localization o f f a k  to chrom osom e 8q in proxim ity to the c -m y c  locus and its copy num ber gains in BICR3I and BICR6. 
(a) C hrom osom es were prepared from  lym phocytes that were arrested in m etaphase using colcim id and probed with both  a D IG - 
labelled centrom eric probe for chrom osom e 8 (visualized as red) and biotin-labelled f a k  p robe (visualized as green), (b) M etaphase 
chrom osom e prepara tions from  BICR31 and BICR6 were probed with both D IG -labelled c -m y c  and  biotin-labelled fa k .  W hite 
arrow s show f a k  and c -m y c  genes at the ends o f isochrom osom es. The chrom osom es were stained with DAP1. (c) 5 p frozen 
squam ous cell carcinom a tum our sections were probed with FITC-labelled f a k  (signals visualized as yellow). The nuclei were 
visualized as red. Cells w ithin the sections act as internal contro ls (arrow  points to nuclei with two copies o f  f a k ,  w hilst broken 
arrow s po in t to tum our cell nuclei which contain m ore than  two copies o f  f a k
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p p l2 5 FAK expression  and tum our invasiveness. H o w ­
ever, desp ite the m ou n tin g  evidence that the expression  
o f  p p l2 5 FAK is e levated  in tum our-derived  cell lines, the  
m echan ism  o f  up -regu la tion  has n o t been addressed. 
H ere w e report that in m align an t k eratin ocytes derived  
from  sq u am ou s cell carcinom as (SC C ), fa k  is up- 
regulated  at the gen etic  level and that this is o ften  
associa ted  w ith increased  exp ression  o f  p p l2 5 FAK 
protein . F urtherm ore, w e observed  increased fa k  gene  
d osage in a variety o f  cell lines derived from  hu m an  
lung, breast and co lo n  tu m ou rs, includ ing  tw o cell lines 
in w hich  fa k  w as am plified . In ad d ition , the p rogres­
sion  o f  co lon ic  ad en om a cells to  carcinom a cells in 
vitro  w as accom p an ied  by increased  p p l2 5 FAK exp res­
sion  and a cop y  num ber gain  o f  the fa k  gene. T hus, w e  
con clu d e that in  m an y  cells derived  from  hum an  
ep ithelia l tum ours, there is increased  fa k  gene d osage  
w hich is often  a ssocia ted  w ith  increased  p p l2 5 FAK 
protein  expression . A lth ou gh  the c-m yc  p ro to -o n co -  
gene is a lm ost a lw ays co-am p lified  or increased in cop y  
num ber a lon g  w ith f a k , increased  exp ression  o f  c -M y c  
protein  w as less frequently  observed  in the invasive cell 
lines w e exam ined . T hese data , togeth er  w ith the 
im portant roles n ow  defined for p p !2 5 FAK in cell 
m otility , in vasion , grow th  and tum our cell survival, 
suggest that p p l2 5 FAK cou ld  con trib u te to  the selection  
pressure that results in the frequent increase in  d osage  
or am plification  o f  the region  o f  ch rom osom e 8q that 
con ta in s the fa k  and  c-m yc  genes.
R esults and discussion
Copy number gains o f  the fak locus in the BICR series 
o f  SC C -derived cell lines
T he gene en cod in g  p p l2 5 FAK has previously  been  
m apped  to m ou se ch rom osom e 15 and to h u m an  
ch rom osom e 8 (F iod erek  and K ay , 1995). L inkage o f  
fa k  to  the p ro to o n co g en e  c-m yc  in the m ou se  suggested  
that hum an 8q24, w here c-m yc  is loca ted , is the likely  
site o f  the fa k  gene in the hum an  gen om e (F ioderek  and  
K ay , 1995). T o  exam in e the fa k  gene in hum an  tum our- 
derived cell lines by fluorescent in situ  h ybrid ization  
(F IS H ), w e iso la ted  a P A C  clon e  con ta in in g  fa k  
sequences as described  in the m ethod s. W e confirm ed  
that the fa k  gene m ap ped  to  the q arm o f  ch rom osom e 8 
and  that norm al lym p h ocytes had tw o cop ies o f  the  
gen e (F igure la ) . F urtherm ore, F IS H  an alysis o f  
ch rom osom e preparations from  a num ber o f  m alignant 
k eratinocyte cell lines derived from  SC C s o f  the h ead  
and  neck (the B IC R  cell lines, E d in gton  et al., 1995) 
dem onstrated  that these had m ore than tw o  cop ies o f  
the fa k  gene in a h igh  percentage o f  nuclei and th at it 
co -loca lized  w ith  c-m yc, con firm in g its p o sitio n  at 
hum an  ch ro m o so m e 8q24 (sh ow n  for B IC R 6 and  
B IC R 31 in  F igure lb ) . In the exam ples sh ow n , B IC R 6  
and B IC R 31 have five and  four cop ies o f  b o th  fa k  and  
c-m yc  respectively , and som e o f  these are present at 
b oth  ends o f  an iso ch ro m o so m e (sh ow n  by  arrow s in  
F igure lb ) . W e fou n d  that all n ine B IC R  cell lines  
exam ined  had greater than tw o cop ies o f  b o th  fa k  and  c- 
m yc  (sh ow n  in T ab le  1). In ad d ition , w e ob served  
elevated  dosage o f  the fa k  gene in frozen  section s o f  
sq u am ou s cell carcin om as derived  from  head  and neck  
(F igure lc ) , in d icatin g  that increased  f a k  w as n o t a
conseq u en ce o f  tum our cell grow th  in culture and  
occurred in vivo during tum ou r p rogression .
Increased  fak gene dosage is associated with increased  
protein expression in m ost cell lines
T o com p are the levels o f  p p l2 5 FAK and  c-M yc p rotein  
in the B IC R  cell lines, w e carried o u t protein  
im m u n ob lo ts. P rotein  con cen tration s were carefu lly  
determ ined and equal am ou n ts o f  to ta l cell lysate  
were separated  by S D S - P A G E , b lo tted  and probed  
w ith p p l2 5 FAK- or c-M yc-specific  an tib od ies. W ith  the 
excep tion s o f  B IC R 16  and B IC R 63 (2 /9  cell lines), the 
m alignant k eratinocytes exam ined  (7 /9  cell lines) 
disp layed  steady state levels o f  p p l2 5 FAK protein  that 
were elevated  m ore than tw ofo ld  ab ove those in hum an  
norm al k eratinocytes (H N K ). A lth o u g h  m ost cell lines 
had increased  levels o f  p p l2 5 FAK, there w as n o  precise  
correlation  betw een  fa k  gene cop y  num ber and protein  
expression . T his is exem plified  by B IC R 6 and B IC R  16 
w hich each h ave five cop ies o f  the fa k  gene, but w hich  
express substan tia lly  different levels o f  p p !2 5 FAK 
protein  (F igure 2a and b). T hu s, a lth ou gh  all o f  the 
B IC R  cell lines exam ined  have increased  fa k  gene co p y  
num ber, and this m ay contribute to elevated  protein  
expression  in som e cell lines, it d oes n ot necessarily  
lead to  a related increase in protein  in all cases. T hese  
ob servation s im ply that ad d itional con tro ls operate , in 
at least som e m align an t cell lines, to con tro l the level o f  
p p l2 5 FAK protein .
A m on gst the B IC R  cell lines exam ined , there was 
considerab le variation  in c-M yc expression  (F igure 2a 
and b). O nly tw o cell lines B IC R 16 and B IC R 78 (2 /9) 
disp layed  m ore than tw ofo ld  elevated  levels o f  c -M yc  
w hen com p ared  to norm al keratin ocytes (F igu re 2a 
and b). T hus, a lth ou gh  the f a k  and c-m yc genes are 
both sim ilarly increased  in co p y  num ber in the B IC R  
cell lines, w e fou n d  that p p l2 5 FAK w as elevated in 6 /9  
cell lines w ith ou t an associated  increase in c-M yc, 
in d icating  that the protein  expression  levels are n ot 
alw ays co -ord in ate ly  regulated. T hese data further  
im ply that c-M yc fu n ction  is unlikely to provide the 
selection  pressure for m ain ta in in g  increased d osage  o f  
the region  o f  8q24 w hich  con ta in s fa k  and c-m yc  in
Table 1 Sum m ary o f  copy num ber gains o f f u k  locus in B IC R  cell 
lines derived from  squam ous cell carcinom as o f the head and neck
C e ll line S ite
S ig n a ls /n u c le u s  
(  m o d e  )
S ig n a ls /n u c le u s  
(  m a x im u m  )
H N K (hum an norm al 
keratinocytes)
2 2
BICR3 Alveolus 4 4
BICR6 H ypopharynx 5 6
B IC R  10 Buccal m ucosa 6 6
BICR16 Tongue 5 6
BICR31 Tongue 4 5
BICR56 Tongue 4 6
BICR63 T ongue 4 6
BICR78 Alveolus 4 6
BICR82 M axilla 4 5
The B IC R  series o f  cell lines were all derived from  invasive 
carcinom as. Those tested (BJCR3, B ICR 6, BICR10, BICR16, 
BICR31 and BICR 56) are all invasive in v i tr o , as determ ined by an 
assay th a t m onito rs upw ard m ovem ent into the reconstituted 
basem ent m em brane M atrigel in v itro , an assay that discrim inates 
between benign and m alignant cells derived from  head and neck 
tum ours (EK  Parkinson, unpublished)
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E x p r e s s io n  o f  pp!25*'AK and c - M y c  in B I C R  ce l l  l in es
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Densitometrie quantitation ol ppl 25FAK and e-Mye protein expression
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PYK2 and p42/ERK2 do not consistently vary in malignant keratinocytes
p42/ERK2
Figure 2 V ariations in expression o f p p l2 5 hAK and c-Myc proteins in BICR cell lines and hum an norm al keratinocytes (H N K ). (a) 
T otal cell lysates (25 //g) were separated by 7.5%  SDS PA G E (upper panel) and 10% SDS PA G E (lower panel), transferred to 
nitrocellulose and probed with anti-pp 1251 VK (upper panel) o r anti-c-M yc (lower panel), (b) Q uan tita tion  by scanning laser 
densitom etry o f  p p I2 5 ,AK (solid bars) and c-M yc (shaded bars) protein in BICR cell lines is shown relative to the expression of 
each in H N K  controls. The im m unoblots and quan tita tions show n are representative o f several replicate experim ents, (c) Lysates 
separated by 7.5%  or 10% SDS PA G E respectively, were probed with anti-PY K 2 (upper panel) o r anti-p42 ERK2 (lower panel)
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m any o f  the B IC R  cell lines exam ined , and suggests  
that p p l2 5 FAK cou ld  be a p oten tia l driv ing force for  
m ainta in in g  these genetic  changes in som e tum our  
cells, at least in vitro. H ow ever, our d ata  d o  n o t rule 
ou t roles for o ther genes at this locus in the frequent 
se lection  o f  co p y  num ber gains in m align an t cells.
A s a con tro l for protein  load in g  and to determ ine  
w hether other p rote in s sim ilarly fluctuated  in m alig ­
nant k eratinocytes, w e exam ined  the exp ression  o f  the  
p p l2 5 FAK h o m o lo g u e , P Y K 2 (L ev et a l., 1995;
A vrah am  et al., 1995; Sasaki et al., 1995), w hich  can  
substitu te  for som e aspects o f  p p l2 5 FAK signalling  (Sieg  
et al., 1998), and  p 4 2 /E R K 2 , a p rotein  k inase that is 
n ot generally  regu lated  by flu ctu ation s in  expression . 
W e fou n d  no con sisten tly  altered exp ression  o f  either  
protein  in the B IC R  cell lines tested  w hen  com pared  to  
norm al keratin ocytes (F igure 2c).
fak gene copy number gains in cell lines from  a variety 
o f  human epithelial tumour types
T o test the generality  o f  fa k  co p y  num ber gains, w e  
carried ou t F IS H  an alysis on  arch ived  ch rom osom e  
preparations from  cell lines derived from  lung, breast 
and co lo n  tu m ours. W e fou n d  that 8/11 lung cancer  
cell lines, 6 /6  c o lo n  cancer cell lines and  6 /6  breast 
cancer cell lines h ad  greater than tw o cop ies o f  fa k  per 
nucleus (T able 2). In ad d ition , the fa k  gene w as 
am plified in tw o  cell lines exam ined , C alu3 (lung) and  
H T 29 (co lon ) tu m ou r cells (F igure 3, T able 2). 
A lth o u g h  we w ere unable to  com p are the p p l2 5 FAK 
p rotein  levels in these cell lines w ith  norm al lun g or 
c o lo n  cell con tro ls, both  cell lines expressed  ab undant 
p p l2 5 FAK (n ot sh ow n ). T hus, m any tum our-derived  cell 
lines from  a variety o f  ep ithelial tum our types have up- 
regulated  fa k  at the genetic  level.
fak  copy number gain accompanies the adenoma to 
carcinoma progression in an in v itro m odel o f  colon 
tumour development
T o address the stage during tum ou r progression  that 
fa k  w as increased , w e utilized  an in vitro system  that 
m odels the co n v ersio n  from  co lo n ic  ad en om a to  
carcinom a. In th is m od el, a cell line w as derived from  
a large tubular a d en om a w ith  m ild  d ysp lasia  (P C /A A ). 
A  c lon ogen ic  varian t ad en om a w as estab lished  (A A / 
C l)  and a fu lly  tu m origen ic  and invasive m align an t cell 
line w as derived by sequ en tia l chem ical treatm ent and  
tissue culture proced ures (A A /C 1 /S B 10; m od el d e­
scribed in  W illiam s et al., 1990; B runton  et al., 1997). 
B oth  the cellu lar and  m olecu lar ch anges during this in 
vitro p rogression  are sim ilar to  th ose  th at occur in vivo 
(M an n in g  et al., 1991; W illiam s et al., 1993), ind icating  
that this is a relevant m od el to  study co lo n  cancer  
progression  and the ch anges required for the transition  
to  an in vasive p h en otyp e. U sin g  F IS H  analysis, w e  
sh ow ed  that the c lo n o g en ic , n on -in vasive  ad en om a cell 
line A A /C 1  h ad  tw o  cop ies  o f  the f a k  gene (F igure 4a); 
in con trast, the in vasive  carcinom a derivative A A /C 1 /  
SB 10 had three cop ies . T hus, acq u isition  o f  an  
addition al co p y  o f  f a k  occurred  during m align an t 
con version  and d id  n o t occur at an earlier stage o f  
tum our d evelop m en t, at least in this m od el. T he tim ing  
o f  the increase in f a k  gene cop y  num ber w as co in cid en t  
w ith  up -regu la tion  o f  p p l2 5 FAK protein  expression
(F igure 4b) and the acquisition  o f  an invasive  
p h en otype (B runton  et al., 1997). T h ese  data  are 
con sisten t w ith the u p-regu lation  o f  p p l2 5 FAK n ot 
being required for tum our in itia tion , or o ther early  
stages o f  tum our d evelopm en t, but su pport its 
p roposed  role in the later acq u isition  o f  an invasive  
phenotype. In ad d ition  to fa k , w e again  fou n d  that the  
carcinom a cells had an add itional co p y  o f  c-myc, 
a lthou gh  n o  increase in the expression  o f  c-M yc  
protein  w as ob ta in ed  as the ad en om a cells progressed  
to becom e invasive carcinom a cells in vitro (C  
Paraskeva, unpublished observation).
General discussion
T he finding that p p l2 5 FAK is o ften  overexpressed  in 
hum an tum ours and tum our-derived cell lines, strongly  
suggests that this ce ll/E C M  ad h esion -lin k ed  tyrosine  
kinase m ight be involved  in the d evelop m en t o f  
invasive cancer. H ere we have used  F IS H  to  confirm  
that ch rom osom e 8q is the gen om ic lo ca tio n  o f  the fa k  
gene and that it m aps very c lose  to  the c-m yc gene, 
defining its p ositio n  at 8q24 w here c-m yc  is k n ow n  to  
reside. W e further dem onstrate that genetic m ech an ­
ism s inclu d in g  cop y  num ber gains, am plification  and  
isoch rom osom e form ation  in vo lv in g  the fa k  locu s, are 
often associated  w ith  elevated p p l2 5 FAK protein  in 
hum an ep ithelia l tum our cell lines and in tum ours in 
vivo. T his, togeth er w ith  the fact that p p l2 5 I AK protein  
has been show n to be elevated  in tum our tissues 
(O w ens et al., 1995), suggests that increased p p l2 5 FAK 
expression  m ay have b io log ica l conseq u en ces for  
tum our d evelop m en t by provid ing the m alignant cells 
w ith a selective advantage. In this regard, the p roper­
ties o f  p p l2 5 FAK, and the nature o f  its docum ented  
binding partners, suggest that it m ay have several 
possib le  fu n ction s during tum our progression .
O ne p ossib ility  is that up-regulated  p p l2 5 FAK 
contrib utes to E C M -d ep en d en t tum our grow th  by  
m ediating  signalling from  fibronectin  to the R as/
Table 2 Sum m ary o f  copy num ber gains o f f a k  locus in lung, colon 
and breast tum our-derived cell lines
C e ll line O rig in S ig n a ls )  n ucleu s
Calu3 L ung  cancer > 1 0
G LC 4 Lung cancer 3
LS274 Lung cancer 3
LS277 L ung cancer 4
LS763 Lung cancer 5
H125 Lung cancer 4
LCPH 3 Lung cancer 2
LSI 11 Lung cancer 2
LS310 Lung cancer 2
L D A N Lung cancer 5
LSI 06 Lung cancer 4
HT29 C olon cancer > 1 0
Colo320 C olon cancer 3
A L T-F C olon cancer 3
A LT-G C olon cancer 3
AA/C1/SB10 C olon cancer 3
BE C olon cancer 3
BT474 Breast cancer 6
M C F-7 Breast cancer 4
M DA436 Breast cancer 4
M DA231 Breast cancer 4
T47D Breast cancer 4
ZR75 Breast cancer 4
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M A P  kin ase cascade that is im plicated  in proliferation  
con tro l (Schlaepfer et a l.. 1994). A n oth er  poten tia l role 
proposed  for p p l2 5 ,AK is in m aking transform ed cells 
able to  grow  in an an chorage-in dependent m anner  
(Frisch et a l.. 1996). A s well as in anchorage-deprived  
cells, p p l2 5 FAK can a lso  act as a survival factor for 
adherent cells (H ungerford et al.. 1996; X u et al.. 1996) 
and is specifically  cleaved and inactivated  by caspases  
during the ap op to tic  process (C rouch et al.. 1996; W en  
et a l., 1997). T hus, p p l2 5 IAK m ay contribu te to E C M - 
dependent grow th and survival o f  tum our cells under 
c o n d itio n s in vivo that w ould  be unfavourable for 
norm al cells.
A s w ell as tum our cell grow th and survival, an other  
likely role for elevated p p l2 5 FAK in tum our cells is in 
the acq u isition  o f  an invasive p henotype. C ancer cell 
invasion  is a com p lex  process that requires cells to  
adhere and m igrate through the underlying ECM .
Amplification o f f a k  gene in some human cancer cell lines 
Calu 3 (lung cancer)
Since pp 125'AK fu n ction s as a key regu lator o f  E C M - 
depend en t cell m igration  (Ilic et a/.. 1995, 1996; 
G ilm ore and R om er, 1996; C ary et al.. 1996), and  
since en d o g en o u s levels o f  F A K  exp ression  can limit 
the rate o f  cell m otility  in som e cell types (C ary et al.. 
1996), it seem s likely that elevated  p p l2 5 I AK in tum our  
cells m ay release norm al con stra in ts on  the rate o f  cell 
m otility , thus en h an cin g  invasive p oten tia l. C onsistent 
w ith this p ossib ility , w e found  that the gain o f  an 
ad d ition a l cop y  o f  the fa k  gene, w hich w as associated  
with elevated  p p l2 5 FAK protein , occurred relatively late 
in an in vitro m odel o f  co lon  carcinom a developm ent 
and w as co incident w ith  acq u isition  o f  an invasive  
p h en otyp e (B runton  e t al.. 1997).
T he results presented here d o  not a llow  us to  
con clu d e w hether n eighbouring  genes, includ ing that 
en cod in g  c-M yc, that are a lso  increased in d osage or 
co-am plified  a lon g  w ith fa k .  con tr ib u te  to m alignant 
d evelopm ent. O ur results w ith the BICR series o f  cell 
lines, and their norm al k eratinocyte counterp arts, show  
that p p l2 5 FAK protein  is up-regu lated  to a greater or 
lesser extent in m any tum our-derived  cell lines. 
H ow ever, a lth ough  c-m yc  is a lso  up-regulated  at the 
genetic level, increased exp ression  o f  c -M yc protein  w as 
less frequently observed . F urtherm ore, a lth ou gh  an
A cquisition o f  an additional fa k  gene during conversion o f colon 
adenom a to carcinom a in v itro
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AA/Cl AA/C1/SB10
Carcinoma
HT29 (colon cancer) PC/AA -*• AA/Cl—*• AA/C1/SBK)
Figure 3 A m plification o f  f a k  gene in Calu3 and HT29 cancer 
cells. FISH  was carried out on archived m etaphase chrom osom e 
p reparations from  Calu3 lung cancer cells (upper panel) and 
HT29 colon cancer cells (lower panel) using biotin-labelled f a k  
probe. Regions o f  am plified f a k  are shown by arrow s. The 
chrom osom es were stained with DAPI
pp125hAK
Densitomctric quantitation
PC/AA -► AA/Cl-*- AA/C1/SB10
Figure 4 A copy num ber gain o f the f a k  gene accom panies 
increased pp 1251 AK protein expression during  colonic adenom a 
to carcinom a conversion in  v itro , (a)  M etaphase chrom osom e 
preparations o f  the A A /C l colon adenom a cell line and its 
invasive derivative A A /C l/S B  10 were p robed with both D IG-c- 
m y c  and  biotin-labelled f a k .  The chrom osom es were stained with 
D A PI. ( b )  p p l2 5 FAK expression levels in the early colonic 
adenom a PC A A, clonogenic adenom a A A /C l and invasive 
carcinom a AA C l SB 10 cell lines were determ ined by im m uno- 
b lo tting  using a n ti-p p l2 5 FA -specific serum  as probe. Q u an tita ­
tion w'as by scanning laser densitom etry  and is expressed as 
O D  x  mm" (arb itrary  units)
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ad d ition a l cop y  o f  the c-m yc  gene w as gained at the 
sam e stage as fa k  during co lo n  carcinom a developm ent  
in the in vitro  m od el, there was no con com itan t  
increase in the exp ression  o f  c-M yc. T ogeth er, these 
d ata im ply that f a k , at least in som e cells, is a stronger  
cand id ate than c-m yc  as the gene responsib le  for  
m aintenance o f  increased  d osage  o f  this region  o f  the 
genom e. T he freq uent genetic u p -regu lation  o f  fa k  that 
w e observed  in cell lines derived from  lun g, breast and  
co lo n  cancers suggests that it cou ld  be an im portant 
event in the d eve lop m en t o f  invasive epithelial 
tum ours. T his, togeth er  w ith  the role o f  p p l2 5 FAK as 
a regulator o f  cellu lar ad h esion , m otility , in vasion , 
survival and cell grow th , processes that are perturbed  
in  cancer, im plies that p p l2 5 FAK m ay be in tim ately  
involved  in  tu m origenesis.
Materials and methods
Ceil culture
N o r m a l  h u m a n  k era t in o cy tes  ( H N K )  were  prepared from  
hu m an  foresk in  essentia l ly  as described in P ark in son  et al. 
(1986),  except  that type I-S trypsin inhibitor  (S igm a C hem ica l  
C o.,  U K )  w as used instead o f  F C S -c o n ta in in g  m ed ium  to 
neutralize trypsin. T h e s e  n orm al ce lls and the  B I C R  cell  lines, 
w hich  w ere derived from  sq u a m o u s  cell ca r c in o m a s  by a 
m eth o d  m odif ied  fro m  that described  in R h e in w a ld  and  
B eckett  (1981),  were  g r o w n  on  lethally  irradiated N I H 3 T 3  
feeder cells in D M E M  su p p lem en ted  with 10% foetal bov ine  
serum  (F B S )  and  h y d r o c o r t iso n e  (0 .4  / /g /m l) .  T h e  A A / C l  
c o lo n  a d e n o m a  and  A A / C l / S B  10 c o lo n  ca rc in o m a  cells were  
cultured in 3T3 c o n d it io n e d  m e d i u m - D M E M  with 10% 
F B S , insulin (0.2  u n i t s / m l )  and  h y d ro co r t iso n e  (1 / ig /m l)  -  as 
described  in B runton  e t al. (1997).
Protein immunoblots
Cells were lysed in 10 m M  Tris (p H  7.5), 1% Triton  X -100 ,  
0 .5%  N P 4 0 ,  150 m M  N a C l ,  1 m M  E D T A ,  1 m M  E G T A ,  
10 m M  N a P P i ,  2 m M  P M S F ,  100 pM N a 3V 0 4, 0 .5  m M  N a F  
and 0 .1%  aprotinin  (Sigm a).  Extracts  w ere  assayed  for 
protein  co n ten t  us ing  the  M icro  B C A  Prote in  A s sa y  Kit  
(Pierce, U S A )  after clarif ication by  high speed centrifugation  
at 4°C. L ysates  were b o i led  in h igh  S D S  (2 .5 % ) sam p le  buffer 
and 25 jig  total  prote in  separated  by d isc o n t in u o u s  S D S -  
P A G E  (7 .5%  gel for  p p l 2 5 HAK and  10% gel for c -M y c )  under  
reducing c o n d i t io n s  prior to  transfer to  n itrocellulose.  
Proteins  were detected  by p ro b in g  with  1 : 5 0 0  d ilution  o f  
a n t i - p p l2 5 FAK (T ra n sd u ct io n  L aborator ies ,  U S A )  or  1 :1 0 0  
dilution o f  a n t i - c -M y c  serum (a gift  from  D a v id  Gillespie ,
References
A k a s a k a  T ,  van  L e e u w e n  R L ,  Y o s h i n a g a  IG ,  M i h m  Jr M C  
an d  B yers  H R .  (1 9 9 5 ) .  J. Invest .  D erm ato l . ,  105, 1 0 4 -  108.
A v r a h a m  S, L o n d o n  R ,  F u  Y ,  O t a  S, H ir e g o w d a r a  D ,  Li J, 
J ia n g  S, P a s z t o r  L M ,  W h i te  R A ,  G r o o p m a n  JE  and  
A v r a h a m  P. ( 1 9 9 5 ) .  / .  Biol. Chem.,  270, 2 7 7 4 2 - 2 7 7 5 1 .
B r u n to n  Y G ,  O z a n n e  B W ,  P a r a s k e v a  C a n d  F r a m e  M C .  
(1 9 9 7 ) .  Oncogene, 14, 2 8 3 - 2 9 3 .
C ary  L A ,  C h a n g  J F  a n d  G u a n  JL. (1 9 9 6 ) .  J. Cell . Sci.,  109, 
1 7 8 7 -  1794.
C h e n  H C ,  A p p e d d u  P A ,  P a r s o n s  JT, H i ld e b r a n d  J D ,  
Sch a l ler  M D  an d  G u a n  JL. (1 9 9 5 ) .  J. Biol. Chem.,  270 ,  
1 6 9 9 5 -  16999.
C h en  H C  a n d  G u a n  JL. ( 1 9 9 4 ) .  Proc. Natl .  Acad .  Sci.  USA,  
91, 1 0 1 4 8 - 1 0 1 5 2 .
Beatson  Institute , G la s g o w ,  U K )  diluted in 5%  n o n -fa t  milk  
in P B S /0 .2 %  (v/'v) T w een  20. D etec t io n  o f  b o u n d  a n t ib o d y  
was by reaction with horseradish p erox id a se -co n ju g a ted  
secondary  a n t ib o d y  (A m er sh a m , U K )  and v isu a l iza t ion  w as  
by enhanced  chem ilum in esc en ce  (A m er sh a m , U K ) .  Q u a n t i ta ­
t ion was by scann in g  laser densitom etry  using ap p rop ria te  
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Abstract
The v-Src oncoprotein, unlike other well studied oncoproteins including Myc, v-Jun 
and E2F-1, can induce cycling under low serum conditions without inducing cell 
death. Here we demonstrate that growth of transformed cells in low serum is 
dependent on v-Src induced survival signals. We used Rat-1 cells transformed by a 
temperature sensitive v-Src to show that when we switched off v-Src under low serum 
conditions, the cells rapidly exited the cell cycle and entered a programme of cell 
death. Death was accompanied by activation of caspases and the stress-activated 
kinases, JNK (Jun N-terminal kinase) and p38 MAP (mitogen activated protein) 
kinase, and was inhibited by overexpression of the anti-apoptotic protein Bcl-2 or by 
combined treatment with a caspase inhibitor, Z-VAD-FMK and a p38 inhibitor, 
SB203580. This suggests that under low serum conditions v-Src transformed cells 
were primed to enter apoptosis, a process involving both p38 and caspases, but this 
was prevented by v-Src or serum induced survival signals. Amongst other effects, v- 
Src activates two downstream kinases, PI3-K (phosphatidylinositol 3-kinase) and 
ERK1/2 (extracellular signal-regulated kinase), which have been shown to mediate 
growth and survival signals and switching off v-Src led to down regulation of the 
activity of both kinases. Using specific inhibitors of PI3-K (LY294002) and the ERK 
activating kinase MEK1 (MAP kinase kinase) (PD98059) we showed that, unlike 
normal Rat-1 cells, v-Src transformed Rat-1 cells grown in low serum could be 
induced to die by the PI3-K inhibitor. We conclude that, under low serum conditions, 
v-Src transformed cells are primed to die by apoptosis but are prevented from doing 
so by v-Src induced survival signals mediated by PI3-K.
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Abbreviations: JNK, Jun N-terminal kinase; Z-, benzyloxycarbonyl; FMK, 
flouromethy Ike tone; PI3-K, phosphatidylinositol 3-kinase; MAP, mitogen-activated 
protein; ERK, extracellular signal-regulated kinase; MEK, MAP kinase kinase/ERK 
kinase; PAK, p21-activated kinase; MEKK, MEK kinase; Z-EK(bio)D-aomk, N-(Na- 
benzyloxycarbonylglutamyl-NE-biotinyllysyl)aspartic acid [(2,6- 
dimethylbenzoyl)oxy]methyl ketone; DAPI, (4’,6-Diamidino-2-pheylindole); BrdU 5- 
Bromo-2’-deoxyuridine; BAD, Bcl-XL/Bcl-2 associated death factor; PBS, phosphate 
buffered saline; EDTA, ethylenediaminetetraacetic acid; DMEM, Dulbecco’s 
modified Eagle’s medium; PAGE, polyacrylamide gel electrophoresis; FITC, 
fluorescein isothiocyanate; ECL, enhanced chemiluminescence; TUNEL, TdT- 
mediated dUTP nick end labelling; TdT, terminal deoxynucleotidyl transferase; RSV, 
Rous sarcoma virus; ts, temperature sensitive; DMSO, dimethylsulphoxide; GSK-3, 
glycogen synthase kinase-3.
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Introduction
A number of cell lines and primary cells of mesenchymal origin become quiescent 
when deprived of growth factors or matrix interactions. Even in the absence of both 
conditions such quiescent cells remain viable for some time 1-3 . In contrast, the same 
cells transformed by either polyomavirus or RSV (Rous sarcoma virus) do not enter 
viable quiescence when denied both serum growth factors and matrix; they either 
multiply in suspension or become non-viable, a phenomenon that permitted the 
selective isolation of revertants of polyomavirus transformed cells and of ts 
(temperature sensitive) transformation mutants of RSV 2 ,3 . We recently characterised 
how v-Src, the oncoprotein of RSV, prevented withdrawal from the cell cycle in the 
absence of growth factors 4 and we now wish to understand how v-Src influences 
viability in these non-quiescent cells.
Several oncoproteins can induce the paradoxical outcomes of cell multiplication and 
senescence or apoptosis, depending on the cellular context 5 . For example c-Myc, 
E2F-1 and v-Jun induce both cell proliferation and apoptosis 6-8 whilst Ras, operating 
through the Raf pathway has similar effects 9 . However, Ras stimulation of PI3-K 
protects against apoptosis 9 and this is thought to be a reason why Ras and other anti- 
apoptotic oncogenes such as Bcl-2 demonstrate oncogenic cooperation with c-Myc 1 0- 
1 2 , each oncogene countering the other’s antiproliferative properties.
The way in which oncoproteins such as Myc and E2F-1 induce apoptosis is beginning 
to be characterised 1 3 ,1 4 . v-Src transformation stimulates c-Myc expression 15,16 
suggesting a likely pro-apoptotic effect. However v-Src can also activate several 
kinases which can inhibit cell death including ERK 1 7 ,1 8  and PI3-K 19 which induces 
cell survival in epithelial cells following detachment via the downstream 
serine/threonine kinase, Akt 2 0 . This suggests that v-Src may promote cell death or 
protect from cell death under different conditions.
We made use of Rat-1 cells transformed by a temperature sensitive v-Src (ts LA 29) 
which we used previously to characterise the mitogenic effects of v-Src 4 ,1 8 ,2 1 . Here 
we use the reversibility of ts v-Src to examine the effect of inactivating v-Src in 
transformed cells grown under low serum conditions. We found that the cells exited 
the cell cycle and were committed to a programme of cell death. We characterised the 
death as apoptosis by morphological changes including membrane blebbing, DNA and 
nuclear fragmentation and biochemical changes including the activation of caspases 2 2  
and the activation of the stress induced kinases, JNK and p38 23-25. Over expression 
of the anti-apoptotic protein Bcl-2 26 prevented cell death and treatment with the 
caspase inhibitor Z-VAD-FMK 2 7  and the p38 inhibitor SB203580 2 8  simultaneously 
but not independently significantly reduced cell death. This suggested that the 
apoptotic pathway required either caspases or p38 and interacted functionally with 
Bcl-2.
Since v-Src transformed cells did not undergo apoptosis when v-Src was active we 
assessed whether apoptosis seen when v-Src was switched off was due to loss of v-Src 
survival signals. We investigated the effect of switching off v-Src on PI3-K and ERK 
activity and found that ERK and Akt (which is activated downstream of PI3-K) were 
rapidly inactivated. We tested whether inactivation of either kinase could induce cell
4
death in v-Src transformed cell using LY294002 to inhibit PI3-K 2 9  and PD98059 to 
inhibit ERK activating kinase (MEK1) 3 0 .  We found that LY294002 was sufficient to 
induce apoptosis when added to v-Src transformed cells in low serum but did not 
induce apoptosis when added to normal Rat-1 cells grown under low serum 
conditions. This suggests that, in the absence of serum survival signals, v-Src 
promotes apoptosis but the transformed cells are protected from cell death by survival 
signals from v-Src mediated by PI3-K which could explain why v-Src does not require 
a co-operating oncoprotein. We suggest that the anti-apoptotic effects of v-Src could 
be as important to the transforming ability of the v-Src oncoprotein as the effects on 
mitogenesis.
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Results
y-Src activity prevents transformed cells undergoing apoptosis in low 
serum
Rat-1 cells expressing the tsLA 29  v-Src mutant of RSV (tsLA29  Rat-1) are 
transformed at the permissive temperature for v-Src activity (35°C) and 
morphologically normal at restrictive temperature (39.5°C). When such cells were 
placed in 0.2 % serum medium (low serum) for 24 h they continue to cycle at 35°C 
(Figure 1A, 0 h and 4 ) .  On inactivating v-Src by shift to 39.5°C we used flow 
cytometry to show that there was the expected rapid reduction in the number of cells 
in S-phase (as judged by the number of cells which incorporated BrdU during a 1 h 
pulse, Figure 1A, 4 h and 8 h). The same phenomenon is seen initially when v-Src is 
inactivated in the presence of serum growth factors 4 . In contrast to the cells’ 
behaviour in high serum, however, v-Src inactivation in low serum led to many cells 
becoming loosely adherent (detached) within a few hours, with rounded or blebbing 
morphology (Figure IB) and fragmented nuclei (Figure 1C) which could be labelled 
using the TUNEL (TdT-mediated dUTP nick end labelling) technique 31 (Figure ID). 
Almost all cells had detached in this way by 24 h after v-Src inactivation.
When detached and still adherent cells were harvested separately 8 h after inactivating 
v-Src in low serum, flow cytometry showed the detached cells to have a peak DNA 
content less than the Go/Gi peak (Figure IE, left) and a smaller cell size (Figure IE, 
right) The still adherent cells were smaller than cells in which v-Src was active 
(Figure IE) but not as small as the detached cells. DNA isolated from detached and 
adherent cells separated into 200 base pair ladders, again the adherent cells had an 
intermediate phenotype with the laddering being more apparent in the detached cell 
DNA (Figure IF). Thus inactivation of v-Src in transformed cells which lack serum 
survival factors led to the rapid onset of changes characteristic of apoptosis; cell 
shrinkage, blebbing and detachment, nuclear fragmentation, TUNEL labelling and 
DNA laddering. These changes could be prevented by replacing serum up to 2 h after 
inactivating v-Src but from 4 h after v-Src inactivation, the cells were progressively 
committed to a programme of cell death (Figure 1G) that eventually involved the 
whole population. Our results indicate that v-Src protected from cell death under low 
serum conditions but cells became committed to death when v-Src was switched off. 
Thus under low serum conditions survival signals from v-Src prevent commitment to 
death in v-Src transformed cells.
Biochemical changes associated with apoptosis induced by switching off v- 
Src
Apoptosis is frequently associated with activation of specific proteases, caspases and 
with the activation of the stress activated kinases p38 and JNK. Using a biotinylated 
peptide, which binds to the large subunits of all active caspases tested 3 2 , we detected 
active caspases in extracts from cells harvested 2.5 h after v-Src inactivation (Figure 
2A). All members of the MAP kinase family including JNK and p38 are activated by 
dual tyrosine, serine/threonine phosphorylation in the catalytic domain by specific 
MAP kinase kinases 3 3 . We used antibodies specific for the dual Thrl83/Tyrl85 form
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of JNK or Thrl80/Tyrl82 form of p38 to determine the amount of active p38 and 
JNK. We detected phosphorylated p38 and JNK 4 h after v-Src inactivation (Figure 
2B). Several different isoforms of JNK have been reported around 54 and 46 kD 
which are produced from three JNK genes by alternative spicing 3 4 . We found an 
isoform of JNK in apoptotic cells whose appearance correlated with a decrease in the 
amount of p54 JNK (Figure 2B), suggesting that it might be derived from the p54 
isoform. We could also detect two JNK isoforms around 45 kD. Thus activation of 
caspases, JNK and p38 and the appearance of morphological changes characteristic of 
apoptosis (Figure 1) were all initiated between 2 and 4 h after inactivating v-Src.
Activation of JNK and p38 can be triggered by caspases which, in some cell types, 
cleave and activate two upstream kinases, MEKK1 and PAK-2 (p21-activated kinase- 
2) 3 5 ,3 6 . Since caspases, JNK and p38 were activated simultaneously (Figure 2A and
B), we investigated whether caspase activity was required for the activation of JNK or 
p38. We added a general caspase inhibitor Z-VAD-FMK 2 7 ,3 7  1 h before switching off 
v-Src and harvested the adherent and detached cells separately after 6 h. Treatment 
with Z-VAD-FMK prevented the cleavage of two known caspase substrates FAK 
(data not shown) and p27 (Figure 3C) 3 8 , indicating that caspase activity was 
inhibited. We found that Z-VAD-FMK slightly reduced the amount of active JNK 
compared to total JNK in detached cells but increased the amount of active JNK in the 
adherent cells (Figure 3A). More markedly, Z-VAD-FMK reduced active p38 in 
adherent cells and almost abolished it in detached cells (Figure 3B). This suggests that 
during apoptosis initiated by switching off v-Src under low serum conditions, the 
activation of p38 was largely dependent on the activation of caspases, while activation 
of JNK was not.
The new form of JNK (Fig 3A, arrows) was present in extracts from control detached 
cells but not in extracts from Z-VAD-FMK treated detached cells, which also retained 
the p54 isoform of JNK. This suggests that the new isoform could have been formed 
by caspase cleavage of p54 JNK. The p54 isoform has a longer C-terminal tail 34 not 
present in p46 JNK which could be the location of the cleavage site. The general 
caspase inhibitor Boc-D-FMK also inhibited the formation of the new JNK isoform 
whereas other caspase inhibitors including Z-DEVD-FMK, Z-YVAD-FMK, Z-IETD- 
FMK, which are designed to inhibit particular subsets of caspases, had no effect (data 
not shown). These results suggest that several caspases are activated in the apoptotic 
cells and that these are responsible for the appearance of the new JNK isoform and 
loss of the p54 isoform.
The role o f caspases and p38 in apoptosis
Since we found that activation of caspases 2.5 h after switching off v-Src (Figure 2A), 
correlated with commitment to cell death (FigurelG), we investigated whether 
inhibiting caspases would prevent cell death. We found that the caspase inhibitor Z- 
VAD-FMK, added at the same time as inactivating v-Src, reduced cell shrinkage in 
the detached cells (compare Figure IE and Figure 4A) but did not prevent cell 
detachment or membrane blebbing (Figure 4B), nuclear fragmentation (Figure 4C), 
DNA laddering (Figure 4D) or TUNEL labelling (Figure 4E). Between 4 and 6 h the 
control cells stopped blebbing and became rounded whereas the cells treated with Z- 
VAD-FMK remained in a blebbing state (compare the number of rounded cells in
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Figure IB and Figure 4B). This suggests that caspases were not required for cell death 
but are required for cell shrinkage and the cessation of cell blebbing.
Previous work has shown that cell blebbing in the presence of Z-VAD-FMK requires 
the activity of p38 2 4 . Cells treated with Z-VAD-FMK retained some p38 activity 
(Figure 3) raising the possibility that signalling through p38 was sufficient to induce 
blebbing and cell death. We added a selective inhibitor of p38, SB203580 2 8  at the 
same time as inactivating v-Src and investigated the effect on cell blebbing and 
TUNEL labelling. We found that SB203580 had no effect on the number of cells 
undergoing cell blebbing (data not shown) and no significant effect on the number of 
TUNEL positive cells (Figure 4E). However, when we added both Z-VAD-FMK and 
SB203580 we observed a 65 % drop in the number of TUNEL positive cells (Figure 
4E) and a similar fall in the number of cells undergoing cell blebbing (data not 
shown). Thus, in order to prevent cell death it was necessary to block both caspases 
and p38 suggesting that either was sufficient to induce cell death under these 
conditions.
v-Src mediated protection against apoptosis
Cell death following v-Src inactivation in low serum may be caused by down 
regulation of v-Src survival signals. Among the many down stream effects of v-Src 
transformation is the activation of two kinases PI3-K and ERK (MAP kinase) both of 
which have been shown to mediate survival signals 1 7 ,2 0 . Therefore we investigated 
the effect of switching off v-Src on the activities of PI3-K and ERK using antibodies 
specific for phospho Ser473 Akt and phospho p44/42 ERK. Akt phosphorylation is a 
good indicator of PI3-K activity since it is recruited to the membrane by the 
phospholipid products of PI3-K where it is activated by phosphorylation at Thr308 
and Ser473 3 9 . ERK is activated by phosphorylation on Thr202/Tyr204 by MEK1 3 3 . 
We found a rapid decline in the activated Akt and ERK after switching off v-Src 
(Figure 5A, upper). The upper band detected with the phospho-ERK antibody at 0 h 
did not appear in all experiments and its identity is not known. ERK phosphorylation 
returned at 4 h, simultaneous with the phosphorylation of p38 and JNK (Figure 2C) 
and the onset of apoptosis, whereas Akt protein was down regulated from 4 h 
consistent with cleavage by caspases as reported by Widmann et a l, (1998) 4 0 . Since 
both the ERK and PI3-K were rapidly inactivated when v-Src was switched off, this 
showed that both were controlled by v-Src activity in ts LA 29 Rat-1 cells and are 
candidate mediators of v-Src induced survival signals.
To test whether either pathway relayed v-Src induced survival signals we used 
PD98059, a specific inhibitor of MEK1, 3 0  to inactivate ERK or LY294002, a specific 
inhibitor of PI3-K 2 9 . We added these two inhibitors to v-Src transformed cells 
cultured for 24 h in low serum medium and harvested them at intervals for 
immunoblotting or TUNEL. Figure 5B shows that adding PD98059 reduced ERK 
phosphorylation while Figure 5c shows that adding LY294002 reduced Akt 
phosphorylation. Figure 5D shows that LY294002 induced about half the number of 
TUNEL positive cells as switching off v-Src whereas PD98059 had no effect either 
alone or when added with LY294002. Importantly, the effect of LY294002 on cell 
survival is specific to v-Src transformed cells since when we added LY294002 to 
serum deprived normal Rat-1 we did not observe any increase in apoptosis after 6 h
(Figure 5E). Furthermore, the susceptibility of v-Src transformed cells to inhibitor 
induced cell death is lost after they are cultured for several days at 39.5°C (Figure 5E). 
This suggests v-Src transformed cells under low serum conditions were dependent on 
survival signals mediated by v-Src induced PI3-K activity.
If PI3-K is responsible for mediating v-Src survival signals we would expect that 
death induced by inhibiting PI3-K would be mediated by the same pathway as death 
induced by switching off v-Src. To investigate this we harvested adherent and 
detached cells treated with LY294002 to examine the appearance of the new isoform 
of JNK, which we showed was dependent on caspase activity (Figure 3A) and the 
activation of p38 and JNK. Cells treated with PD98059 (most of which remained 
attached) served as a control. Treatment of serum deprived v-Src transformed cells 
with LY294002 induced p38 and JNK phosphorylation and the new isoform of JNK 
in the detached cells whereas PD98059 had no effect (Figure 5F). In contrast to results 
shown in Figs 2B and 3B we did not see any active p38 in the adherent cells in Figure 
5F suggesting that cells with active p38 were weakly attached and could be harvested 
with detached cells. These results indicate that apoptosis induced by inhibiting PI3-K 
under low serum conditions is accompanied by similar biochemical events to that 
induced by switching off v-Src, supporting the role for PI3-K in mediating v-Src 
survival signals.
Cell death is inhibited by the anti-apoptotic protein Bcl-2
Over expression of Bcl-2 or B c1-X l can inhibit some but not all types of apoptosis 
4 1 ,4 2 . Therefore we tested whether over expression of Bcl-2 would inhibit cell death 
induced by switching off v-Src. We transfected ts LA 29 Rat-1 cells with a 
mammalian expression vector for mouse Bcl-2 and isolated clones which over express 
Bcl-2 to differing extents (Figure 6A). We found that Bcl-2 inhibited cell death 
induced by v-Src inactivation or by LY294002 in a dose dependent manner (TUNEL 
labelling shown in Figure 6B). However, Bcl-2 did not block the fall in Akt or ERK 
phosphorylation after v-Src was switched off (Figure 6C). These results show that 
Bcl-2 blocks cell death due to switching off v-Src or inhibiting PI3-K without 
blocking inactivation of Akt.
The Bcl-2 family of anti-apoptotic proteins inhibit apoptosis by preventing activation 
of caspases, JNK and p38 2 6 ,4 1 ,4 3 -4 5 . Our results suggest that Bcl-2 blocked cell death 
downstream of Akt, thus to define more precisely where Bcl-2 acted we determined if 
it could inhibit phosphorylation of JNK and p38 or the caspase dependent mobility 
shift in JNK. JNK and p38 did not become phosphorylated in clones expressing high 
levels of Bcl-2 whereas they were phosphorylated in clones containing the plasmid 
alone (Figure 6D). Similarly, the new JNK isoform (indicated by arrows) was not seen 
in clones with high Bcl-2 levels (Figure 6D). These results suggest that Bcl-2 blocks 
cell death upstream of the activation of caspases, JNK and p38 and downstream of 
PI3-K and Akt.
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Discussion
The apoptotic activities resulting from the activation of mitogenic oncoproteins may 
protect normal cells from unscheduled proliferation and this is one postulated reason 
for co-operation between mitogenic and anti-apoptotic oncogenes 1 0 -1 2 . Unlike other 
oncoproteins, the deregulated tyrosine kinase v-Src does not require a co-operating 
partner to induce full neoplastic transformation, however, as a potent mitogen, v-Src 
might also be expected to promote apoptosis. If so, then v-Src itself must induce a 
countervailing anti-apoptotic process if it is to succeed in inducing neoplasia on its 
own. We show here that v-Src does indeed induce both pro-apoptotic and anti- 
apoptotic effects in Rat-1 cells cultured with insufficient serum survival factors.
The potentially deleterious effect of v-Src on cell viability was implied in very early 
studies, which showed that, in low serum, v-Src expressing cells either multiplied or 
died, but could not become quiescent 3. We demonstrate here that v-Src transformed 
cells in low serum are primed to die by apoptosis when v-Src is switched off (Figure 
1) or PI3-K is inhibited (Figure 5D). Apoptosis was specific to v-Src transformed cells 
in low serum, since inhibition of PI3-K in low serum did not lead to apoptosis in 
normal Rat-1 cells or ts LA 29 Rat-1 cells in which v-Src had been inactive for several 
days (Figure 5E). Since ts LA 29 Rat-1 cells display this apoptosis upon switching off 
v-Src in low serum, either the oncoprotein or serum must provide an overriding 
survival signal (Figure 1G). The speed and magnitude of the apoptotic response in this 
conditional system may make it useful for studying details of apoptotic commitment 
and execution. We, however, have concentrated on the dual roles of v-Src in this 
phenomenon and their consequences for Src biology.
Possible mechanisms o f priming apoptotis by v-Src under low serum  
conditions
A proapoptotic effect of v-Src in low serum has not been previously described and, 
although we do not know how it is mediated, the properties of v-Src offer several 
interrelated possibilities.
Firstly, v-Src upregulates c-Myc, which has been shown both to promote cell 
proliferation and to prime Rat-1 cells for apoptosis under low serum conditions 
(comprehensively reviewed recently in 4 6 ) .  Secondly, there is evidence that activated 
Ras promotes apoptosis through Raf signalling 9  and v-Src also activates this pathway 
1 8 . Thirdly, v-Src disrupts cell cycle controls 4 ,1 8 ,2 1  and the ability to induce apoptosis 
under low serum conditions, common to mitotic oncoproteins such as E2F-1 6 ,4 7 , v- 
Jun 8 and c-Myc 7 , could be a consequence of deregulated cell cycle progression. 
Variations of the dual signal model for Myc function postulate that the oncogene 
coordinately stimulates distinct pathways for apoptosis and proliferation 4 6 . v-Src 
may also show this functional duality since addition of the MEK1 inhibitor, PD98059, 
throughout the 24 h incubation in low serum arrested v-Src transformed Rat-1 in 
G0/G1 but did not prevent apoptosis when v-Src was switched off (data not shown).
Finally, v-Src phosphorylation leads to disruption and turnover of the components of 
cellular adhesions and linking cytoskeletal elements 4 8 , a process that became more 
pronounced during the 24 h incubation in low serum employed in our experiments 
(data not shown). The consequent attenuation of integrin signalling may be a signal
1 0
for apoptosis, analogous to detachment induced cell death (“anoikis”) in epithelial 
cells 49. Serum-deprived mesenchymal cells can survive in the absence of integrin 
signalling 1-3  and ts LA29 Rat-1 cells at the restrictive temperature and normal Rat-1, 
which both have a normal morphology, resist apoptosis following PI3-K inhibition 
(Figure 5E). This implies that, in mesenchymal cells, either integrin mediated or other 
signals are sufficient to induce survival. These signals can substitute for one another 
since we showed previously that surrogate integrin signalling can protect serum- 
deprived fibroblasts from Myc-induced apoptosis 5 0 . In serum-deprived ts LA29 Rat-1 
cells at the permissive temperature inactivation of v-Src or inhibition of PI3-K may 
remove another survival signal from cells whose integrin survival signalling has been 
disrupted by morphological transformation, resulting in the onset of cell death.
v-Src induced survival signals
We showed that the v-Src survival signal is mediated, at least in part, by PI3-K, since 
the PI3-K inhibitor, LY294002, induced significant apoptosis in v-Src transformed 
cells grown under low serum conditions (Figure 5D). v-Src can bind and activate PI3- 
K 19 and, when we switched off v-Src, we observed inactivation of PI3-K, as 
evidenced by reduced Akt phosphorylation (Figure 5A). Furthermore, LY294002 
inhibited Akt phosphorylation, showing that this inhibitor did, indeed, act on the PI3- 
K pathway (Figure 5C). Taken together, these results show that v-Src survival signals 
mediated by PI3-K protect cells from v-Src-primed apoptosis. Previous reports 
showed that v-Src survival signals mediated by PI3-K protected epithelial cells from 
anoikis 51 and Rat-1 cells from UV induced apoptosis 5 2 , suggesting that this is a 
general mechanism whereby v-Src can provide a survival signal to protect against 
different apoptotic stimuli.
The effectors of v-Src primed apoptosis
Survival signals mediated by Akt have been shown to impinge on the apoptotic 
machinery in a number of ways including phosphorylation of Bad (Bcl-XL/Bcl-2 
associated death factor) 53  and pro-caspase 9 5 4 . Phosphorylation prevents pro-caspase 
9 activation while phosphorylated Bad is held within the cytosol in a complex with 
14-3-3 protein 5 3 ,5 5 . When Akt is inactivated Bad is de-phosphorylated and moves to 
the mitochondrial membranes where it may titrate out the anti-apoptotic Bcl-2 family 
members. This may allow pro-apoptotic Bcl-2 family members to homodimerize and 
interact with pores in the mitochondrial membranes resulting in release AIF 5 6  and 
cytochrome c 2 6  which in turn activates caspase 9. Thus dephosphorylation of Bad 
and/or caspase 9 provides a possible mechanism of both caspase activation and its 
inhibition by Bcl-2 when v-Src or PI3-K was switched off. Consistent with this we 
have found that ts LA29 Rat-1 cells express Bad protein (D. Johnson and C. Dive 
unpublished).
Additional mechanisms are required to explain why apoptosis induced by switching 
off v-Src or inhibiting PI3-K was simultaneous with the activation of both caspases 
and stress activated kinases, JNK and p38 (Figure 2). Either caspases or p38 were 
sufficient to induce cell death, although not necessarily all the stigmata of apoptosis, 
but inhibiting both enhanced cell survival (Figure 4). In addition the activation of p38 
was partly caspase dependent (Figure 3B) which may be due to the cleavage and
1 1
activation of an upstream kinase analogous to cleavage of PAK 2 3 6  or MEKK1 35. 
Therefore switching off v-Src or inhibiting PI3-K engaged at least two independent 
pathways. These are similar to those reported downstream of Fas 45,57 since ligation of 
Fas or other death receptors activated the p38 and JNK pathways 58-61  and 
independently stimulated the activation of caspase 8 5 7 . Ras induced PI3-K activity 
down regulated Fas expression 6 2 . If v-Src induced PI3-K activity has a similar effect 
then switching off v-Src or inhibiting PI3-K would increase Fas expression which may 
activate the Fas pathway. Bcl-2 can inhibit Fas induced cell death in some cells and 
can inhibit activation of JNK 4 5  and caspase 8 41 at the cell membrane. We found that 
Bcl-2 inhibited the activation of JNK, p38 and caspases when v-Src or PI3-K were 
switched off in low serum. If inhibiting PI3-K in ts LA 29 Rat-1 cells in low serum 
induced Fas expression then Bcl-2 may prevent cell death by blocking JNK, p38 and 
caspase activation downstream of Fas. Possible pro-apoptotic signalling downstream 
of switching off v-Src is summarised in Figure 7.
Conclusions
v-Src can both prime for apoptosis and protect against it. Apoptosis priming is not 
unique to tsLA29 Rat-1, since we observed it also in v-Src transformed chick embryo 
fibroblasts but not in transformed NIH3T3 cells (data not shown). Pro- and anti- 
apoptotic functions are also shown by activated Ras 9 v-Src and Ras share, at least in 
part, the same anti-apoptotic pathway. However, Ras, unlike v-Src, requires 
cooperating oncogenes for primary cell transformation, in which its pro-apoptotic 
function prevails over the anti-apoptotic effect. With v-Src, the priming for apoptosis 
is only apparent when serum survival factors are limiting, conditions under which v- 
Src transformed cells are finely balanced between proliferation and death. These 
phenomena may, nonetheless, have implications for a role for Src in neoplasia. Many 
tumours, particularly those of the colon, have high levels of c-Src expression 6 3 ,6 4  and 
a few metastatic colon tumours have mutated c-Src which could be important in 
tumour progression 6 5 . We showed previously how v-Src induces transformation via 
effects on cell growth and behaviour 4 ,1 8 ,2 1 ,6 6 . Here we suggest that the ability to 
induce cell survival could be an equally important transforming activity of v-Src and 
could be another mechanism whereby deregulated c-Src contributes to tumour 
formation in vivo. Manipulating pathways involved in the alternative death priming 
effects of v-Src could have therapeutic potential, therefore it would be interesting to 
characterise these pathways in v-Src transformed Rat-1 cells.
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Materials and Methods
Cell culture and induction of cell death
Rat-1 cells and ts LA 29 Rat-1 cells were maintained as in 4. BrdU incorporation and 
labelling was as in 4. For the induction of cell death cells were seeded at 1.5 x 106 per 
90 mm plate, the following day the medium was replaced with medium containing 
0.2% serum. After 24 h they were either shifted to restrictive temperature (39.5°C) to 
inactivate v-Src or various inhibitors were added.
To harvest adherent and detached cells we seeded 6 x 106 cells on a 150 mm plate. 
The following day the medium was replaced with medium containing 0.2% serum. 
After 24 h they were shifted to 39.5°C for 6 to 8 h. The detached cells were harvested 
by washing carefully and the adherent cells were either harvested by trypsinization or 
lysed on the plate.
BrdU immunostaining, Propidium iodide staining and flow cytometry
As in 4.
Generation of cell lines which over express Bcl-2
pSFFV-Bcl-2 expression plasmid was from Stanley J Korsmeyer, Washington 
University, St Louis, Missouri, USA. ts LA 29 Rat-1 cells were transfected with 
pSFFV-Bcl-2 or pSFFV using DOTAP (Boehringer Mannheim). Single G418 
resistant colonies were isolated, grown up and tested for expression of Bcl-2 by 
immunoblotting. All colonies isolated from cells transfected with pSFFV-Bcl-2 
expressed Bcl-2 but we could not detect Bcl-2 in colonies from cells transfected with 
pSFFV.
Western blot analysis
As in 4  except phospho-specific antibodies were used as recommended by the 
manufacturers.
Antibodies
Phospho-specific antibodies to Akt, JNK and p38 were from New England Biolabs 
(#9271S, #9251L, #9211S), phospho-ERK was from Promega (#V8031). Total JNK 
antibody, raised against full length recombinant JNK was a gift from Billy Clark, 
Beatson Institute, Glasgow and the p42 ERK antibody, raised against a peptide from 
the C-terminus of p42 ERK (EETARFQPGYRS), 6 7  was a gift from Anne Wyke, 
Beatson Institue, Glasgow. Bcl-2 antibody was from Pharmingen (#15021A), p27 
andtibody was kind gift of Steve Coats, Amgen, CA, USA.
Inhibitors
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Inhibitors were purchased from CalBiochem. Stocks were made in DMSO 
(dimethylsulphoxide) as follows: Z-VAD-FMK 10 mM stock, used at 100 pM, 
SB203580 66mM stock, used at 50pM, LY294002 80 mM stock, used at 50 pM, 
PD98059 10 mM stock used at 50 pM.
DAPI (4’,6-Diamidiiio-2-pheylindole) staining
Cells were grown in chamber slides, 1 x 104 cells per chamber in 0.4 ml culture 
medium. They were washed twice in PBS (phosphate buffered saline) then fixed in 
3.7% formaldehyde in PBS for 10 mins. They were washed in PBS and permeabilized 
in 0.5% Triton-X-100, 1% BSA in PBS for 30 mins. They were washed once in PBS 
then mounted in Vectasheild (Vector Labs) containing 0.1 [xg/ml DAPI.
DNA Laddering
Cells were harvested by trypsinization, washed in PBS then suspended in TNE (10 
mM Tris-Cl pH 8.2, 400 mM NaCl, 2 mM EDTA (ethylenediaminetetraacetic acid)) 
at a concentration of 5 x 106 per ml. Cells were lysed by addition of 0.5% SDS and 
proteins digested by adding 0.25 mg/ml proteinase K and incubating at 37°C 
overnight. The lysates were extracted with water saturated phenol then chloroform and 
precipitated with 1.5 volumes of 100% ethanol and spun for 5 mins in a microfuge. 
After a 70% ethanol wash the pellet was dissolved in 100 pi 10 mM Tris pH 8.0, 1 
mM EDTA and 0.1 mg/ml DNase free RNase A was added. Tubes were incubated at 
37°C for 30 mins then 5 to 10 pg was run on a 2 % agarose gel.
TUNEL
31. Cells were harvested and washed once in PBS. They were fixed for 15 mins on ice 
in 1% formaldehyde in PBS then centrifuged at 1000 rpm for 5 mins. They were 
resuspended in 100 pi PBS and 1 ml ice cold 70% ethanol was added. They were 
stored overnight at 4°C and the next day they were rehydrated in PBS on ice for 30 
mins. Aliquots of 106 cells were spun and resuspended in 0.2 M potassium cacodylate, 
2.5 mM Tris-HCl pH 6.6, 2.5 mM C0 CI2, 0.25 mg/ml, BSA, 5 units of TdT (terminal 
deoxynucleotidyl transferase) and 0.5 nmoles of biotinylated dUTP per tube. They 
were incubated at 37°C for 30 mins, washed in 1 ml of PBS then spun and 
resuspended in 100 x^l 4 x SSC (1 x SSC = 0.15 M NaCl, 0.015 M NaCitrate), 0.1% 
Triton X-100, 5% low fat dried milk and 5 pg/ml avidin-FITC (fluorescein 
isothiocyanate). They were incubated for 30 mins at room temperature in the dark then 
washed by addition of 1 ml PBS containing 0.1% Triton X-100, spun and resuspended 
in 500 pi of PBS containing 10 pg/ml propidium iodide. They were analysed by flow 
cytometry and the percentage TUNEL positive cells determined by FITC fluorescence.
Detection o f active caspases
3 2  Cells were lysed by freezing on dry ice and thawing at 37°C three times then 
incubated with Z-EK(bio)D-amok (N-(Na-benzyloxycarbonylglutamyl-N£- 
biotinyllysyl)aspartic acid[(2,6-dimethylbenzoyl)oxy]methyl ketone) (lpM  added 
from a 25pM stock in DMSO) at 37°C for 15 mins. They were diluted with 2 x SDS
14
sample buffer, boiled for 3 minutes and sonicated briefly. They were subject to SDS- 
PAGE (polyacrylamide gel electrophoresis) on 16% gels, transferred to nitrocellulose, 
probed with peroxidase-labeled streptavidin and visualised using ECL (enhanced 
chemiluminescence).
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F igure L egends
Figure 1. Inactivation of v-Src under low serum conditions causes cell cycle exit and 
apoptosis. (A) At intervals after inactivation of v-Src cells were allowed to 
incorporate BrdU for 1 h. They were then fixed and stained with FITC labelled 
antibodies against BrdU and the DNA stain, propidium iodide and analysed by flow 
cytometry. The dot plots show propidium iodide staining on the X-axis and FITC 
labelling (BrdU) on the Y-axis. Cells which incorporated BrdU and were in S-phase 
are indicated. (B and C) ts-LA 29 Rat-1 cells 6 h after inactivation of v-Src. (B) 
photographed under phase contrast and (C) fixed and stained with DAPI. (D) Cells 
were harvested at intervals after v-Src inactivation, fixed and labelled by the TUNEL 
technique. Graph shows the means and standard errors of 7 experiments. (E and F) 
Flow cytometric and DNA analysis of v-Src transformed cells under low serum 
conditions (Oh) and following inactivation of v-Src for 8 h when loosely adherent 
(det.) and adherent cells (adh.) were harvested separately. (E) Cells were fixed, stained 
with propidium iodide and analysed by flow cytometry. Left panel shows cell number 
against propidium iodide staining while right panel shows cell number against cell 
size (forward scatter). (F) DNA extracted from the cells was analysed by 2 % agarose 
gel electrophoresis and stained with ethidium bromide (M - markers). (G) At intervals 
after inactivation of v-Src we added 5% serum. Cells were harvested 6 h after v-Src 
inactivation, fixed and labelled by the TUNEL technique. A representative experiment 
is shown.
Figure 2. Activation of caspases, JNK and p38 during apoptosis. (A) We extracted 
proteins from cells harvested at intervals after v-Src inactivation and incubated with a 
biotinylated peptide (Z-EK(bio)D-amok) which binds to the active site of caspases. 
The proteins were separated by SDS PAGE and immunoblotted with streptavidin 
linked to horseradish peroxidase. Active caspases were detected by ECL. (B) We 
extracted proteins from cells harvested at intervals after v-Src inactivation and 
immunoblotted using antibodies against Thrl83/Tyrl85 JNK or Thrl80/Tyrl82 p38 
(upper panels) or total JNK or p38 (lower panels). Arrows indicate an isoform of JNK 
which appeared at 4 h.
Figure 3. The effect of the caspase inhibitor Z-VAD-FMK on (A) p27 (B) JNK 
activation and (C) p38 activation. (A) Proteins extracted from control or Z-VAD- 
FMK treated cells at 0 h and adherent and detached cells 6 h after v-Src inactivation 
were analysed by immunoblotting antibodies against p27. (B and C) Proteins extracted 
from control or Z-VAD-FMK treated cells at 0 h and adherent and detached cells 6 h 
after v-Src inactivation were analysed by immunoblotting antibodies against 
Thrl83/Tyrl85 JNK or Thrl80/Tyrl82 p38 (upper panels) or total JNK or p38 (lower 
panels) (Arrows indicate the new isoform of JNK in detached cells)..
Figure 4. The effect of Z-VAD-FMK and SB203580 on cell death. (A) Z-VAD-FMK 
treated adherent or detached cells were harvested 6 h after inactivating v-Src. They 
were fixed and stained with propidium iodide then analysed by flow cytometry. Left 
panel shows cell number against propidium iodide staining while right panel shows 
cell number against cell size (forward scatter). (B) 6 h after inactivating v-Src cells 
treated with Z-VAD-FMK were photographed under phase contrast or (C) fixed and 
stained with DAPI. (D) We extracted DNA from control [C] or Z-VAD-FMK treated
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[Z] adherent or detached cells harvested 6 h after inactivating v-Src and analysed it by 
2% agarose gel electrophoresis and staining with ethidium bromide. (E) 6 h after 
inactivating v-Src cells treated with Z-VAD-FMK or SB203580 were harvested, fixed 
and labelled by the TUNEL technique. Results shown are the average and standard 
errors of 4 replicates from 2 different experiments.
Figure 5. The role of ERK and PI3-K pathways in cell death. (A) We extracted 
proteins from the cells at intervals after v-Src inactivation and analysed them by 
immunoblotting using antibodies against phosphoThr202/Tyr204 p42/44 ERK or 
phospho-Ser473 Akt (upper panels) or p42 ERK or total Akt (lower panels). (B and
C) v-Src transformed cells were incubated in low serum at the permissive temperature 
for 24h. (B) Cells were harvested at intervals after the addition of PD980959 and 
proteins extracted from the cells were analysed by immunoblotting using antibodies 
against phosphoThr202/Tyr204 p42/44 ERK (upper) or p42 ERK (lower). (C) Cells 
were harvested at intervals after the addition of LY294002 and proteins extracted 
from the cells were analysed by immunoblotting using antibodies against phospho- 
Ser473 Akt (upper) or total Akt (lower). (D) v-Src transformed cells incubated in low 
serum for 24h were harvested at intervals after the addition of PD980959 (dashed 
line), LY294002 (fine line), both inhibitors (dotted line) or after switching off v-Src 
(heavy line). Cells were fixed and labelled using the TUNEL technique. The graph 
shows a representative experiment of cells treated with inhibitors and means and 
standard errors of 7 experiments when v-Src was switched off. (E) Rat-1 cells or ts LA 
29 Rat-1 cells were grown at the permissive (35°C) or restrictive (39.5°C) temperature 
for the v-Src oncoprotein. Cells were transferred to low serum for 24 h then treated 
with LY294002 for a further 6 h, harvested, fixed and labelled by the TUNEL 
technique. (F) v-Src transformed cells incubated in low serum for 24h were harvested 
6 h after treatment with PD98059 or LY294002 or switching off v-Src. Proteins 
extracted from the adherent or detached cells were analysed by immunoblotting using 
antibodies against Thrl83/Tyrl85 JNK or Thrl80/Tyrl82 p38 (upper panels) or total 
JNK or p38 (lower panels). Arrows show the new isoform of JNK seen in detached 
cells.
Figure 6. Inhibition of cell death by Bcl-2. (A) We extracted proteins from cell lines 
engineered to over express Bcl-2 or containing plasmid DNA and analysed the level 
of Bcl-2 expression by immunoblotting with antibodies specific for Bcl-2. (B) v-Src 
transformed Bcl-2 expressing or control cells were incubated in low serum for 24 h. 
LY294002 was added or v-Src switched off and the cells were harvested 6 h later, 
fixed and stained using the TUNEL assay. The results shown are representative of 
several different experiments. (C) v-Src transformed Bcl-2 expressing and control 
cells were incubated in low serum for 24 h then harvested cells at intervals after 
switching off v-Src. Proteins were extracted and analysed by immunoblotting using 
antibodies against phospho-Ser473 Akt or phosphoThr202/Tyr204 p42/44 ERK 
(upper panels) or Akt or p42 ERK(lower panels). (D) The v-Src transformed Bcl-2 
expressing and control cells were incubated in low serum for 24 h then harvested 6 h 
after switching off v-Src (-Src) or adding LY294002 (LY). Proteins were extracted 
and analysed by immunoblotting using antibodies against Thrl83/Tyrl85 JNK or 
Thrl80/Tyrl82 p38 (upper panels) or total JNK and p38 (lower panels). Arrows 
indicate the new isoform of JNK.
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